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RÉSUMÉ
Le système de différenciation entre le « soi » et le « non-soi » des vertébrés 
permet la détection et le rejet de pathogènes et de cellules allogéniques. Il 
requiert la surveillance de petits peptides présentés à la surface cellulaire par 
les molécules du complexe majeur d’histocompatibilité de classe I (CMH I). Les 
molécules du CMH I sont des hétérodimères composés par une chaîne lourde 
encodée par des gènes du CMH et une chaîne légère encodée par le gène β
2
-
microglobuline. L’ensemble des peptides est appelé l’immunopeptidome du 
CMH I. Nous avons utilisé des approches en biologie de systèmes pour définir 
la composition et l’origine cellulaire de l’immunopeptidome du CMH I pré-
senté par des cellules B lymphoblastoïdes dérivés de deux pairs de fratries 
avec un CMH I identique. Nous avons découvert que l’immunopeptidome du 
CMH I est spécifique à l’individu et au type cellulaire, qu’il dérive préférentiel-
lement de transcrits abondants, est enrichi en transcrits possédant d’éléments 
de reconnaissance par les petits ARNs, mais qu’il ne montre aucun biais ni vers 
les régions génétiques invariables ni vers les régions polymorphiques. Nous 
avons également développé une nouvelle méthode qui combine la spectromé-
trie de masse, le séquençage de nouvelle génération et la bioinformatique pour 
l’identification à grand échelle de peptides du CMH I, dont ceux résultants 
de polymorphismes nucléotidiques simples non-synonymes (PNS-ns), appelés 
antigènes mineurs d’histocompatibilité (AMHs), qui sont les cibles de réponses 
allo-immunitaires. La comparaison de l’origine génomique de l’immunopepti-
dome de sœurs avec un CMH I identique a révélé que 0,5% des PNS-ns étaient 
représentés dans l’immunopeptidome et que 0,3% des peptides du CMH I se-
raient immunogéniques envers une des deux sœurs. En résumé, nous avons 
découvert des nouveaux facteurs qui modèlent l’immunopeptidome du CMH 
I et nous présentons une nouvelle stratégie pour l’indentification de ces pep-
tides, laquelle pourrait accélérer énormément le développement d’immuno-
thérapies ciblant les AMHs.
MOTS CLÉS : complexe majeur d’histocompatibilité, antigène de leucocytes 
humains, immunopeptidome, antigène mineur d’histocompatibilité, spectro-
métrie de masse, lignées de cellules B lymphoblastoïdes, séquençage de nou-
velle génération 
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ABSTRACT
The self/nonself discrimination system of vertebrates allows detection and 
rejection of pathogens and allogeneic cells. It requires the surveillance of short 
peptides presented by major histocompatibility class I (MHC I) molecules on 
the cell surface. MHC I molecules are heterodimers that consist of a heavy chain 
produced by MHC genes and a light chain encoded by the β
2
-microglobulin 
gene. The peptides presented by MHC I molecules are collectively referred to 
as the MHC I immunopeptidome. We employed systems biology approaches 
to define the composition and cellular origin of the self MHC I immunopep-
tidome presented by B lymphoblastoid cells derived from two pairs of MHC-
identical siblings. We found that the MHC I immunopeptidome is subject- and 
cell-specific, derives preferentially from abundant transcripts, is enriched in 
transcripts bearing microRNA response elements and shows no bias toward 
invariant vs. polymorphic genomic sequences. We also developed a novel per-
sonalized approach combining mass-spectrometry, next-generation sequenc-
ing and bioinformatics for high-throughput identification of MHC I peptides 
including those caused by nonsynonymous single nucleotide polymorphisms 
(ns-SNPs), termed minor histocompatibility antigens (MiHAs), which are the 
targets of allo-immune responses. Comparison of the genomic landscape of 
the immunopeptidome of MHC-identical siblings revealed that 0.5% of ns-SNPs 
were represented in the immunopeptidome and that 0.3% of the MHC I-pep-
tide repertoire would be immunogenic for one of the siblings. We discovered 
new factors that shape the self MHC I immunopeptidome and present a novel 
strategy for the identification of MHC I-associated peptides that could greatly 
accelerate the development of MiHA-targeted immunotherapy.
KEYWORDS : major histocompatibility complex, human leukocyte antigen, 
immunopeptidome, minor histocompatibility antigens, mass-spectrometry, B 
lymphoblastoid cell lines, next-generation sequencing 
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OVERVIEW
The ability to discriminate between self and non-self is a fundamental re-
quirement for life. Multicellular organisms use self/non-self discrimination 
primarily in immune defense. The adaptive immune system of jawed verte-
brates has taken advantage of the protein fragments (peptides) generated by 
the ubiquitin-proteasome degradation machinery to use them as flags in self/
non-self discrimination. These protein fragments, collectively known as the 
MHC I immunopeptidome, need to be processed and presented on MHC class 
I molecules on the surface of the cell. Under steady state conditions, the MHC 
I immunopeptidome is composed solely of self peptides. The immune sys-
tem keeps track of intracellular protein content by sampling the universe of 
self peptides produced in search of: i) altered (transformed) peptides or neo-
self peptides that may reveal dysfunction (e.g. cancer, stress, inflammation) or 
ii) non-self peptides resulting from alteration of steady state conditions (e.g. 
infection, pregnancy, transplantation). While the adaptive immune system is 
vital for combating pathogens and neoplastic transformation, it represents a 
significant barrier for foreign (allogeneic) transplantation in a clinical context. 
Moreover, alteration of the self/nonself discrimination system may lead to 
autoimmune diseases.
The MHC I immunopeptidome is the end result of the antigen processing and 
presentation pathway, which behaves as a complex system involving input, 
processing and output of data. Complex systems can be studied from a ho-
listic perspective. Systems biology is an inter-disciplinary field that combines 
high-content multiplexed measurements with computational methods to bet-
ter understand and model biological function at various scales. Accordingly, 
recent large-scale (-omic) studies have yielded unprecedented insights into the 
genesis, molecular composition and plasticity of the MHC I immunopeptidome. 
The aim of the present multidisciplinary work was to unravel the biogenesis 
and composition of the MHC I immunopeptidome of human B lymphoblastoid 
cell lines by applying data-driven systems biology approaches.
The results from this work will be presented in six chapters and two appen-
dixes. The first chapter includes the general introduction and objectives. The 
xxi
second chapter corresponds to a published review article about the origin and 
plasticity of MHC-I associated self peptides. The third chapter includes a pub-
lished article in which we report the relationship between the MHC I immuno-
peptidome, the transcriptome and the microRNAome. The forth chapter cor-
responds to a review article to be submitted about identification methods and 
molecular mechanisms responsible for the generation of MHC I peptides that 
cause immune reactions in allogeneic transplantation (i.e. minor histocompat-
ibility antigens). The fifth chapter includes a submitted manuscript showing 
the impact of single nucleotide polymorphisms on the MHC I immunopepti-
dome. The results from this work are collectively discussed in the sixth chap-
ter. The first appendix is a published work that I started during my Masters 
studies and completed during my Ph.D. studies. It shows the effect of ER stress 
on the processing of MHC class I-associated peptides. The second appendix is 
the summary of my contribution to a published article showing the impact of 
immunproteasome deletion on the repertoire of MHC I-associated peptides.
Our studies reveal how various factors in different functional genomic levels 
such as genomic polymorphisms, transcript abundance and the presence of 
microRNA response elements, influence the human self MHC I immunopepti-
dome. Moreover, this work significantly expand the number of sequenced and 
characterized human MHC I peptides and constitute a precious resource of 
exome, transcriptome and miRNAome sequencing and analyses of human B 
lymphoblasts. Lastly, we provide a novel approach relying on next-generation 
sequencing, bioinformatics and mass spectrometry for high-throughput dis-
covery of minor histocompatibility antigens. Therefore, our work provides ma-
jor insights on the biogenesis of the MHC I immunopeptidome and contributes 
to the advancement of cancer immunotherapy.     
CHAPTER 1
21. Introduction
1.1 The innate and adaptive immune system
In vertebrates, the effective recognition and elimination or containment of in-
fectious microorganisms is achieved by the synergic and complementary ac-
tion of the innate and adaptive immune systems [1]. The immune system is 
not only equipped with potent effector mechanisms to clear pathogen, toxins 
and allergens, but it also has the ability to distinguish self from non-self and 
avoid damaging self-tissues that can lead to auto-immune diseases [2]. This 
immunosurveillance mechanism is known as self tolerance and it is mani-
fested both in the innate and the adaptive immune responses [2]. 
The innate immune (or non-specific) system allows initial host defense against 
microbial pathogens and comprises innate mechanisms that are encoded in 
their mature functional forms by germline genes [2]. It includes i) physical bar-
riers such as respiratory, gastrointestinal and genitourinary epithelia, ii) small 
molecules including complement proteins and defensins that are constitutive-
ly present in fluids or are released from activated cells, iii) soluble proteins 
such as cytokines, chemokines and enzymes, and iv) membrane-bound recep-
tors and cytoplasmic proteins of phagocytic immune cells that bind molecular 
patterns of microbial origin [3]. The innate immune system is non-specific as 
the distinction of microbial pathogens from host cells is made through recog-
nition of conserved molecules shared by many microbes [2]. These molecules 
are recognized by a limited repertoire of receptors, such as the Toll family, 
expressed on phagocytic immune cells [4]. Because the recognition molecules 
are expressed broadly on a large number of cells, the cells are rapidly activated 
(within hours of contact) and this constitutes the initial host response [2]. Of 
note, the efficacy of the innate response is not increased by previous exposure 
to the same pathogen [3]. 
By contrast, the adaptive (or specific) immune system is composed of small 
numbers of cells with specificity for any individual pathogen. These special-
ized cells are T and B lymphocytes that express antigen-specific receptors on 
their cell surface [2]. The T cell receptors (TCR) and the B-cell receptors (BCR) 
3are acquired during the lifetime of the organism as a result of somatic rear-
rangement of gene segments and allow the formation of millions of different 
antigen receptors, each with a unique specificity for a different antigen [2]. In 
this way, the adaptive immune system provides flexibility to respond to nu-
merous and highly variable targets. This response is less rapid (within days of 
contact) than the innate response since the responding cells must proliferate 
after encountering the antigen to attain sufficient numbers to mount an effec-
tive response [2,3]. Hence, the adaptive response generally arrives temporarily 
after the innate response in host defense [2]. Following recognition of specific 
antigens of a given microorganism, the lymphocytes and the antibodies they 
produce persist as immunological memory and are rapidly protective on re-
exposure to the same pathogen, albeit in an antigen-dependent manner [1]. 
The phenomenon of immunological memory is exploited in vaccination, in 
which antigens are inoculated to stimulate an individual’s adaptive immunity 
to a pathogen [1]. 
Both B and T lymphocytes provide defense against extracellular pathogens via 
recognition of antigens, although by different mechanisms. B lymphocytes (or 
B cells) mature in the bone marrow and trigger what is typically known as the 
humoral immune response (or antibody-mediated system). This response 
is characterized by recognition of intact antigens in the extracellular milieu 
through secreted immunoglobulins (antibodies) produced by B cells and sur-
face immunoglobulins that compose the BCRs on the surface of B cells [3]. By 
contrast, T lymphocytes (or T cells) develop in the thymus from common 
lymphoid progenitors and trigger the cellular immune response (or cell-me-
diated system). In this response T cells are activated by antigen-presenting 
cells (APCs) (e.g. dendritic cells (DCs), macrophages, B cells) and consequently 
eliminate infected cells and activate other cells of the immune system [3,5]. 
Activation of T lymphocytes is initiated upon recognition of peptide fragments 
of antigen (i.e. epitopes) presented by MHC molecules encoded by the major 
histocompatibility complex (MHC) on the surface of APCs [3]. Hence, T cells 
recognize a molecular complex composed of a self-component (the MHC) and 
a non-self structure (the epitope) [2].
41.2 T lymphocytes
T lymphocytes are classified into several T cell subsets that are distinguished 
based on the composition of their TCR (αβ or γδ), their antigenic specificity 
(determined by expression of the CD4+ or CD8+ coreceptor molecules) and 
their state (e.g. naive, effector, regulatory) [6]. The composition of the TCR de-
termines its specificity for a given target [7]. While T cells that express the αβ 
TCR react to peptides presented by MHC molecules, those that express the γδ 
TCR are not MHC-restricted and play a role in the surveillance of tissue stress 
[6]. αβ T cells (referred as T cells hereinafter) constitute the majority of the T 
cell population in lymphoid organs [5]. The αβ TCR is an heterodimer made 
from two separate chains that arise from somatic gene rearrangement of vari-
able (V), diversity (D), joining (J) and constant (C) gene fragments during T cell 
development [7]. In this process, nucleotides are inserted and deleted at V(D)
J junctions in each chain, resulting in an extensive repertoire of TCRs, whose 
reactivity against self MHC-peptide complexes is screened thereafter during 
thymic selection [7].
In the thymus, thymic selection of T cells is achieved through positive and 
negative selection. During positive selection, immature double-positive 
(CD4+CD8+) thymocytes that are capable of forming a minimal interaction 
between the αβ TCR and self MHC-peptide complexes on cortical thymic epi-
thelial cells, are rescued [8,9]. Positive selection is assumed to enrich the rep-
ertoire of self-MHC-restricted T cells capable of react against potential for-
eign antigens [10]. Hence, double-positive T cells bearing a TCR that do not 
bind MHC-self-peptide complexes die by neglect. During negative selection 
(or clonal deletion), thymocytes are exposed to a variety of tissue-specific 
peptides ectopically expressed and presented by medullary epithelial cells and 
medullary APCs [6,8]. In this process, T thymocytes that bind with high avid-
ity to self MHC-peptide complexes are eliminated [8]. The removal of these 
self-reactive T cells is essential for preventing autoimmunity and illustrates 
one mechanism of central tolerance [6]. Double-positive thymocytes passing 
both positive and negative selection develop into mature CD4+ or CD8+ T cells 
expressing large amounts of TCRs [5]. This pre-immune repertoire of naive 
T lymphocytes potentially reactive to foreign but not self antigens, exit the 
5thymus and migrate to secondary lymphoid organs, where they can encounter 
non-self peptides presented by MHC molecules on APCs and thereafter prolif-
erate and differentiate into effector T lymphocytes [11]. Activation of CD8+ 
(or cytotoxic) T cells (CTLs) and CD4+ (or helper) T cells is triggered by rec-
ognition of peptides bound on MHC class I and class II molecules, respectively, 
encoded by the major histocompatibility complex (MHC) genes (see next sec-
tion). Upon activation, CD4+ T cells produce cytokines that activate other cells 
including macrophages and B cells and thereby regulate cellular and humoral 
immune responses, while CD8+ T cells differentiate into effector T cells that 
directly contact infected or transformed cells and destroy them via release of 
perforin and granzymes [5]. 
1.3 The human major histocompatibility complex (MHC)
The major histocompatibility complex (MHC) is a large multigenic region 
found in most vertebrates containing at least 128 genes in humans, of which 
more than 20% encode proteins of the immune system [4,12]. The human MHC 
is the most gene-dense and polymorphic region and is part of the so-called 
extended MHC region, covering 7.6 Mb of the short arm of the chromosome 6 
[4]. The MHC region contains, among others, highly polymorphic genes encod-
ing the aforementioned MHC molecules that present protein-derived peptides 
(antigens) to T cells [1]. These type of antigen-presenting molecules are known 
as classical MHC molecules [3]. There are also structurally related molecules 
that are monomorphic or oligomorphic, known as non-classical MHC mol-
ecules [3,13]. Non-classical MHC molecules are involved in immune and non-
immune processes and some can function in the presentation of peptide anti-
gens [13]. Besides, the MHC region contains genes involved in the processing 
of antigens [4]. 
For historical reasons, the human MHC is also referred to as the human leuko-
cyte antigen (HLA) complex, since the first MHC gene products were discov-
ered on the surface of leukocytes [4]. Three distinct regions have been identi-
fied within the human MHC: the MHC class I (MHC I), MHC class II (MHC II) 
and MHC class III (MHC III) (Figure 1). The MHC I and II regions encode both 
classical MHC and non-classical MHC molecules. The MHC I region contains 
6among other genes, the classical MHC I genes (also known as MHC Ia genes) 
HLA-A, HLA-B and HLA-C and the more ancient non-classical MHC I genes 
(also known as MHC Ib genes) HLA-E, HLA-F and HLA-G [4,13]. The MHC II re-
gion covers the classical MHC II genes HLA-DP, HLA-DQ and HLA-DR, as well 
as non-classical MHC II genes HLA-DM and HLA-DO [4]. Some non-classical 
MHC I molecules play a role in activating specialized classes of T cells, whereas 
non-classical MHC II molecules regulate peptide loading into classical MHC 
class II molecules. The MHC III region is located between the class I and class 
II regions and encloses miscellaneous non-HLA genes (e.g. MICA, MICB) encod-
ing proteins with or without immune function [12]. 
1.4 The classical MHC class I and II molecules 
MHC I and MHC II molecules are cell-surface glycoproteins with a similar three-
dimensional structure and similar function in presenting peptide fragments 
or antigens to the immune system [15].  Nevertheless, these molecules differ 
in their tissue distribution and in the type of antigenic peptides they display 
that reflects different antigen processing pathways [16]. The 3 classical human 
MHC I genes (HLA-A, HLA-B and HLA-C) are co-dominantly expressed on the 
cell surface of all nucleated cells and play a major role in adaptive immunity. 
Figure 1. Location and organization of the human MHC 
complex on chromosome 6. Adapted with permission 
from [14]. Copyright Massachusetts Medical Society
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7On the contrary, surface expression of MHC II molecules is restricted mainly 
to APCs such as macrophages, B cells and DCs, although it can be induced by 
interferon-γ (IFN-γ) and other stimuli in non-APCs like mesenchymal stromal 
cells, fibroblasts, endothelial cells and activated human T cells [5,16]. 
1.4.1 The MHC II molecules and associated peptides
MHC II molecules are transmembrane glycoproteins with short cytoplasmic 
domains, composed of one α and one β chain. The membrane-proximal re-
gion consists of one conserved domain that is part of the α subunit and an-
other conserved domain of the β subunit (Figure 2c). MHC II molecules exhibit 
enormous amino acid sequence variation in the region that interacts with the 
peptide named the peptide-binding groove [17] (Figure 2d). Consequently, dif-
ferent alleles bind different sets of peptides. The groove is formed by the jux-
taposition of the N-terminal regions of the α and β chains. The peptide-binding 
groove is open at both ends and hence, long peptides, generally between 15 
and 24 amino acids long, can bind and overhang the binding groove resulting 
in more or less restrictive binding motifs [17] (Figure 2d). 
1.4.2 The MHC I molecules and associated peptides
The molecular target of the TCR of CD8+ T cells is the complex formed by the 
MHC I and the associated peptide [2]. MHC I molecules are cell-surface het-
erodimers composed of a polymorphic transmembrane 44-kd heavy (α) chain 
and a 12-kd invariant light chain, known as β2-microglobulin (β2m) [2,14,16] 
(Figure 2a). The heavy chain consists of 3 extracellular domains (α1, α2 and 
α3), a transmembrane domain and a short intracellular domain that anchors 
the protein in the cell membrane [18]. The α1 and α2 domains form a platform 
with a groove, in which antigenic peptides can bind noncovalently through the 
N and C termini [17] (Figure 2a). The main anchor residues of the peptide to 
the peptide-binding groove are frequently the second and the last C-terminal 
residue [15] (Figure 3b). In some exceptional cases, the main anchors are lo-
cated in positions P3 (as in HLA-A1-associated peptides) and P5 (as in HLA-B8-
associated peptides). The peptide-binding groove is blocked at both ends by 
bulky aromatic amino acids that typically limit the length of the bound peptide 
8to 8-10 residues [15] (Figure 2b). Less frequently, MHC I molecules can bind 
longer peptides [19-21], in which case the central part of the peptide protrudes 
and the binding is presumably less stable [15,22]. 
A prominent characteristic of the human MHC I molecules is their high degree 
of polymorphism [1,23]. The IMGT/HLA database of the international ImMuno-
GeneTics project (http://www.ebi.ac.uk/ipd/imgt/hla) registers thousands of 
MHC I alleles in their last release (2013-07-25): 2,365 HLA-A, 3,005 HLA-B and 
1,848 HLA-C alleles. Besides, HLA-B is the most polymorphic gene in the hu-
man genome [24]. Most polymorphisms in exons 2 and 3 of the HLA-A, HLA-B 
and HLA-C genes lead to amino acid substitutions in the floor and sides of the 
peptide-binding groove of the corresponding MHC I protein [17,25]. Thereby, 
different MHC I allelic products display distinct amino acid preferences at key 
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Figure 2. Three-dimensional structures of peptide-bound 
MHC I and MHC II molecules
(a) and (b) HLA-A2 molecule complexed with influenza derived 
peptide. (c) and (d) HLA-DR1 molecule complexed with influ-
enza derived peptide. Highly polymorphic residues proximal 
to the peptide-binding groove are highlighted in yellow; the 
peptide is shown in red. Adapted with permission from [17].
9positions in the peptide sequence. These MHC-specific amino acid patterns are 
known as peptide-binding motifs (or binding specificities) [26] (Figure 3a). 
Consequently, different MHC I allelic products bind different sets of peptides 
[27]. Moreover, MHC I molecules are promiscuous since each type of MHC I al-
lelic product can bind a diversity of peptides that differ in their sequences but 
share 2-3 anchoring amino acid residues (i.e. the same binding motif) [14,28]. 
At the individual scale, this variability means that each subject who is hetero-
zygous at the 3 HLA loci will have 6 distinct peptide-binding grooves. Con-
sequently, on a population level, the diversity of peptide-binding motifs is 
colossal. This characteristic supports a hypothesis whereby variations in the 
MHC I binding groove allow the various MHC I molecules in the population 
to bind and present different portions of viral or intracellular pathogens for 
immune recognition [29]. Hence, this huge diversity protects the population 
against microbes that evade recognition through mutations in antigens that 
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Figure 3. Examples of peptide-binding motifs of some HLA molecules
(a) Peptide-binding motifs. Anchor residues are highlighted in yellow. (b) Lon-
gitudinal section through the peptide-binding groove of an MHC I molecule. 
P1-P9 indicates amino acid positions. Adapted with permission from [14]. Copyright Massachusetts Medical Society
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impair MHC I binding [2,30]. It is believed that this overwhelming variability 
of antigenic structures and the ability of pathogens to mutate and avoid host 
detection have driven the evolution of the adaptive immune system [31]. The 
enormous degree of MHC polymorphism, although highly desirable in healthy 
individuals for dealing with infections, poses great problems in a transplant 
setting, as the search for a suitable bone marrow or organ donor may be ex-
tremely difficult.
1.5 Antigen processing and presentation
Typically, MHC I molecules bind peptides that derive from proteins translated 
within the cell (endogenous antigens), and present them to CD8+ T cells. By 
contrast, MHC II molecules sample the extracellular milieu through binding of 
peptides derived from exogenous proteins that have been ingested by APCs 
and degraded in the endocytic pathway, and expose them to CD4+ T cells 
[2,16]. In the next sections, the MHC II antigen processing pathway will be 
briefly described followed by a detailed review of the MHC I pathway. 
1.5.1 MHC II antigen processing and presentation
The transmembrane α and β chains of MHC II are assembled in the endoplas-
mic reticulum (ER), where they associate with the invariant chain (Ii) and form 
the Ii-MHC II complex (Figure 4). The complex is transported to endosomal 
compartments through the recognition of sorting motifs in the cytoplasmic 
tail of Ii [16]. Once the complexes reach late endosomal compartment named 
MHC class II compartment (MIIC), Ii is digested leaving a residual Ii peptide 
named class II-associated Ii peptide (CLIP). CLIP lies in the peptide-binding 
groove where it is exchanged for a specific peptide through the action of HLA-
DM. In B cells, HLA-DO associates with HLA-DM and restricts HLA-DM activity 
to more acidic compartments [32]. MHC II-peptide complexes are exported 
from the MIIC via the trans-Golgi network to the plasma membrane. 
MHC II-associated peptides arise from the degradation of exogenous proteins 
in the endosomal pathway (Figure 2b). Antigens are internalized through en-
docytosis and targeted into lysosomes for processing by lysosomal proteases 
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and loading on MHC II molecules [16]. Cytosolic (endogenous) proteins de-
graded through autophagy, as well as membrane proteins degraded in the 
lysosome, can be presented by MHC II molecules [33-36]. Information about 
the MHC II-peptide repertoire can be found in the section “The MHC class II 
immunopeptidome” of the review article included in chapter 2. 
Figure 4. Simplified overview of the MHC II antigen processing and 
presentation pathway
(a) MHC II-Ii assembly. (b) Internalization of antigens. (c) Ii digestion and 
peptide binding in the MIIC (MHC class II compartment). (d) Export of 
MHC II-peptide complexes. Adapted with permission from [17].
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1.5.2 MHC I antigen processing and presentation
Peptide-bound MHC I molecules are the end product of the MHC I-antigen pro-
cessing and presentation pathway. This pathway begins with the degradation 
of proteins source of peptides inside the cell. In a stepwise manner, proteolytic 
intermediate fragments are generated and protected until they yield the final 
peptides that can fit MHC I molecules in the ER and be exported as MHC I-pep-
tide complexes to the cell surface [37]. Accordingly, the antigen presentation 
pathway is composed of two merging cellular processes (Figure 5). In the first 
one, peptides suitable for loading the MHC I molecules are generated, whereas 
in the second pathway, peptide-receptive MHC I molecules are assembled [38]. 
This highly specialized system, operating with essentially conserved compo-
nents, is nonetheless capable of generating highly diverse sets of peptides that 
satisfy a large number of different MHC I molecules
BiP
MHC I
heavy chain
TAP1
Proteasome and
proteases 
Cellular proteome
Cytosol
Plasma membrane
CD8
T cell receptor
Cytotoxic T cell
Golgi
Ribosome
Translocon TAP2
ERAAP
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ER
β2m
a
b
c
d
Tapasin
Figure 5. General overview of the MHC I antigen processing and presenta-
tion pathway.
(a) Production of peptides. (b) Assembly of MHC I heterodimers (c) Loading 
of MHC I molecules with peptide. (d) Export of MHC I-peptide complexes. 
PLC: peptide-loading complex. Adapted with permission from [39].
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1.5.2.1 Peptide processing in the cytoplasm
Generation of peptides suitable for loading MHC I molecules starts in the cyto-
plasm. This is the major site of protein turnover, because even ER proteins are 
retrieved into the cytosol for degradation [37]. In the cytoplasm, peptide pre-
cursors of variable lengths (2-25 amino acids) are generated from degradation 
of endogenous proteins through the action of the proteasome and other prote-
ases [22,40,41] (Figure 6). Cytosolic proteins first associate with the chaperone 
Hsp90α, are then ubiquitinated by the ubiquitin ligase CHIP and consequent-
ly degraded by the multicatalytic proteasome [17,42,43]. Of note, different 
proteasome variants such as the immunoproteasome (induced by IFN-γ and 
IFN-α) [44], mixed proteasomes [45] and the thymoproteasome (restricted to 
cortical thymic epithelial cells) [46] are suppliers of peptide precursors (3-22 
residues in length) [22,47,48]. Treatment of cells with proteasome inhibitors 
has revealed that most but not all MHC I peptides require the proteasome for 
their generation [49,50], suggesting the contribution of other proteases to the 
peptide pool [22]. Additionally, proteasomes are thought to generate the final 
C-terminal residues of MHC I-binding peptides [43,51], although this notion 
have been questioned by recent studies [52-57]. 
Proteasomal degradation yield truncated protein fragments that can associate 
with the chaperone protein TRiC [58,59]. In this way, protein fragments are 
protected from cleavage by cytosolic amino- and endopeptidases that recycle 
amino acids and prevent their accumulation [60]. Before transport into the 
ER, most peptide epitopes require additional trimming at the amino terminus 
[61]. Various cytosolic aminopeptidases, such as leucine aminopeptidases, pu-
romycin-sensitive aminopeptidase and bleomycin hydrolase have been shown 
to cleave the amino terminus [22,39,50,62] (Figure 6). Of particular interest 
is the cytoplasmic tripeptidyl peptidase II (TPPII), involved in trimming of 
proteasomal products over 15 amino acids in length, in contrast to most other 
aminopeptidases that only cleave peptides smaller than 14 residues [22,63]. 
Studies using TPPII inhibitors have shown that TPPII plays a role in the presen-
tation of selected peptides [22,53]. TPPII has also been shown to participate 
in proteasome-independent pathway for epitope generation [53]. Recently, the 
cytosolic peptidases insulin-degrading enzyme (IDE), thimet oligopeptidase 
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(TOP), nardilysin and DPP9 have been implicated in the generation of some 
epitopes in a proteasome-dependent or independent manner [54,55,64]. Nev-
ertheless, mice deficient for different cytosolic peptidases have shown that de-
spite being essential for the generation of particular MHC I peptides, they are 
not required for production of the bulk peptide pool [22,50,65-67]. Further-
more, a caspase-mediated epitope production has been discovered in apop-
totic cells upon infection with vaccinia virus, and this mechanism has been 
proposed to explain the increased immunogenicity of apoptotic cells [68].
PLC
Figure 6. The MHC I antigen processing and presentation pathway
PLC: peptide-loading complex. Adapted with permission from [16].
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Paradoxically, the cytoplasm constitutes not only the place where antigenic 
peptides are born, but also the site where most peptides are rapidly destroyed 
owed to excess trimming by cytosolic peptidases [60]. Indeed, peptides have 
a half-life of 6-10 seconds in the cytosol [60] and more than 99% of peptides 
are degraded by cytosolic peptidases before they reach the ER [69]. Cytosolic 
chaperones, such as Hsp70 and Hsp90, are thought to protect peptides from 
exhaustive degradation [42,58,70] This rapid degradation by the proteasome 
and cytoplasmic enzymes limits the availability of peptides and accounts for 
the inefficiency of the peptide presentation pathway [37,71]. For instance, cy-
tosolic efficiency has been measured to produce one MHC I-peptide complex 
for each 500-5,000 viral translation products degraded [72].
At this point, the resulting protein fragments constitute precursors of the MHC 
I-peptide repertoire and are ready to be translocated into the ER. Nonetheless, 
these precursors need further trimming in the ER in order to be suitable for 
loading receptive and correctly assembled MHC I molecules [73].
1.5.2.2 Generation of peptide-receptive MHC I molecules
Production of MHC I peptides requires a concomitant pathway that generates 
peptide-receptive MHC I molecules in the ER. Similar to what occurs with the 
peptide precursors, both the MHC I heavy chain (α chain) and the β2m polypep-
tides are cotranslationally translocated into the ER [74]. During translocation, 
the nascent MHC I heavy chains are bound by the chaperone binding immuno-
globulin protein (BiP) and modified into a monoglucosylated form by glucosi-
dases I and II [75] (Figure 5). Subsequently, early folding and oxidation of MHC 
I heavy chain is mediated by the chaperone calnexin [39,76]. These events are 
followed by 2m association and replacement of calnexin by another lectin-like 
chaperone, calreticulin, which is part of the peptide-loading complex (PLC) 
[39] (Figures 5 and 6). The multisubunit PLC includes the MHC I heavy chain, 
2m, carltericulin, the transmembrane protein tapasin, the oxidoreductase 
ERp57 and the transporter associated with antigen processing (TAP) [39]. 
The luminal domain of TAP acts as a binding platform for calreticulin and 
ERp57, which provide quality control and mediate the formation of disulphide 
bonds, supporting the correct folding of MHC I in the PLC [76-78]. In this way, 
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this multisubunit structure keeps the MHC I molecules in a peptide-receptive 
state [39]. Binding to a high-affinity peptide is needed for the stabilization of 
MHC I heterodimers, which otherwise are destroyed by the ERAD system [76]. 
1.5.2.3 Peptide processing in the ER
 
Besides retaining empty MHC I molecules, TAP is responsible for the active 
transport of peptide precursors (8-16 amino acids length) from the cytosol 
into the lumen of the ER [79], where they can access empty MHC I heterodi-
mers [78]. The TAP complex is a heterodimer composed of the TAP1 and TAP2 
molecules and shows substrate specificity when selecting peptides for trans-
location [80,81] (Figure 5). Most MHC I peptides are TAP-dependent, as evi-
denced by impaired surface expression of MHC I-peptide complexes in cells 
lacking TAP1 or TAP2 [81]. 
Peptide precursors are translocated into the ER where they can follow one 
or more different fates. They can bind MHC I molecules, be protected by ER 
chaperones, be trimmed by ER aminopeptidases, be degraded or be retrotrans-
located back into the cytosol [82]. Together, these processes keep a low con-
centration of peptides in the ER such that only the most recent peptides are 
available for MHC I binding and do not have to compete with those that arrived 
earlier [69]. 
Peptides entering the ER via TAP bind to newly synthesized MHC I molecules 
immediately, as long as the appropriate motif is present [62]. At this point, 
the length is not yet crucial [62]. This initial peptide binding is followed by 
peptide exchange and editing in the ER [83]. Generation of correct MHC I pep-
tides sometimes requires trimming by ER aminopeptidases. The key enzyme 
responsible for generation of quality peptides and final N-terminal trimming 
are the ubiquitously expressed ER amino peptidases associated with antigen 
processing, ERAP1 and ERAP2 in humans (ERAAP in mice) [84] (Figure 6). 
ERAP1 recognizes the peptide carboxyl terminus and trims the amino terminus 
to generate peptides 8-10 residues in length [85]. Of note, ERAP1 is induced by 
IFN-γ [84,86] and it serves a unique function in modifying the quantity and the 
quality of the MHC I-peptide repertoire and influencing CD8+ T cell responses 
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[87,88]. ERAP1 deficiency (through small interfering RNA or in ERAAP knock-
out mice) leaves some peptides unaffected, whereas others are either absent 
or dramatically upregulated [22,65,85]. Consistent with these findings, mass 
spectrometry analysis revealed a drastic increase in MCH I peptide length in 
mice lacking ERAAP [52,89]. ERAP2 also trims residues from the N terminus 
of the peptide, but in contrast to ERAP1, the former is more active in cleav-
ing N-terminal basic residues, does not stop trimming peptides smaller than 
8-9 residues in length and its silencing only reduced overall MHC I expression 
by ~10% [56,65]. Additionally, the C-terminal editing of proteasome-produced 
peptide precursors can be performed by the carboxypeptidase angiotensin-
converting enzyme (ACE) in the ER [57].
Peptide precursors can also bind ER chaperones that protect them from degra-
dation [82,90]. The protein disulfide isomerase (PDI) appears to be the most 
efficient peptide-binding ER chaperone, as it binds to peptides of different 
length and sequence [91]. Peptides not bound either to ER chaperons nor to 
MHC I molecules, can be trimmed and destroyed by ERAP1/ERAP2 [92], or 
retrotranslocated back into the cytosol for ER-associated degradation (ERAD) 
[82]. In this way, they no longer compete for space in the local compartment. 
1.5.2.4 Peptide loading and presentation
The PLC orchestrates the final assembly of MHC I molecules with peptides 
(now 8-11 amino acids), delivered into the ER by TAP, for generation of stable 
MHC class I-peptide complexes [61]. The transfer of translocated peptides to 
peptide-receptive MHC I molecules is facilitated by 2 tapasin molecules that 
act as bridge. Tapasin interacts not only with TAP and ERp57, but also re-
cruits MHC I-β2m heterodimers and calreticulin to the PLC [17,93] (Figure 5). 
Moreover, tapasin plays a peptide-editing role, mediating the binding of high-
affinity peptides at the expense of low-affinity peptides, as shown in tapasin-
negative cells in which MHC I surface complexes are less stable [94]. A recent 
study using  -deficient mice has revealed that this enzyme plays a role in de-
fining the C-terminus of MHC I peptides [52], a function previously attributed 
to the proteasome [43]. Tapasin function is well complemented with that of 
the UDP-glucose-glycoprotein glucosyltransferase 1 (UGT1) enzyme, which 
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reglucosylates the heavy chain of MHC I molecules with suboptimal peptides, 
allowing reentry of the MHC I into the PLC and exchange for high affinity 
peptides [17,75,95]. Thus, the chief function of the PLC is to provide ‘quality 
control’ by selectively retaining MHC I molecules loaded with suboptimal pep-
tides for replacement by higher affinity peptides [74]. High-quality peptides 
that confer stability to the MHC I molecules share two important properties: 
the precise length and amino acid sequence required for a given MHC class I-
binding motif [74]. When any of the PLC constituents are missing or inhibited 
by viruses, intracellular MHC I molecules can suffer unfolding, degradation 
and indiscriminate peptide loading, all of which can compromise the stability, 
expression and function of MHC I-peptide complexes at the surface (see some 
exceptions in the next section) [74,88]. 
Successful peptide loading induces dissociation of the MHC I molecule from 
tapasin, removal of the glucose residue by glucosidase II and export of the 
MHC I-peptide complexes escorted by the tapasin-related protein (TAPBPR) 
[96] through the Golgi cisternae [61],. In the Golgi, suboptimally loaded MHC 
I molecules can be retrieved to the ER or be directed through the constitutive 
secretory pathway to the cell surface [39]. MHC I-peptide complexes segregate 
into peptide-specific clusters that have been associated with increased T cell 
sensitivity [97].
1.5.2.5 The end of MHC I life
Surface MHC I-peptide trimolecular complexes can be released through meta-
loprotease cleavage [98],  or be recycled via the endocytic pathway [16] (Figure 
6). A fraction of endocytosed MHC I molecules can be recycled after peptide 
exchange with high affinity endosomal peptides [16,99] (see next section). The 
proteins MARCH4 and MARCH9 have been shown to control the half-life of 
MHC I molecules through ubiquitination that promotes MHC I internalization 
and lysosomal degradation [100]. 
Peptide-free MHC I dimers are also recycled via the endocytic pathway [99]. 
Peptide-free MHC I heavy chains without or with very weakly bound β2m are 
known as open MHC I conformers and can result from dissociation of the 
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heterodimer caused by low-affinity peptides or acidic pH [99,101]. Empty MHC 
I heavy chains have a shorter half-life on the cell surface than trimeric MHC 
I-peptide complexes [99]. Empty MHC I heavy chains have been shown to inter-
act in cis and trans with various receptor molecules including those for insulin, 
interleukin 2 and growth factors [102]. 
1.5.3 Alternative MHC I antigen presentation pathways
The proteasome-TAP pathway is considered as the conventional processing 
route. However, MHC I peptide presentation can take place (albeit frequently 
modified) in the absence of one or more molecules of the pathway [103-105]. 
Viral evasion strategies targeting different stages of the antigen processing 
pathway have been very useful not only to understand the classical pathway, 
but also to elucidate non-traditional alternative pathways [106-108]. Moreover, 
polymorphisms in MHC I molecules not only result in different peptide-bind-
ing grooves, but can also affect aspects of the antigen processing such as MHC 
I assembly and the rate of transport to the cell surface [16,30,109,110]. Ac-
cordingly, studies using proteasome inhibitors have shown a variable effect 
on MHC surface expression depending on the HLA class I allomorph, suggest-
ing the existence proteasome-independent mechanisms for the generation of 
peptides that bind specific HLA I variants such as HLA-B27 [111,112]. Interest-
ingly, characterization of proteasome-independent ligands associated to HLA-
B27 has revealed that these peptides originate mostly from small and basic 
proteins and suggest the contribution of additional proteases [113]. 
Allelic variation in MHC I molecules also influences their dependence on tapa-
sin for peptide loading [103] and their association with TAP, calreticulin and 
the PLC [30,103,109,114-119]. Neisig and coworkers have tested the in vitro 
association of HLA-A, -B and –C heavy chains with TAP and demonstrated that 
most HLA-A and HLA-C alleles efficiently interacted with TAP, whereas the ma-
jority of HLA-B alleles showed inefficient association [114]. Additionally, HLA-
C molecules are more selective in their peptide binding than HLA-A and HLA-B, 
resulting in prolonged association with TAP [120]. This prolonged association 
has been proposed to explain the lower surface levels of HLA-C molecules in 
comparison to HLA-A and HLA-B molecules [120,121].
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The import of some peptides appears to be TAP-independent [122]. TAP-inde-
pendent peptides include peptides derived from signal sequences (or leader 
sequences) of certain ER-targeted proteins that are cleaved by signal peptide 
peptidases, can be further processed in the ER and bind particularly HLA-A2 
and HLA-B51 molecules [123-125]. However, it is unclear how the loading of 
these peptides occurs [105]. Interestingly, mutations in the TAP gene are re-
sponsible for HLA I deficiency in human subjects who manifest a reduced 
functional CD8+ population but nevertheless may appear asymptomatic for 
long periods of their lives [126,127]. Also, it has been demonstrated that the 
proteases furin and PC7, located in the trans-Golgi and/or endocytic vesicles 
network, can process some peptide epitopes from secretory proteins [127-
130]. 
There is a growing amount of evidence suggesting that there is a variety of 
alternative pathways for generation of MHC I peptides (Figure 7). For instance, 
autophagy, which is responsible for clearance of old or damaged cellular com-
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ponents, might contribute to the peptide repertoire [17,34,35]. During autoph-
agy, acidic double-membrane vacuoles (autophagosomes) target ubiquitylated 
cytoplasmic protein aggregates for degradation through fusion to lysosomes 
without involving the endocytic or vacuolar protein sorting pathways [35]. 
Autophagy has been shown to contribute to MHC I presentation of endog-
enous viral peptides in macrophages infected with Herpes simplex virus (HSV) 
[131,132].
1.5.3.1 Cross-presentation 
One of the most remarkable alternative MHC I presentation routes is the cross-
presentation (or cross-priming) pathway. Cross-presentation occurs routinely 
in APCs such as macrophages and DCs, in which exogenous proteins are inter-
nalized to generate antigens that are presented by MHC I molecules [35,133]. 
The display of exogenous peptides on MHC I molecules links the MHC I and 
II processing pathways and is important for effective immune responses to 
tumors and viral infections [134]. The molecular mechanisms of cross-pre-
sentation are not completely understood yet and many pathways have been 
described, including TAP-dependent and TAP-independent mechanisms, even 
though the former seem to dominate [17,35]. APCs can internalize antigens 
by endocytosis, phagocytosis, receptor-mediated endocytosis, pinocytosis and 
even gap-junctions [50]. Moreover, different intracellular compartments have 
been proposed for the loading of cross-presented peptides with MHC I mol-
ecules such as endosomes or phagosomes, the ER and lysosomes/vacuoles 
[135]. In either case, peptides in the phagosome destined to cross-presentation 
have to enter MHC I presentation before lysosomal degradation and before 
loading onto MHC II molecules [134]. Besides, cross-presentation routes seem 
to vary according to the maturation state and subset of APCs [136]. 
The two studied popular cross-presentation pathways are the phagosome-
to-cytosol pathway and the vacuolar pathway. In the phagosome-to-cytosol 
pathway, antigens need to be exported from the endosome or phagosome to 
the cytosol for proteasomal degradation and further processing via the ER 
and the classical pathway in a TAP-dependent manner [137,138]. It remains 
unclear yet how does the transport from the endocytic pathway to the cytosol 
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occur. Proposed mechanisms involve transient physical rupture or leaking of 
the endosomal membrane and the action of a specific channel or translocator, 
such as SEC61 or the ER translocon of the ERAD machinery resulting from ER-
phagosome fusion [35,129,139,140]. Alternatively, antigens might make use of 
an established retrograde pathway leading from endosomes to the ER via the 
Golgi. Form the ER, they may reach the cytosol using the translocation chan-
nel involved in retrotranslocation during protein degradation [140]. It has also 
been suggested that an alternative transport pathway (such as lipid droplets) 
could connect the phagosome and the ER without any direct ER-phagosome 
fusion [35].
In the vacuolar pathway, antigens are bound onto MHC I molecules within 
phagosomal compartments and thus outside of the ER. Indeed, internalized 
surface MHC I molecules can be present in phagolysosomal compartments 
[34,35,99]. The peptides are either processed in the cytosol (phagosome to cy-
tosol to phagosome model) or in the phagosome itself [34,50]. In either case, 
the phagosome needs to be equipped with molecules necessary for peptide 
loading onto MHC I molecules.
Internalized antigens can take many different forms, ranging from cell debris 
from apoptotic or necrotic cells to proteins or chaperone-associated peptides 
[140]. For instance, DCs can ingest infected non-immune cells, cancer cells or 
cell-derived fragments and generate antigens from these sources [141]. Also, 
exogenous proteins introduced directly into the cytosol of a cell are recog-
nized by CD8+ T cells [142]. This is the case of listeriolysin, a protein secreted 
by the intracellular pathogen Listeria monocytogenes after its internalization 
by macrophages [143]. The mannose receptor has been implicated in the inter-
nalization and routing of some antigens into a distinct endosome subpopula-
tion where they are protected from lysosomal degradation and can be further 
processed for cross-presentation [144]. This early endosome subpopulation 
do not mature to late endosomes, in which peptides are loaded into MHC II 
molecules. Besides, it has been shown that MHC I-peptides can be transferred 
from an infected cells to APCs through gap-junctions [145]. 
Internalized antigens can be processed (or destructed) by endosomal and ly-
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sosomal proteases. Mechanisms that reduce the activity of endosomal hydro-
lases in DCs have been shown to enhance the efficiency of cross-presentation 
[61]. Cathepsins have been involved in the generation of MHC I peptides in 
endolysosomal compartments in a proteasome- and TAP-independent manner 
[146]. Additionally, the insulin-regulated aminopeptidase (IRAP) exclusively 
trims peptides in endosomes for cross-presentation [56,135]. Proteases acting 
in the endogenous pathway are presumably also involved in the processing of 
ligands for cross-presentation [50]. 
Despite being less common, cross-presentation is essential to trigger immune 
responses to viruses that do not infect APCs such as Epstein-Barr virus (EBV) 
and hepatitis B virus [147]. Also, tumor antigens released from tumors can 
be cross-presented in draining lymph nodes and this property is boosted by 
chemotherapy and can lead to stimulation of antitumor immunity [134]. More-
over, cross-presentation allows CD8+ T cell recognition of antigens coming 
from tissues that do not express MHC I molecules, such as placental tropho-
blasts [148]. In this way, antigens of fetal origin can be presented by maternal 
APCs thus eliciting a maternal immune response to the fetus [148].  
1.6 The origin of MHC I-associated peptides
Peptides displayed by MHC I molecules derive from degradation of proteins 
acquired from an exogenous source (cross-presentation) or from proteins en-
dogenously synthesized (direct presentation) [37] (Figure 8). The complexity of 
the MHC I-immunopeptidome reflects the equally complex milieu of intracel-
lular proteins [37]. When and how intracellular proteins are chosen for entry 
into the antigen processing pathway? This is an interesting yet not completely 
solved question. What is now clear based on various studies including ours, 
however, is that the MHC I-peptide repertoire is not a random sample of the 
proteome. More details about this bias can be found in the section “The SMII 
is complex and is not a representative excerpt from the proteome” of our pub-
lished review article included in chapter 2 and in our published article “MHC 
I-associated peptides preferentially derive from transcripts bearing microRNA 
response elements“ included in chapter 3. In the following section, the mecha-
nisms by which endogenous proteins can give rise to peptides are described.
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1.6.1 Endogenous proteins as source of peptides
  
Most of the peptides destined for presentation on MHC I molecules are generat-
ed by proteasome-mediated cleavage of endogenous polypeptides [149]. How-
ever, the source of proteasomal substrate is quite varied. Peptide ligands for 
MHC I molecules can derive from the degradation of correctly folded “stable” 
proteins, defective ribosomal products (DRiPs), non-classical transcription or 
translation products or from proteins destined to the secretory pathway that 
are retrotranslocated from the ER to the cytosol (Figure 8). Identification of the 
primary source of MHC I-associated peptides has remained a very controver-
sial topic for years. The DRiPs hypothesis [150], which points rapidly degraded 
and defective proteins as the main source of MHC I-associated peptides, is cur-
rently the most popular yet controversial hypothesis. 
1.6.1.1 Rapidly versus slowly degraded polypeptides 
Proteins exhibit a wide range of degradation rates: from minutes to weeks, 
with an overall half-life of 1-2 days [151]. Polypeptides have been segregated 
Figure 8. Endogenous and exogenous sources of MHC I-associated peptides
Sources include (i) cytosolic proteins, (2) alternative translation products and 
DRiPs, (3) proteins retrotranslocated from the ER to the cytosol, (4) and (5) 
endocytosed proteins. Adapted with permission from [140].
DRiPs
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into two general pools: (i) those degraded with an average half-life of ~30 min-
utes, named rapidly degraded polypeptides (RDPs), and (ii) those degraded 
with an average half-life from hours to weeks (in average ~2000 minutes), 
referred to as slowly degraded polypeptides (SDPs) [151]. In mammalian cells, 
approximately 30% of total proteins correspond to RDPs [149].
1.6.1.2 The DRiPs hypothesis
If MHC I peptides derive exclusively from the degradation of proteins that are 
at the end of their functional lives, it would be expected that the time between 
the synthesis of a protein and the presentation of its peptides should reflect 
the half-life of the protein. Yewdell and coworkers pointed out that this rate 
is inconsistent with in vitro assays showing that cells become recognizable by 
CD8+ T cells soon after they are infected and thereby that peptide production 
must begin very shortly after protein synthesis [150]. In fact, one remarkable 
aspect of the antigen presentation pathway is the speed with which peptides 
can be generated following infection. 
Early experiments showed that expression in cells of unstable truncated pro-
teins generated MHC I-peptide complexes as effectively as full-length pro-
teins [17,152]. Consequently, Yewdell et al. proposed that immediate peptide 
supply is driven not by degradation of mature proteins but by newly synthe-
sized proteins that are defective, termed DRiPs [150] (Figure 9). DRiPs include 
polypeptides that fail to achieve its native structure, owing to imperfections 
in transcription, splicing, translation, alternative reading frame usage, post-
translational modifications or protein folding, and are flagged by the quality-
control machinery and rapidly degraded [72,150,153-156]. Accordingly, ~30% 
of all proteins made are immediately degraded after synthesis before forming 
functional proteins [149,157].
A significant proportion of peptides appear to result from the degradation of 
newly synthesized, but rapidly degraded polypeptides as opposed to slowly 
degraded polypeptides [149,157,159]. This is consistent with MS-based stud-
ies reveling the absence of correlation between the proteome and the MHC 
I-peptide repertoire of the same cell [160]. Accordingly, some MHC I peptides 
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derive from proteins that are undetectable in the cell [161,162]. It is still not 
clear what proportion of RDPs represents truly short-lived proteins and how 
much represents DRiPs. Strong evidence has been published supporting the 
idea that translation and protein folding must be error prone [61] and that 
newly generated polypeptides, including DRiPs, represent the main source of 
antigens entering the MHC I processing pathway [151,163]. Thus, it has been 
suggested that MHC I molecules preferentially sample what is being translated 
as opposed to what has been translated [157,161,164]. Therefore, the concen-
tration of peptides, which is related to the rate of protein synthesis, is the rate-
limiting step for MHC I-peptide presentation [16]. 
Some indirect evidence initially supported the DRiPs hypothesis. First, ear-
ly studies showed that mutant and misfolded proteins induced in the pres-
ence of certain compounds are immediately degraded after their synthesis 
[158,165,166]. Second, a considerable fraction of newly synthesized proteins 
is rapidly turned over. This fraction has been estimated to correspond to 30-
40% per hour [149]. Third, increasing the degradation rate of an antigen con-
siderably augments peptide production [167]. The DRiPs hypothesis was sub-
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Figure 9. The DRiPs hypothesis
Accumulated errors can lead to defective proteins that are target-
ed for rapid degradation with some products ultimately becoming 
MHC I-associated peptides. Adapted with permision from [158].
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sequently supported by studies showing that peptide production ceased 30 
minutes after inhibition of protein synthesis, suggesting that mature protein 
turnover is too slow to contribute significantly to the peptide pool [157,163]. 
It is not entirely clear what exact mechanisms drive DRiPs formation. Recent 
work from Fahraeus and coworkers points toward normal translational pro-
cesses such as the nonsense-mediated decay [168]. They demonstrated that 
an mRNA with a premature stop codon and degraded after a single round of 
translation, can generate an epitope efficiently recognized by T cells [168]. No-
tably, this process is distinct from typical translation as it is eIF4G-dependent 
and eIF4E-independent. Also, a recent study points toward hydrophobicity as 
a key signal for immediate degradation and consequently peptide presenta-
tion [169]. Presence of longer hydrophobic sequences such as transmembrane 
domains enhanced generation of MHC I-peptide complexes [169].  It has also 
been proposed that DRiPs are produced predominantly by ribosomes lacking 
associated chaperones that directly transfer DRiPs for proteasomal degrada-
tion [156]. This model extends the concept of the ‘‘immunoribosome’’, a ri-
bosome subset that exclusively and efficiently generates proteins targeted to 
antigen processing and that is distinct from ribosomes responsible for con-
ventional translation [151]. Accordingly, Apcher and coworkers demonstrated 
that the production of antigenic peptides and full length proteins do not occur 
at the same time and suggested that they could be produced by alternative 
ribosomal complexes [168]. In line with this, Eisenlohr and coworkers have 
suggested that most nascent polypeptides are not inherently defective as the 
linear sequence is correct, and that defectiveness might be considered to lie 
more with the ribosome and its associated chaperones [169]. 
Some aspects of the DRiPs hypothesis have been questioned [158]. First, a 
DRiP has not yet been conclusively identified nor produced [163,170]. Second, 
a window of 30 minutes for peptide production implies a very short half-life 
(15 minutes or less) for the substrates from which the peptides are derived 
and a fast disposal of defective proteins [72]. This seems not to be in line with 
current concepts of protein production and quality control arguing against 
the DRiPs model [158]. There is an ever growing list of ‘natively’ or ‘intrinsi-
cally’ unfolded proteins that bypass the quality control machinery and are not 
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degraded [158,171]. Additionally, many misfolded proteins can be rescued by 
prolonged interaction with heat shock proteins [172]. Accordingly, increased 
degradation is not always the fate of misfolded proteins as they can enter ag-
gregates that resolve very slowly or become candidates for ubiquitin-mediated 
autophagy and not proteasomal degradation [173]. The DRiPs model has also 
been called into question by evidence showing that newly synthesized poly-
peptides are mostly protected from proteasomal degradation during and im-
mediately after translation and that preexisting proteins represent the main 
proteasome substrates [159].
An alternative model not excluding the DRiPs hypothesis, proposes that a sub-
set of nascent polypeptides is neglected by the folding machinery and stochas-
tically delivered to the 20S proteasome independent of quality control deci-
sions [158]. For a given antigen, the basal level of peptide presentation from 
immediately degraded substrate by the 20S proteasome will be complemented 
by the subset of newly synthesized proteins that is successfully captured by 
the folding machinery [158]. According to this hypothesis, the more defective 
the protein is, the sooner and greater the presentation of the peptide will be, 
which is due to more rapid rejection by the quality control machinery [158]. 
1.6.1.3 Stable proteins as source of peptides
Long-lived intact proteins can also contribute to the peptide pool although pos-
sibly in a lesser extent [151]. MHC I-peptide ligands can be obtained from fold-
ed and functional proteins that have passed the quality control, as evidenced 
by presentation of several species of posttranslationally modified peptides 
[174]. Post-translational modifications evidenced in MHC I peptides include N-
glycosylation [175,176], cytosolic O-GlcNAc glycosylation [177], deamidation 
[175,178-181], methylation [182], acetylation [183], phosphorylation on serine 
and threonine residues [184-186] and cysteinylation [187,188].
1.6.1.4 Cryptic translation as a source of naturally processed peptides
In addition to conventional translation products, cells can also generate peptide 
ligands for MHC I molecules from cryptic translation products. Cryptic trans-
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lation refers to polypeptides that are synthesized by unconventional trans-
lational mechanisms [189]. These include peptides encoded by open reading 
frames (ORF) contained within 5’ and 3’ “untranslated” regions (UTR), alterna-
tive open-reading frames (ARF), introns, intron-exon junctions or from non-
AUG start codon initiation on both endogenous and viral mRNAs [189-191]. 
The list of MHC I-peptides derived from cryptic translation has been steadily 
growing and many examples of peptides of viral origin or in tumor cells have 
been described [189,192-194]. Some nonclassical peptides were found to arise 
from aberrant transcription of intronic sequences [195-197] or reverse strand 
sequences [198]. Others resulted from translation of UTRs [199] or of alterna-
tive open reading frames [20,200,201], even involving leucine-tRNA-mediated 
initiation of translation at a CUG codon, instead of classical AUG codon [202-
204]. Cryptic peptide also result from translational errors including ribosomal 
frameshifting whereby ribosomes may initiate at the primary ORF start co-
don but slip either forward or backwards and continue translation in an ARF 
[189,205]. Importantly, cryptic peptides can induce tolerance in transgenic 
mice that generate cryptic peptides, and elicit CD8+ T-cell responses in normal 
mice [206]. Overall, studies on cryptic peptides have shown that they are im-
munologically significant and can provide a protective role in viral infections 
[189].  
1.6.1.5 Peptides derived from peptide splicing
It has been reported that MHC I ligands can contain sequences not encoded in 
the genome. Reported examples include peptides derived from non-contigu-
ous sequences in the original protein and resulting from the splicing of neigh-
boring or non-contiguous peptides by the proteasome either in the initial or 
reverse order [179,207-211]. For instance, Vigneron and coworkers described 
an HLA-A32-associated nonamer that was derived from a 13 amino acid pre-
cursor by excision of 4 internal residues followed by splicing by the protea-
some [208]. Another example includes one peptide resulting from the splicing 
of two non-contiguous peptides from the same protein in the reverse order by 
the proteasome [210]. 
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1.6.1.6 Peptides derived from proteins destined to the secretory pathway
Secretory and membrane proteins are a known source of MHC I-peptides. Many 
peptides derived from transmembrane or secretory proteins correspond to se-
quences in the transmembrane regions or signal sequences [37]. In order to be 
degraded, these proteins have to exit the ER because there are no proteasomes 
present in the ER lumen [212]. Proteins destined to the secretory pathway can 
gain access to the cytosol after being retrotranslocated from the ER, in a pro-
cess that typically results in ubiquitination and proteasomal degradation via 
the ERAD pathway [176]. Generation of peptides via ERAD of glycoproteins 
was evidenced by the discovery of epitopes in which the asparagine residue 
(normally present in the source glycoprotein) was replaced by an aspartic acid 
residue. This deamidation of asparagine residues reflected the conventional 
deglycosylation step of glycoproteins in the cytosol that follow the ERAD path-
way [178,179]. 
1.7 The MHC I immunopeptidome: exposing the inside of the cell to the 
immune system
The repertoire of peptides presented by MHC I molecules, is collectively re-
ferred to as the MHC I immunopeptidome (for the sake of simplicity hereaf-
ter referred to as immunopeptidome) [213,214]. Different estimations have 
been made regarding the number of surface MHC I molecules per cell: 50,000-
100,000 [215], 30,000-120,000 [216], 10,000-500,000 [217] or at least 50,000 
[218], although these numbers may vary depending on the cell type and cell 
condition [219]. The immunopeptidome is estimated to be composed of more 
than 10,000 different complexes reflecting its high complexity [219]. Many 
peptides are present at one or less copies per cell [220,221] and most peptides 
are represented at 10-400 copies per cell [216]. Notably, a single viral peptide 
can be presented at 100,000 copies per cell [222]. Recent semi-quantitative 
MS-based studies have estimated that the number of peptide copies associated 
to intracellular HLA molecules varies from 1 to 16,500 copies per cell [218]. 
Notably, even a single MHC I-peptide complex may be sufficient to trigger a T 
cell [223,224].
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Here, a brief introduction of the immunopeptidome is presented and more de-
tails can be found in the published review article “Origin and plasticity of MHC 
I-associated self peptides” included in chapter 2.
1.7.1 Biological roles of the MHC I immunopeptidome
The primary function of the immunopeptidome is to present antigens to T-cell 
receptors and thus to provide protection against pathogens and neoplastic 
transformation [4]. In the absence of infection, cell surface MHC I molecules 
are associated solely with self-peptides that play vital and diverse roles [213]. 
The immunopeptidome shape the repertoire of developing thymocytes through 
regulation of positive and negative selection [225-227]. In addition, self MHC 
I-peptide complexes transmit survival signals to mature CD8+ T cells [228]. 
The immunopeptidome also allows immunosurveillance of neoplastic cells 
[229,230]. It reflects the state of the cell as mutations, or genes overexpressed 
in tumors modify and shape the self immunopeptidome [153,231,232]. 
Self MHC I-peptide complexes can also contribute to the recognition of nonself 
MHC I-peptide complexes by the TCR and in this way amplify T cell responses 
against intracellular pathogens [233]. Upon infection, the MHC I-peptide reper-
toire reflects not only the intracellular protein milieu but also additional pro-
teins such as those derived from intracellular pathogens [153,232,234,235]. 
Notably, viral infection can not only generate viral antigens, but it can modify 
the presentation of self MHC I-peptides and/or lead to the presentation of 
neo-self MHC I peptides [236,237], reflecting metabolic changes in the cell 
[238]. Altogether, these modifications render the otherwise invisible internal 
proteome available for surveillance by cytotoxic CD8+ T cells, which have the 
ability to detect and eliminate cells expressing viral proteins or tumor antigens 
[191].
MHC molecules also provide a link between the innate and the adaptive im-
mune systems. Changes in MHC I surface expression can be a sign of infection, 
cancer or invading cells from another person (e.g. pregnancy) [239]. Natural 
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killer (NK) cells monitor other cells for the quality and quantity of their MHC I 
expression through killer cell immunoglobulin-like receptors (KIRs) on their 
cell surface [239]. Interaction of KIRS with MHC I molecules at a site distant 
to the peptide binding groove provides positive or negative signals to NK cells 
through immunoreceptor tyrosine-based activating motifs (ITAM) or immu-
noreceptor tyrosine-based inhibitory motifs (ITIM) localized within KIR mol-
ecules [1,240,241]. In this way, immune evasion of a pathogen or a tumor cell 
that has downregulated MHC I antigen presentation, can be avoided [4,240]. 
Interestingly, inhibition of NK cells resulting from KIR recognition of MHC I 
molecules can be impaired by certain incompatible amino acids at positions P7 
and P8 of nonamer peptides bound to the MHC I, leading to NK cell activation 
[241].
The MHC I immunopeptidome is also involved in immunopathology.  It can 
be targeted by autoreactive T cells that initiate autoimmune diseases such as 
diabetes [242-245]. In addition, tumor-associated antigens can elicit paraneo-
plastic autoimmune disorders [246]. Moreover, MHC I-peptide complexes can 
be targeted by alloreactive T cells that cause graft rejection and graft-versus-
host disease following transplantation [247] (more details are given in chap-
ters 4 and 5). It has been recently shown that the drug abacavir used for the 
treatment of HIV, can affect the MHC I peptide repertoire through binding to 
one of the HLA-B*5701 pockets [248]. Also, inhibitors of the carboxipeptidase 
ACE are used to treat patients with hypertension and congestive heart failure 
and this enzyme has been shown to increase, decrease or have not effect on 
the surface expression of individual epitopes [57]. Thus, ACE inhibitors pre-
sumably change the peptide repertoire with potential consequences difficult 
to predict with our current knowledge.
The aforementioned roles of the immunopeptidome highlight its immuno-
therapeutic potential. In line with this, peptides overexpressed and/or spe-
cific to neoplastic cells can be used as targets in cancer immunotherapy 
[153,232,234,249,250], whereas viral antigens could be used in vaccination 
strategies against infections [251,252]. On the other hand, knowledge about 
the origin of viral or tumor-associated antigens could be exploited to induce 
immunity [253].
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Apart from its role in immune function, the MHC I-peptide repertoire has been 
shown to influence mating preferences and other behaviors in mice [254] and 
humans [255]. According to these studies males and females favor mates ex-
pressing dissimilar MHC molecules and females prefer males exhibiting MHC 
heterozygosity [255-257]. These observations could be related with a seminal 
work demonstrating that dissociated MHC I peptides (and not MHC I-peptide 
complexes) can activate sensory neurons in the vomeronasal organ, which is 
specialized in initiation of behavioral or endocrine responses in mice [254,258]. 
These studies have revealed that MHC genes play an essential role in determin-
ing individual differences and preferences in body smell [256]. Furthermore, 
MHC I molecules have been shown to participate in neuronal development and 
function and regulate synaptic plasticity in the hippocampus through recogni-
tion by non-TCR receptors [259]. 
All these examples illustrate the global role of the MHC I immunopeptidome 
in communicating the intracellular milieu to the surrounding environment 
[191,260].
1.7.2 Characterization of the immunopeptidome by mass spectrometry
The first attempts to characterize MHC I peptides were done by the group 
of Rammensee in 1990, who purified MHC I molecules from whole cells, ex-
tracted the bound antigens and fractionated them by high-performance liquid 
chromatography (HPLC). After analyzing the peptide mixture by Edman deg-
radation they discovered the presence of dominant amino acids that were de-
pendent on the MHC I molecule from which the peptides were isolated, i.e. the 
anchor residues of peptide-binding motifs [26,261,262]. These seminal studies 
were followed by the first characterization of MHC I peptides by HPLC and 
tandem mass spectrometry (MS) in 1992 performed by the groups of D. Hunt 
and V. Engelhard, who identified endogenous peptides bound to HLA-A*0201 
[220]. These studies significantly contributed to the understanding of the fac-
tors that control the binding of peptides to MHC I molecules and in conjunc-
tion with increasingly sensitivity of mass spectrometers, have prompted the 
large-scale identification of MHC I-peptides [16]. 
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MS has also enable to estimate the representation of individual peptides and 
the global complexity of the immunopeptidome [216]. Besides, MS-based stud-
ies have allow the identification of different types of peptides: tumor-asso-
ciated antigens [178,216,263], transplantation antigens (see chapters 4 and 
5), antigens derived from intracellular bacteria [264], antigens with posttrans-
lational modifications [174] and antigens associated to autoimmune disease 
[265]. In addition, studies of the immunopeptidome by MS under particular 
conditions such as absence of tapasin or TAP or variations of the proteasome, 
have contributed to the understanding of the antigen presentation pathway 
[19,48,108,123-125,216]. A review of large-scale studies aiming to characterize 
the immunopeptidome in different human and mouse cell types or tissues is 
shown in tables 1 and 2 of the published review article “Origin and plasticity 
of MHC I-associated self peptides” included in chapter 2.
  
Numerous strategies for qualitative and quantitative analysis of the immuno-
peptidome have been developed. These strategies require first the isolation of 
MHC I peptides, followed by their identification and their quantification [219] 
(Figure 10). 
Isolation of MHC I peptides can be performed by mild acid elution, immuno-
affinity purification or by using soluble MHC I molecules. Mild acid elution 
induces the dissociation of β2m, denaturation of the MHC and peptide disso-
ciation [101]. Mild acid elution of peptides from viable cells has the advantage 
Immunoaffinity
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Figure 10. Simplified flowchart of analysis of MHC 
I-associated peptides by MS
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of capturing peptides that are indeed exposed on the cell surface and that 
bind to all MHC I molecules with all ranges of affinities, but its main caveat is 
the elution of non-MHC contaminant peptides [101,219,266]. Immunoaffinity 
purification is a more targeted method in which the MHC I is immunoprecipi-
tated by affinity column from cell lysates and peptides are eluted with strong 
acid [267]. This is currently the most used method and although the isolated 
peptides are MHC-specific, the lysis detergent constitutes another source of 
contamination [219]. Moreover, the immunopurified peptides correspond to 
intracellular peptides and the isolated repertoire is influenced by the anti-
body’s affinity and availability for any given MHC allotype [219]. Consequent-
ly, peptides with strong binding affinity are favored [266]. The third isolation 
method is based on the transfection of cells with MHC molecules lacking the 
transmembrane domain [268-270]. These molecules are secreted and further 
purified by immunoprecipitation. This technique has the advantage of provid-
ing high amounts of peptides but its main disadvantage is the induction of 
non-physiological conditions since MHC overexpression could affect the qual-
ity and quantify of presented peptides [219]. Furthermore, it is only applicable 
to “transfectable” cell lines impeding its use in primary tissues [219]. A very 
recent approach by Admon and coworkers has combined immunoprecipita-
tion technique to analyze soluble MHCs. They have found that large amounts 
of soluble peptide-bound HLA molecules are present in the plasma of cancer 
patients and thus they have isolated the immunopeptidome from soluble plas-
ma MHC I molecules [271]. Notably, the peptide repertoire of soluble HLA was 
similar to that of membranal HLA, highlighting the potential of this approach 
in a clinical context [272]. 
Following peptide isolation, the peptide mixture is fractionated and peptides 
in each fraction are separated, ionized and analyzed by MS [273].
MS is a way to accurately measure the weight of a molecule, or more precisely 
its mass-to-charge ratio (m/z), using electromagnetic fields in a vacuum [273]. 
To do so, molecules must first be electrically charged and transferred into the 
gas phase by electrospray ionization, where the m/z ratio of molecules can 
be determined with different types of instruments (e.g. TOF, Orbitrap, etc). In 
addition to the exact mass of a peptide, the peptide sequence is determined 
by fragmentation of each peptide by collision with an inert gas (CID, collision 
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induced dissociation or HCD, high collision dissociation) [273]. This results in 
a list of m/z ratios for different fragments of each peptide, called an MS/MS 
(or tandem MS) spectrum. Peptides are very difficult to detect in very complex 
mixtures such as mixtures of MHC I-peptides and hence, peptides are sepa-
rated and ionized by HPLC coupled directly via electrospray to the mass spec-
trometer (LC-MS/MS) [214]. Because of the complexity of the eluted peptide 
sample mixture, an additional separation step such as strong cation exchange 
(SCX) is performed before the analysis to enrich a specific peptide population 
[273,274]. The measured fragment spectra and peptide masses are matched 
against protein databases using search engines (e.g. SEQUEST, MASCOT, etc.) 
[219].
Several MS techniques can be used to do an absolute or relative quantification 
of MHC I peptides [216]. For instance, a relative quantification can be made by 
measuring the intensity of detection of a given peptide, which is an estimate 
of its abundance. Peptide intensities can be compared for each peptide in two 
different samples analyzed in the same run and in this way detect changes in 
peptide abundance [48,232,260]. Absolute quantitation (i.e. number of pep-
tide copies per cell) is made by comparing the abundance of isolated peptides 
to known amounts of their corresponding isotopically-labelled versions. More 
details on MS-based approaches to quantify and analyze MHC I peptides can 
be found in [274].
1.7.3 Immunoinformatics and prediction of the immunopeptidome
Advances in mass spectrometry have allowed the identification of increasingly 
number of peptides and hence a better characterization of peptide-binding 
motifs specific for most common HLA molecules [219,220,275,276]. Informa-
tion on peptide-binding motifs as well as the precise amino acid sequence for 
MHC I-peptides characterized so far, is readily available in public databases 
such as the immune epitope database (IEDB) [277] and the SYFPEITHI database 
[28]. The progress in MHC I peptide discovery and in unraveling peptide pro-
cessing has prompted the development of prediction algorithms for antigen 
processing [278-280], peptide binding to MHC molecules [281-285] and inter-
action between MHC I-peptide complexes and the TCR [286,287]. In particular, 
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MHC I binding prediction algorithms have been shown to be very accurate and 
have facilitated the characterization of the immunopeptidome [276,283,288].
 
1.8 Objectives
The ensemble of MHC I peptides or MHC I immunopeptidome presented on 
the surface of a cell establishes its immunologic identity (chapter 2). The self 
MHC I immunopeptidome regulates all key events during the lifetime of classic 
adaptive CD8 T cells: positive and negative selection in the thymus and sur-
vival in the periphery. Eventually, CD8T cells detect and/or react to changes 
in the self immunopeptidome and to non-self or transformed self MHC I pep-
tides (chapter 2). Moreover, MHC I peptides are the targets of several immune 
reactions including autoimmunity, graft rejection, graft-vs-host disease and 
antitumor activity (chapter 4). Despite the important role of the MHC I immu-
nopeptidome in defining the self-nonself boundary in health and disease, we 
know little about its biogenesis. 
Recent progress in high-throughput mass spectrometry analyses of the immu-
nopeptidome has remarkably contributed to defining the molecular definition 
of self for CD8 T cells (chapter 2). Nevertheless, current MS approaches are 
still blind to MHC I peptides resulting from non-synonymous genomic poly-
morphisms, known as MiHAs. MiHAs are the targets of nonself-driven immune 
reactions of great importance in clinical transplantation. The identification of 
MiHAs is technically challenging and no more than 30 MiHAs were known at 
the beginning of this work despite the vast number of genetic polymorphisms 
present in the human population. Therefore, we were particularly interested 
in implementing high-throughput mass spectrometry combined with other 
“omic” approaches to study the biogenesis and composition of the human 
MHC I immunopeptidome and to discover MiHAs.
1.8.1 Research questions and hypothesis
A variety of molecular players and numerous steps at all functional genomic 
levels (e.g. genome, transcriptome, proteome, degradome) underlie the gen-
eration of MHC I peptides and thus have the potential to shape the MHC I im-
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munopeptidome. Moreover, a major proportion of MHC I-peptides is believed 
to derive from the rapid degradation of defective ribosomal products (DRiPs), 
whose physical nature remains unclear. This complexity and recent studies 
showing a minimal correlation between the proteome and the immunopep-
tidome of the same cell, support the hypothesis that the MHC I immunopep-
tidome is not a stochastic representation of the cellular proteome and that 
some intrinsic factors may favor the presentation of some self peptides with a 
particular origin over others.
Of note, we performed data-driven (as opposed to purely hypothesis-driven) 
studies to address two main questions:
•	 Which cell intrinsic factors play a role in defining the MHC I immu-
nopeptidome?
•	 What is the impact of genomic polymorphisms on the human MHC I 
immunopeptidome?
1.8.2 General objective
The main goal of this work was to unravel the biogenesis and composition of 
the MHC I immunopeptidome of human B lymphoblastoid cell lines by means 
of systems biology approaches.
1.8.3 Specific objectives
Aim 1 : To characterize the global landscape of the MHC I-peptide repertoire 
of two pairs of MHC-identical siblings and to gain insights into the MHC I im-
munopeptidome biogenesis (chapter 3).
Aim 2 : To discover the impact of non-MHC polymorphisms on the immuno-
peptidome of two MHC-identical siblings. In other words, we wished to eluci-
date the relation between the genomic self and the immune self (chapter 5). 
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1.9 Cellular model
We studied the MHC I immunopeptidome presented by human EBV-infected 
B lymphocytes (B-LCLs). B-LCLs were derived from peripheral blood mono-
nuclear cells (PBMCs) purified from the blood of four subjects. EBV infec-
tion of normal human B cells generally results in the establishment of au-
tonomously proliferating lymphoblastoid cell lines. We used B-LCLs because 
they can be obtained from practically any subject, they proliferate exten-
sively in vitro, express high levels of MHC I molecules at the surface and 
have been shown to be a reliable tool for high-throughput genomic studies. 
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2.1 Abstract
Endogenous peptides presented by MHC I molecules represent the essence 
of self for CD8 T lymphocytes. These MHC I peptides (MIPs) regulate all key 
events that occur during the lifetime of CD8 T cells. CD8 T cells are selected 
on self-MIPs, sustained by self-MIPs, and activated in the presence of self-MIPs. 
Recently, large-scale mass spectrometry studies have revealed that the self-
MIP repertoire is more complex and plastic than previously anticipated. The 
composition of the self-MIP repertoire varies from one cell type to another and 
can be perturbed by cell–intrinsic and –extrinsic factors including dysregula-
tion of cellular metabolism and infection. The complexity and plasticity of the 
self-MIP repertoire represent a major challenge for the maintenance of self 
tolerance and can have pervasive effects on the global functioning of the im-
mune system.
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2.3 Background
Self/non-self discrimination is a fundamental requirement of life. All organ-
isms rely on their capacity of self/nonself discrimination to detect and reject 
allogeneic cells and microbes. While unicellular eukaryotes primarily employ 
self/nonself discrimination to avoid self-mating and germline parasitism, mul-
ticellular organisms use self/nonself discrimination primarily in immune de-
fense [1, 2]. In a remarkable example of convergent evolution, agnathans and 
jawed vertebrates have evolved adaptive immune systems based on somati-
cally diversified and clonally expressed Ag receptors [3, 4]. By allowing genera-
tion of exceedingly diversified repertoires of Ag receptors, somatic diversifica-
tion conveys a decisive advantage in recognition of nonself. However somatic 
diversification comes at a price: some Ag receptors on adaptive lymphocytes 
happen to be self-reactive [4]. Therefore, while failure to respond to nonself 
can lead to death from infection, untoward adaptive immune response to self 
paves the way to autoimmunity. Furthermore, recognition of self has a perva-
sive influence on the development and function of the immune system because 
the adaptive lymphocytes of jawed vertebrates are eminently self-referential: 
they are selected on self-molecules, sustained by self-molecules, and activated 
in the presence of self-molecules [5, 6]. This raises the fundamental question: 
what is the molecular definition of self for the adaptive immune system? We 
will focus herein on the self recognized by CD8 T cells because recent large-
scale (-omic) studies have yielded unprecedented insights into its genesis, mo-
lecular composition and plasticity [7-30] (Tables 1 and 2). 
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Table 1. MS-based studies of human MIPs
Cell line/ Tissue Origin MHC molecules Reference
Panc-1 Pancreas HLA-A02/11, B38/38, 
Cw12/12
[19]
MCF-7 Breast cancer HLA-A02/02, B18/44, 
Cw05/05
[19]
PC3 Prostate cancer HLA-A2, B7 [7]
UCI-107, UCI-101 Ovarian cancer HLA-A2, B7 [7]
MDA-231, MCF-7 Breast cancer HLA-A2, B7 [7]
C1R B cell leukemia HLA-A2, B7 [7]
Fresh plasma Healthy donors 
and MM, AML and 
ALL patients
Many [23]
HeLa Cervical cancer HLA-B27 [24]
SW-1353, 
C-20/A4 
Chondro- sarcoma 
and immortalized 
chondrocytes)
HLA-B27 [24]
UCI-107 Ovarian cancer HLA-Cw4 [24]
MDA-231 Breast cancer HLA-Cw4 [9]
K562 Myelogenous leu-
kemia
HLA-B*3501, 3502, 3503, 
3504, 3506, 3508
[16]
Central nervous 
system  
Brain autopsy 
samples of pa-
tients with mul-
tiple sclerosis
HLA-A01/02/03/11/25/30/68, 
B07/08/14/15/18/35/44/51, 
Cw-03/04/05/07/08
[22]
MCF-7, MDA-
MB-231, and 
BT-20
Breast cancer HLA-A*0201 [17]
MCF10A Breast mammary 
gland
HLA-A*0201 [17]
HIV-infected and 
uninfected Sup-
T1 cells
Lymphoma, T cell HLA-B*0702 [8]
721.221 EBV-transformed 
B lymphoblasts
HLA-B*1801 [10]
Colon carcinoma Colon carcinoma HLA-A01/68, B08/44 [11]
Colon tissue Normal colon HLA-A01/68, B08/44 [11]
Awellis EBV-transformed 
B lymphoblasts
HLA-A*0201/0201, HLA-
B*4402/4402
[11]
UCI-107 Ovarian cancer HLA-A02 [12]
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SKOV3-A2,  OV-
CAR3
Ovarian cancer HLA-A2/3/29/68, 
B7/18/35/58
[15]
CRL-5865 Human lung ad-
enocarcinoma
HLA-A02, B35/50 [26]
CRL-5944 Human lung ad-
enocarcinoma
HLA-A2/32, B14/51 [26]
Normal and 
neoplastic renal 
tissue
Surgical biopsies HLA-A01/02/03, B07/08/50, 
Cw06/07
[21]
Influenza A vi-
rus- infected and 
uninfected HeLa 
cells
Cervical cancer HLA-A*0201 [25]
Normal and 
neoplastic renal 
tissue
Surgical biopsies HLA-A02/03/68, B07/18/27/
B57
[14]
TAP1/2–deficient 
and –sufficient 
cell lines 
EBV-transformed 
B lymphoblasts
HLA-A02 [18]
DM331 and SLM2 Melanoma HLA-A*0201 [13]
COV413 Ovarian carci-
noma
HLA-A*0201 [13]
B lymphoblasts EBV-transformed 
B lymphoblasts
HLA-A*0201 [13]
MM: multiple myeloma; AML: acute myeloid leukemia; ALL: acute lymphoblastic leu-
kemia; EBV: Epstein-Barr virus
Table 2. MS-based studies of mouse MIPs
Cell line/ Tissue Origin MHC molecules Reference
Bone-marrow-de-
rived dendritic cells
C57BL/6 mice, Lmp7-/-
Mecl1-/- mice
H2Kb, H2Db, Qa1, Qa2 [29]
Fresh splenocytes C57BL/6 mice H2Kb, H2Db [20]
Fresh thymocytes C57BL/6 mice H2Kb, H2Db, Qa1, Qa2 [28]
EL4 Thymoma cell line H2Kb, H2Db, Qa1, Qa2 [28, 30]
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2.4 The nature and role of the immune self recognized by CD8 T cells
The TCR of classic adaptive CD8 T cells recognizes MHC I-associated pep-
tides (MIPs). MHC I genes are polygenic, extremely polymorphic and represent 
the most conserved MHC genes [31]. In most modern human populations, the 
majority of MHC I alleles have been acquired by introgression from archaic 
humans (Neanderthals and Denisovans) [32]. Under steady state conditions (in 
the absence of infection), all MIPs derive from endogenous self proteins: these 
MIPs are referred to as self MIPs or the self MHC I immunopeptidome (SMII) 
[33, 34]. Upon infection, pathogen derived nonself MIPs become the proverbial 
needle in the haystack (of self MIPs) against which the immune system must 
quickly respond. Self MIPs constitute the essence of self for classical adaptive 
CD8 T cells. The SMII regulates all key events that occur during the lifetime of 
CD8 T cells: positive and negative selection in the thymus and survival in the 
periphery [35-37]. The role of the SMII is not limited to orchestration of CD8 
T-cell development and homeostasis. Constitutive expression of self MIPs al-
lows CD8 T cells to monitor expression of neo-self MIPs on neoplastic cells and 
to behave as an extrinsic tumor suppressor system [38, 39]. Furthermore, evi-
dence suggests that self MIPs excreted in body fluids act as chemosensory sig-
nals for neurons in the vomeronasal organs and may thereby influence mate 
selection and social behaviours in several vertebrates [40-42]. 
The MHC complex contains multiple MHC I loci that belong to two major class-
es: modern classical MHC Ia genes (e.g., HLA-A,-B,-C in humans) and more an-
cient MHC Ib genes (e.g., HLA-E and -G) [43]. MHC Ib are oligomorphic, some 
but not all present MIPs, they are involved in several immune and non-immune 
processes but are less important in adaptive immunity than MHC Ia genes [43]. 
In the present review, we will focus on MHC Ia genes which play a dominant 
role in adaptive immunity [44]. All MHC Ia allelic products bind MIPs and MHC 
Ia genes are the most polymorphic genes known [45]. In humans, HLA-B, with 
its 1,605 alleles, is the most polymorphic gene of the entire genome (http://
www.ebi.ac.uk/imgt/hla/stats.html). MHC Ia molecules have a peptide binding 
groove containing in general 6 pockets; the size, shape and electrochemical 
properties of these pockets determine the peptide-binding motif of each MHC 
I allelic product [46]. The combination of polygenicity and polymorphism has 
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two important consequences: it ensures that each individual will be able to 
present a broad range of MIPs and that populations will consist of individuals 
presenting different MIP repertoires [27]. Hence, in outbred animals, individu-
als present different SMII and consequently different T-cell repertoires. As a 
corollary, susceptibility to a variety of infectious and autoimmune diseases is 
dictated by the MHC I genotype because it regulates the ability to present and 
respond to various self and nonself MIPs [47-52].
2.5. A synopsis of MHC I processing – making the most out of misbe-
gotten polypeptides
The general mechanisms of MIP genesis and presentation have been elucidated 
by extensive studies on microbial Ags and model Ags such as ovalbumin [53-
56]. The molecular composition of the SMII is intertwined with protein me-
tabolism and is ultimately shaped by two processes: protein translation and 
degradation [54, 57]. Hence, generation of MHC I-associated peptides ceases 
abruptly in the presence of molecules that inhibit protein synthesis or protea-
some function [58-61]. In brief, MIP genesis begins with polypeptide degrada-
tion by the proteasome in the cytosol and nucleus [53]. Peptides generated by 
proteasomal digestion are then exposed to several peptidases [62, 63]. These 
peptides have only a few seconds to bind to the transporter for antigen pro-
cessing (TAP; an heterodimeric peptide transporter located in the endoplasmic 
reticulum and Golgi), and thereby escape total digestion [54]. TAP-bound pep-
tides are translocated into the endoplasmic reticulum or the Golgi where they 
can be further trimmed by aminopeptidases [55, 64]. Peptides of appropriate 
length (8-11 mers) which are able to bind MHC I allelic products expressed by 
the cell can then be inserted into MHC I proteins by the MHC I loading complex 
and exported at the cell surface [65]. Large-scale MS studies have established 
the major impact of several components of the MHC I processing pathway on 
the MIP repertoire [18, 66].
Only a small proportion of peptides derived from proteasomal digestion be-
come MIPs: a cell generates approximately 2 million peptides per second, but 
only 150 are presented by MHC I molecules at the cell surface [54]. Perhaps the 
most salient feature of MIPs is that they derive mainly from defective ribosom-
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al products (DRiPs), that is, polypeptides that fail to achieve native structure 
owing to imperfections in transcription, translation, post-translational modi-
fications or protein folding [54, 67-70]. Several MIPs have been shown to origi-
nate from mRNAs that do not yield native full-length proteins [71, 72]. While 
the mean half-life of native (well structured and folded) proteins is about 24 
h, that of DRiPs is about 10 min. Using DRiPs as a source of MIPs provides a 
mechanism for monitoring the expression of  25% of cellular proteins that 
are targeted to the secretory pathway: cell surface or secreted proteins are 
degraded by extracellular proteases but their DRiPs are degraded by the pro-
teasome and can therefore be inserted in the SMII. While compelling evidence 
suggests that DRiPs are the main source of MIPs, two basic questions have yet 
to be elucidated. First, why are DRiPs more successful than other polypep-
tides in generating MIPs? Perhaps because MIPs originate preferentially from a 
subset of ribosomes (immunoribosomes) that would possess specific features 
such as a high DRiP rate, lack of chaperones or tethering to TAP (which would 
couple translation to entry in the MHC I processing pathway) [73-75]. Second, 
what is the physical nature of DRiPs? In theory, DRiPs may include miscoded 
or misfolded proteins, premature translation-termination products, polypep-
tides produced by non-conventional translation mechanisms or intrinsically 
disordered proteins [74]. Studies on cells transfected with shRNA or mRNAs 
carrying premature stop codons have revealed that the nonsense-mediated 
decay pathway is a source of both DRiPs and MIPs [72, 76]. However, in the 
absence of large-scale study of “natural” MIPs, the physical nature of self MIPs 
remains elusive.
2.6 Different types of proteasomes generate different MIP repertoires
All eukaryotes possess constitutive proteasomes (CPs) whose 20S proteolytic 
core is hollow and provides an enclosed cavity open at both ends in which pro-
teins are degraded [77]. The 20S particle is composed of 14 different subunits 
organized in a barrel-shaped complex with the stoichiometry α7β7β7α7. Three 
subunits of the two inner β-rings (β1, β2, and β5) participate directly in pep-
tide bond cleavage. Jawed vertebrates also express immunoproteasomes (IPs). 
In IPs, the three catalytic β-subunits expressed in CPs are replaced by three 
IFN-γ–inducible homologues (immunosubunits): low molecular weight protein 
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(LMP)-2 (or β1i) for β1, multicatalytic endopeptidase complex–like (MECL)-1 (or 
β2i) for β2, and LMP7 (or β5i) for β5 [78]. Under steady-state conditions, IPs are 
expressed at high levels in some cell types (e.g., thymocytes and DCs) but in 
low amounts in other cell types [79]. IFN-γ secretion enhances IP biogenesis 
in all cell types [80]. The overall impact of IPs on the SMII was assessed by 
comparing MIPs present on primary DCs obtained from either wild type (WT) 
or Mecl1-/-Lmp7-/- (dKO) mice [29]. Out of 417 MIPs eluted from WT DCs, 212 
were expressed at similar levels on dKO DCs. However, 199 peptides were 
overexpressed in WT relative to dKO DCs. Among those 199 peptides, 60 were 
detected exclusively in WT DCs. Only 6 peptides were slightly overexpressed 
(3 to 5-fold) in dKO relative to WT DCs and none were unique to dKO DCs. 
Consistent with these findings, expression of cell surface H2Db and H2Kb was 
decreased by 2-fold on dKO relative to WT DCs [29, 81]. Furthermore, follow-
ing immunization with WT DCs, both dKO and Lmp7-/- mice generated WT-
specific cytotoxic T cells whereas WT mice did not generate cytotoxic effectors 
against Lmp7-/- or dKO cells [29, 82] Therefore the presence of IPs has a major 
impact on the SMII, by increasing both the abundance and the diversity of 
MIPs. There are however rare exceptions to this rule since IPs have been shown 
to destruct several tumor-associated Ags that can be produced by CPs [83]. In 
particular, CPs are more effective than IPs for generation of spliced MIPs [84, 
85]. It should be noted that generation of MIPs is not the sole function of IPs. 
Indeed, IPs have non-redundant effects on gene expression and protein ho-
meostasis that are probably of considerable biological relevance [29, 86, 87].
The most recently discovered proteasome subunit is being at the origin of a 
fascinating story. Murata and colleagues found that cortical thymic epithelial 
cells (TECs) express a unique variety of proteasome, called the thymoprotea-
some (TP) [88]. The catalytic subunits of TPs are β1i, β2i and β5t. β5t (encoded 
by the Psmb11 gene) is found exclusively in cortical TECs [88]. Cortical TECs 
from Psmb11−/− express normal amounts of MHC I at the cell surface and 
contain IPs rather than TPs. However, Psmb11−/− mice are unable to support 
positive selection of most polyclonal and TCR-transgenic CD8 T cells [89]. 
Furthermore, Psmb11−/− CD8 T cells are defective in mounting immune re-
sponses to allogeneic and viral antigens [89]. Together, these studies provide 
compelling, though indirect, evidence that cortical TECs express a unique set 
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of MIPs that are essential for positive selection of classic TCRαβ CD8 T cells. 
The global impact of TPs on the MIP repertoire of cortical TECs has yet to be 
evaluated. Nonetheless, in vitro activity-based profiling studies suggest that 
β5t has a substrate preference distinct from β5 and β5i [90]. 
2.7 The SMII is complex and is not a representative excerpt from the 
proteome
A typical cell expresses about 105 MHC I molecules. What is the breadth and 
nature of their peptide repertoire? Currently, this question can be answered 
only by mass spectrometry (MS) analyses of MIPs. Progress in this field has 
been heralded by the development of MS instruments whose sensitivity, dy-
namic range and mass accuracy are orders of magnitude superior to those 
of analyzers available a decade ago [91-93]. State-of-the-art MS instruments 
can sequence low femtomole amounts of peptides and have greatly facilitated 
high-throughput analyses of MIPs. MS can provide absolute peptide quanti-
tation (i.e., number of peptide copies per cell) by comparing the abundance 
of endogenous MIPs to known amounts of their corresponding isotopically-
labeled counterparts. However, given the considerable complexity of the SMII, 
this effort has been largely undermined by the sizable peptide synthesis chal-
lenges needed for absolute quantitation of SMII components. Most quantita-
tive proteomics analyses have therefore focused on the relative quantification 
of MIPs in different samples [27]. 
Theoretical estimates suggest that the SMII accommodates only a small por-
tion of the proteome. Thus, a typical cell (human leukocytes for instance) ex-
presses about 18,000 different proteins [94] with a mean length of 466 amino 
acids [95] (containing 458 potential nonamers) and would therefore contain 
over 8 x 106 distinct nonamers (the mean length of MIPs). Furthermore, by 
adding peptides generated by translation of alternate reading frames or post-
translational modifications [71, 96-103], the total number of nonamers is 
probably greater than 107. On the other hand, MS analyses suggest that the 
number of distinct MIPs present at the cell surface is about 104 [27, 104]. This 
would mean that the SMII comprises about 0.1% (104/107) of the polypeptide 
sequences found in the proteome. Does the SMII derive essentially from highly 
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abundant proteins? Milner et al. performed MS analyses of MIPs eluted from a 
tumor cell line transfected with an expression vector coding soluble secreted 
HLA-A2.1 (lacking a functional transmembrane domain) to evaluate the rela-
tionship between protein abundance and the SMII [12]. Remarkably, they only 
found a minimal correlation (about 6%) between the amounts of MIPs and the 
relative abundance of their source protein: a large proportion of MIPs derived 
from low abundance proteins, and many highly abundant proteins did not 
generate MIPs in detectable amounts [12]. In order to evaluate the identity 
and properties of proteins that generate MIPs, Hickman et al. sequenced by 
MS over 200 MIPs derived from a B cell line engineered to secrete soluble 
HLA-B*1801 This seminal study showed that MIPs derive from a wide variety 
of proteins coded by genes located on all chromosomes [10]. Consistent with 
subsequent reports, MIP source proteins were distributed in all cell compart-
ments but showed a significant enrichment in intracellular relative to extracel-
lular proteins [10, 28, 105]. These and other high-throughput studies provided 
direct evidence that the SMII is complex [10, 12, 14, 28-30]. The poor correla-
tion between the proteome and the SMII can be rationalized by the DRiP model 
[12]. Almost all protein species have two half-lives: a longer one for the well-
conformed native protein and a short one for DRiPs. While the proteome es-
sentially contains native proteins, MIPs originate mostly from DRiPs [54, 67]. It 
is therefore assumed that proteins have different DRiP rates and that self MIPs 
originate mostly from proteins with high DRiP rates [106, 107]. 
2.8 The SMII conceals a tissue-specific signature
High-throughput MS-based analyses of self MIPs eluted from primary mouse 
thymocytes revealed that the SMII is molded by the transcriptome. In thy-
mocytes, the percentages of transcripts expressed at high/intermediate/low 
levels were 9/29/62 for total mRNAs and 42/38/20 for those coding for MIPs 
[28]. Hence, even though some low abundance transcripts can generates MIPs, 
the SMII is biased toward MIPs translated from highly abundant mRNAs. This 
concept was confirmed in a bioinformatic study of the expression profile of 
transcripts coding for MIPs listed in the SYFPEITHI database [108]: out of the 
2.5% most abundant mRNAs expressed in a pool of hematopoietic tissues, 41% 
encoded MIPs [105]. The correlation between mRNA abundance and MIP abun-
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dance is consistent with evidence that the rate of translation initiation directly 
correlates with MIP presentation [58, 61]. As a corollary, since abundance of 
discrete mRNAs varies among different cell types, different tissues should 
display different SMIIs. This assertion was evaluated by comparing the SMII 
of primary thymocytes and myeloid dendritic cells (DCs) from C57BL/6 mice. 
Since MHC I molecules are more abundant on DCs than on thymocytes, more 
MIPs were eluted from DCs than from thymocytes. Nonetheless, the key find-
ing was that over 40% of MIPs were cell type specific [29]. The MIP repertoire 
of myeloid DCs was enriched in peptides encoded by genes regulating protea-
some function, myeloid differentiation and TLR signaling. In thymocytes, MIP 
source genes were biased toward cell cycle regulation, purine metabolism and 
tight junction formation. The fact that a substantial proportion of self MIPs 
are cell type-specific increases the complexity of the immune self at the organ-
ismal level. 
2.9. Neoplastic transformation has a broad impact on the SMII 
Neoplastic transformation perturbs the two key processes that mould the SMII: 
protein translation and proteasomal degradation [109, 110]. With hindsight, 
MIPs expressed exclusively or at increased levels on tumor cells (tumor-asso-
ciated MIPs) were therefore bound to exist. Over the last two decades, numer-
ous tumor-associated MIPs have been molecularly defined and many of them 
were shown to be immunogenic for CD8 T cells [111, 112]. Tumor-associated 
MIPs are encoded by a variety of mutated and non mutated genes. A well cu-
rated and up-to-date database on human tumor-associated MIPs can be found 
at http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm. The 
majority of tumor-associated MIPs were discovered using biased approaches 
targeting principally oncogenes and other genes overexpressed in cancer cells. 
Recently, two studies have used unbiased large-scale MS-based strategies to 
evaluate more globally how neoplastic transformation impinges on the SMII 
[14, 28]. Though the experimental design of these studies was different, they 
yielded strikingly concordant results. Weinzierl et al. evaluated the relative 
abundance of MIPs isolated from three human renal cell carcinomas and au-
tologous normal kidney tissue. They sequenced a total of 273 MIPs, of which 
45 (16%) were differentially expressed on neoplastic relative to normal kidney 
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tissue: 30 MIPs were more abundant on tumor tissue (including 10 MIPs found 
only in carcinoma cells) and 15 MIPs were more abundant on normal tissue 
[14]. Fortier et al. compared the SMII of normal vs. neoplastic C57BL/6 mouse 
thymocytes. Out of 196 MIPs, 43 (22%) were differentially expressed: 21 MIPs 
were more abundant on tumor cells (including 9 tumor-specific MIPs) while 22 
were more abundant on normal thymocytes [28]. Tumor-associated MIPs are 
of prime interest, mainly for two reasons: they represent potential targets in 
cancer immunotherapy and they can elicit paraneoplastic autoimmunity [113, 
114]. Notably, in both renal carcinoma and thymoma cells, changes in the SMII 
induced by neoplastic transformation did not correlate closely with changes 
in the transcriptome [14, 28]. Thus, for 74% of thymoma-associated MIPs, in-
creased peptide abundance did not correlate with increased mRNA levels [28]. 
Two conclusions can be drawn from these two studies. First, neoplastic trans-
formation has a broad impact on the SMII as it led to differential expression of 
about 20% of self MIPs. The breadth of this impact is commensurate with the 
profound perturbations in protein metabolism that characterize cancer cells 
[38]. Second, global changes in the SMII can be detected only by MS-based ex-
pression profiling approaches and cannot be inferred from mRNA expression 
levels. As a corollary, we infer that genesis of tumor-associated MIPs involves 
mainly posttranscriptional mechanisms that have yet to be characterized. 
Cells release low amounts of soluble HLA molecules into the blood. Remark-
ably, Admon’s team recently demonstrated that MS analyses of the SMII bound 
to plasma soluble HLA molecules allowed identification of tumor-associated 
MIPs in subjects with leukemia or multiple myeloma [23]. MS analyses of the 
plasmatic SMII may hold considerable potential for diagnosis and monitoring 
of various illnesses.
2.10 Viral infection causes presentation of cryptic self MIPs
Alike neoplastic transformation, intracellular pathogens drastically impinge 
on the synthesis and degradation of host cell proteins [115, 116]. This led Hil-
debrand’s group to test whether viral infection might lead to presentation of 
neo-self MIPs. To this end, they analyzed HLA-B*0702-bound peptides extract-
ed from a cell line infected or not with HIV-1 [8]. MS analyses led to the iden-
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tification of 15 MIPs unique to or upregulated on HIV-1 infected cells. These 
MIPs derived from a variety of proteins: chaperones, proteins involved in RNA 
transcription or translation, and components of the ubiquitin-proteasome sys-
tem. The abundance of transcripts coding for MIPs unique to or upregulated 
on infected cells was not significantly increased. Thus, differential MIP presen-
tation was likely due to posttranscriptional mechanisms [8]. More recently, MS-
based comparison of HLA-A*0201-transfected HeLa cells infected or not with 
influenza A virus identified 20 MIPs unique to infected cells [25]. One salient 
implication emerges from these studies: infected cells present two classes of 
neo-MIPs to the immune system, some derive from the pathogen others from 
the host. The appearance of neo-self MIPs on infected cells raises the possibil-
ity that the SMII might conceal a molecular signature of host proteins hijacked 
by the virus.
2.11 The SMII conveys to the cell surface an integrative view of cellular 
regulation
While neoplastic transformation and infection are relatively rare events, cells 
are constantly subjected to variations in nutrients and growth factors concen-
trations. Is the molecular composition of the SMII affected by cellular meta-
bolic activity? To investigate this issue, our group used a quantitative high-
throughput MS-based approach to study the MIP repertoire of EL4 mouse cells 
treated or not with the mTOR inhibitor rapamycin. mTOR integrates environ-
mental cues (nutrients and growth factors), and mTOR signaling is regulated 
in numerous physiological and pathological conditions in all types of cells 
[117-119]. Treatment with rapamycin for up to 48h led to a progressive in-
crease	(≥	2.5-fold)	in	the	abundance	of	98	MIPs,	6	of	which	were	present	only	
on treated cells [30]. Analyses of transcripts levels, translational activity (poly-
somal loading), protein abundance and stability revealed that variations in MIP 
abundance were regulated at multiple levels inside the cell. Upregulation of 
MIPs	could	be	ascribed	to	enhanced	transcriptional	activity	in	some	cases	(≤	
36%)	and	to	co-	or	post-translational	events	in	most	cases	(≥	64%).	Important-
ly, analyses with the STITCH and STRING interaction databases showed that 
genes coding for differentially expressed MIPs segregated in 7 main functional 
modules and were tightly connected to the mTOR interactome. These data 
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show that the SMII is extremely plastic and that it projects at the cell surface 
a representation of biochemical networks and metabolic events regulated at 
multiple levels inside the cell. Since perturbation of a single signaling pathway 
can lead to significant changes in the composition of the SMII, cells can com-
municate their metabolic status to the adaptive immune system.
2.12 The immunogenicity of neo-MIPs
It is now clear that several MIPs that are absent on resting healthy cells are 
present at the surface of transformed, infected or metabolically perturbed 
cells. But are these neo-MIPs recognized by CD8 T cells? For neo-MIPs that ap-
pear on cancer cells, the answer is clearly yes: CD8 T cells specific for tumor-
associated neo-MIPs spontaneously expand in tumor-bearing hosts and can 
expand further following immunization [112, 120, 121]. In a few cases, infec-
tions have been found to induce autoimmune CD8 T cell responses against 
self MIPs. Specific examples include autoreactivity to MIPs derived from vin-
culin in HIV-infected subjects and from HSP90 and IFI-6-16 following measles 
(rubeola) [122, 123]. Finally, when coated on dendritic cells, MIPs upregulated 
on rapamycin-treated cells were found to elicit CD8 T cell responses in mice, 
suggesting that metabolic perturbations lead to expression of immunogenic 
neo-MIPs [30]. 
The biologic relevance of neo-MIPs expressed on tumor cells is compelling. 
Though contradictory views exist [124], the dominant paradigm holds that rec-
ognition of tumor-associated MIPs by CD8 T cells prevents the occurrence or 
progression of a substantial proportion of cancers [38, 39, 125]. Furthermore, 
adoptive immunotherapy targeted to tumor-associated MIPs can mediate dura-
ble complete responses in patients with metastatic melanoma and represents 
a promising treatment for other types of cancer [114, 126]. However, we ignore 
whether self MIPs presented on infected or metabolically stressed cells can 
elicit meaningful immune responses. It has been speculated that CD8 T-cell re-
sponses against stress-induced self MIPs could be of considerable importance 
because under real life conditions, the cells that CD8 T lymphocytes must deal 
with (infected and transformed cells) are stressed [127, 128]. Indeed, infection 
and transformation increase protein synthesis and thereby cause endoplasmic 
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reticulum stress [129, 130]. This is particularly true for cells submitted to hy-
poxia, nutrient deprivation or low pH in poorly vascularized tumors and sites 
of inflammation [131, 132]. A correlation between infection and anti-tumor im-
munity is supported by epidemiologic evidence that childhood infections (e.g., 
mumps and measles) lower the risk for certain adult cancers including ovar-
ian cancer and non-Hodgkin’s lymphoma [133]. Also, in patients with acute 
myeloid leukemia undergoing allogeneic hematopoietic cell transplantation, 
cytomegalovirus infection reduces the leukemic relapse risk [134]. However, 
the potential protective value of immune response against neo-MIPs expressed 
on non-neoplastic stressed cells has yet to be addressed experimentally. 
2.13 The complexity and plasticity of the SMII – A challenge for self 
tolerance
A key finding emerging from large-scale peptidomic studies is that the SMII 
is more complex and plastic than previously anticipated (Fig. 1). At the or-
ganismal level, the composition of SMII varies from one cell type to another. 
Furthermore, the SMII of a cell can be perturbed by dysregulation of cellular 
metabolism and infection, hence by both cell–intrinsic and –extrinsic factors. 
Therefore, events that occur frequently under real life conditions lead to pre-
sentation of neo-self MIPs to the immune system [30]. The complexity and 
plasticity of the SMII most likely represent a major challenge for the main-
tenance of self tolerance. They may justify the need for self tolerance to be 
maintained by multiple dominant and recessive mechanisms involving diverse 
hematopoietic and non-hematopoietic stromal cells in the thymus and second-
ary lymphoid organs [35, 135-137]. Despite these sophisticated mechanisms of 
tolerance, autoimmune diseases represent a major medical burden [52, 138]. 
2.13.1 Neo-self MIPs induced by infection
Environmental factors play a major role in the occurrence of autoimmune 
disease. In particular, a variety of microbial infections are associated with 
autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatic 
fever, systemic sclerosis and spondyloarthritis [52, 139, 140]. Arguably the 
most popular hypothesis to explain the association between infection and au-
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toimmunity is molecular mimicry between microbial peptides and self MIPs. 
Though evidence for a role of molecular mimicry has been gathered for se-
lected cases [141], its overall importance in autoimmunity remains difficult to 
assess. Demonstration that infection leads to presentation of neo-self MIPs [8, 
25] raises an alternative explanation: autoreactive T cells could be specific neo-
self MIPs presented on infected cells. The latter hypothesis does not require 
any crossreactivity between microbial peptides and self MIPs. That neo-self 
MIPs elicit biologically relevant responses would be consistent with the fact 
that our immune system is not tolerant to all peptides that can be encoded by 
the genome, but only to self MIPs presented at physiological levels [142]. This 
principle was recently reiterated following the immune rejection of autologous 
induced pluripotent stem cells [143]. These cells had a perfectly normal ge-
nome but were recognized as non-self by autologous CD8 T cells that reacted 
to undefined neo-self MIPs. 
Figure 1. Plasticity of the SMII
The SMII is shaped by both intrinsic and extrinsic fac-
tors that affect the abundance and the diversity of MIPs.
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2.13.2 Neo-self MIPs induced by metabolic disturbances
Growing interest in the field of immunometabolism is being fuelled by the 
recognition that obesity-induced inflammation promotes a variety of chronic 
conditions including atherosclerosis [144]. Evidence suggests that obesity-in-
duced inflammation is initiated by CD8 T cells: the adipose tissue attracts and 
activates CD8 T cells that in turn initiate and maintain adipose tissue inflam-
mation and systemic insulin resistance [145]. Excessive amounts of nutrients 
induce endoplasmic reticulum stress in adipocytes [146]. Given that metaboli-
cally stressed cells express neo-self MIPs [30], it would be interesting to evalu-
ate whether neo-self MIPs on overloaded adipocytes might be specifically rec-
ognized by CD8 T cells that initiate obesity-induced inflammation. 
2.14 The MHC class II immunopeptidome
For most autoimmune disorders, MHC genes have by far the strongest single 
genetic effect. Autoimmunity is frequently linked primarily to MHC II alleles 
that are strongly associated with the presence of specific circulating autoanti-
bodies [147]. Table 3 shows some representative examples of autoantibodies 
associated with specific HLA-DR and HLA-DQ alleles. These autoantibodies can 
be both pathognomonic and pathogenic [148, 149]. Disease-associated MHC II 
alleles presumably present self peptides to CD4 T cells that “help” autoreactive 
B cells. HLA-DR and HLA-DQ alleles can also be associated with autoimmune 
disorders where no antibody marker has been identified [150]. These data beg 
the question: what is the nature of self MHC II-associated peptides recognized 
by autoreactive CD4 T cells. In comparison to the SMII, characterization of 
the self MHC II-immunopeptidome represents a greater challenge due to the 
less-restrictive binding motifs of MHC II alleles and the scarcity of peptide 
sequencing data [151]. High-throughput analysis of MHC II-associated pep-
tides are absolutely required to help improve current prediction algorithms 
and understand the structure of the MHC II-restricted self [152]. Systems level 
analyses of the self MHC II immunopeptidome should also pave the way to a 
molecular definition of pathogenic MHC II-associated self peptides. 
79
Table 3. Representative examples of autoantibodies associated with specific 
MHC II alleles
MHC II allele Autoantibody Disease Reference
HLA-DRB1*13 F-actin Autoimmune hepatitis 
1, 2
[147]
HLA-DRB1*03 Antinuclear antibodies 
(ANA)
Autoimmune hepatitis 
1, 2
[147]
HLA-DRB1*03 Liver cytosol type 1 (LC1) Autoimmune hepatitis 2 [162]
HLA-DRB1*07 Liver kidney microsomes 
type 1 (LKM-1)
Autoimmune hepatitis 2 [147, 162]
HLA-
DQβ1*0301
Anti-basement membrane 
zone (anti-BMZ)
Pemphigoid [163]
HLA-DRB1*11-
DQB1*0301
Anti-topoisomerase I 
(Topo)
Systemic sclerosis [164]
HLA-DRB1*01-
DQB1*0501
Anti-centromere (ACA) Systemic sclerosis [164]
HLA-
DRB1*0404-
DQ8, DR3-DQ2
Anti-21-hydroxylase (21-
OH)
Type 1 diabetes [165, 166]
HLA-DR4, HLA-
DQ8
Anti-insulin (IAA) Type 1 diabetes [165, 167]
HLA-DRB1 SE a,  
HLA-DRB1*04
Anti-citrullinated 
α-enolase peptide 1 (CEP-
1)
Rheumatoid arthritis [168] [169]
aHLA-DRB1 SE: HLA-DRB1 shared epitope
2.13 Perspective –toward a more comprehensive definition of the im-
mune self
It is noteworthy that the complexity of the SMII is also spelled in words that 
go beyond a simple germline-encoded 20-amino acids alphabet. The complex-
ity of the SMII is enhanced by three processes: non-conventional translation 
mechanisms, post-translational modifications and genetic polymorphisms. 
Thus, cryptic MIPs include peptides that arise from untranslated regions of the 
mRNA as well as peptides encoded in alternate translational reading frames 
and from non-AUG start codon initiation on mRNAs [71, 96-98]. Furthermore, 
peptides can undergo several post-translational modifications such deamida-
tion, phosphorylation, transpeptidation and proteasomal splicing [13, 99-103]. 
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Peptide splicing leads to the production of MIPs made of two noncontiguous 
fragments of a protein that are linked together after the excision of the in-
tervening segment [85, 153]. Finally, genetic polymorphisms that hinder MIP 
generation (e.g., gene deletion) or the structure of a MIP (e.g., single nucleotide 
polymorphisms) can impinge on the SMII [154-156]. Accordingly, some MIPs are 
present in some individuals but absent in other MHC-matched subjects [156, 
157]. These polymorphic MIPs are traditionally referred to as minor histocom-
patibility antigens (MiHAs). While MiHAs are of great biological relevance [114, 
158], the global impact of genomic polymorphisms on the SMII (i.e. the num-
ber of MiHA differences between MHC-identical subjects) is totally unknown, 
with	theoretical	estimates	ranging	from	≈15	to	thousands	[154,	155,	159].	Im-
portantly, peptide identification by tandem MS is generally based on search 
algorithms that evaluate matches between observed peptide fragments and a 
reference proteome. It follows that peptides with post-translational modifica-
tions and peptides generated by alternative reading frames, protein splicing or 
genomic variations are largely missed by current database search algorithms. 
Furthermore, current binding motif prediction algorithms rely on known pep-
tide sequences, limiting our knowledge of peptides associated to rare alleles 
and to MHC class II molecules. Thus, unmined MS datasets harbor a whole 
immunopeptidome universe that awaits to be uncovered by novel analytical 
approaches including de novo MS/MS peptide sequencing and enrichment of 
peptide bearing discrete post-translational modifications [160, 161]. 
2.15 Take-home messages
•	 The self-MIP repertoire is complex and is not a representative excerpt 
from the proteome.
•	 Different types of proteasomes generate different MIP repertoires. 
•	 The self-MIP repertoire conceals a tissue-specific signature. 
•	 Neoplastic transformation, viral infection and metabolic changes have a 
broad impact on the MIP repertoire and lead to presentation of cryptic 
self-MIPs. 
•	 The self-MIP repertoire conveys to the cell surface an integrative view of 
cellular regulation. 
•	 The complexity and plasticity of the MHC I-restricted self represent a ma-
81
jor challenge for the maintenance of self tolerance.
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3.2 Abstract
MHC I-peptides (MIPs) play an essential role in normal homeostasis and diverse 
pathological conditions. MIPs derive mainly from defective ribosomal products 
(DRiPs), a subset of nascent proteins that fail to achieve a proper conforma-
tion and whose physical nature remains elusive. We used high-throughput pro-
teomic and transcriptomic methods to unravel the structure and biogenesis of 
MIPs presented by HLA-A and -B molecules on human EBV-infected B lympho-
cytes from four subjects. We found that although HLA-different subjects pres-
ent distinctive MIPs derived from different proteins, these MIPs originate from 
proteins that are functionally interconnected and implicated in similar biologi-
cal pathways. Secondly, the MIP repertoire of human B cells showed no bias 
toward conserved vs. polymorphic genomic sequences, derived preferentially 
from abundant transcripts, and conveyed to the cell surface a cell type-specif-
ic signature. Finally, we discovered that MIPs derive preferentially from tran-
scripts bearing miRNA response elements. Furthermore, while MIPs of HLA-
disparate subjects are coded by different sets of transcripts, these transcripts 
are regulated by mostly similar miRNAs. Our data support an emerging model 
in which i) the generation of MIPs by a transcript depends on its abundance 
and DRiP rate, and ii) the DRiP rate is regulated to a large extent by miRNAs. 
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3.3 Introduction
All nucleated cell types constitutively express MHC class I molecules that pres-
ent self peptides to CD8 T cells. MHC I-associated peptides (MIPs) play crucial 
roles in many processes including development and homeostasis of CD8 T 
cells, self/non-self discrimination, tumor immunosurveillance, tissue rejec-
tion, graft-vs.-host disease and odorant-based mate selection.1-6 Classical MHC 
I molecules are encoded by three genes in humans, HLA-A, -B, and –C, which 
have an astounding allelic diversity.7 Genetic polymorphisms that distinguish 
HLA allomorphs affect mainly their peptide-binding groove. Accordingly, stud-
ies on presentation of various peptides suggest that a minority of peptides 
may bind to several MHC I molecules but that different HLA allomorphs pres-
ent largely non-overlapping sets of peptides.8, 9 Generation of MIPs is tightly 
linked to protein economy because it depends on protein synthesis and deg-
radation.10, 11 Nevertheless, the most striking (and intriguing) feature of MIPs is 
that they derive mainly from defective ribosomal products (DRiPs).12, 13 DRiPs 
are a subset of nascent proteins that fail to achieve a proper conformation, 
and are therefore rapidly degraded by proteasomes. A key unresolved issue is 
the physical nature of DRiPs. In theory, DRiPs could originate from a variety of 
processes that impinge on transcription, translation, post-translational modi-
fications and protein folding.12, 13 
No algorithm can predict the amount of DRiPs produced by a gene.14 Further-
more, the composition of the self MIP repertoire (or immunopeptidome) does 
not correlate with the abundance of MIP source proteins.15 Finally, studies on 
the relation between the transcriptome and the immunopeptidome have yield-
ed seemingly conflicting results.9, 16 Therefore, large-scale mass spectrometry 
(MS) studies represent the sole approach that can yield a global appraisal of 
the MIP landscape. MS studies have highlighted the complexity of the MIP rep-
ertoire and shown that MIPs derive from all cell compartments.5, 16-19 They also 
revealed that the immunopeptidome is plastic, conveys to the cell surface an 
integrative view of cellular regulation, and that it can be affected by cell-intrin-
sic and –extrinsic factors.17, 18 
Given the quintessential importance of self MIPs, it is imperative to develop 
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and exploit systems-level quantitative methods that will yield insights into 
MIP biogenesis and enable modeling of the immunopeptidome. Here, we used 
high-throughput proteomic and transcriptomic methods to unravel the struc-
ture and biogenesis of MIPs presented by HLA-A and -B molecules on human 
EBV-infected B lymphocytes. Our results show that different HLA allomorphs 
present MIPs derived from distinct but functionally related source proteins. 
We further demonstrate that two features determine whether a transcript will 
generate MIPs: the transcript abundance and whether it contains microRNA 
(miRNA) response elements (MREs). 
 
3.4 Material and Methods
3.4.1 Cell culture and HLA typing
This study was approved by the Comité Éthique Recherche de l’Hôpital Maison-
neuve-Rosemont and all subjects provided written informed consent. Peripher-
al blood mononuclear cells (PBMCs) were isolated from blood samples of 4 sub-
jects (2 pairs of HLA-identical siblings). Epstein-Barr virus (EBV)-transformed B 
lymphoblastoid cell lines (B-LCLs) were derived from PBMCs with Ficoll-Paque 
Plus (Amersham) as described.20 Established B-LCLs were maintained in RPMI 
1640 medium supplemented with 10% fetal bovine serum, 25 mM of HEPES, 
2mM L-glutamine and penicillin-streptomycin (all from Invitrogen). HLA ge-
notyping was performed at the Maisonneuve-Rosemont Hospital. Siblings of 
sibship 1 are HLA-A*0101/*0205, HLA-B*1501/*5001, HLA-C*0602/*0701 
and DRB1*0101/*1104. Siblings of sibship 2 are: HLA-A*0301/2902, HLA-
B*0801/*4403, HLA-C*0701/*1601 and DRB1*0301/*0701. HeLa and HEK293 
cell lines were maintained in DMEM medium supplemented with 10% fetal bo-
vine serum, 2mM L-glutamine and penicillin-streptomycin (all from Invitrogen).
3.4.2 Mass spectrometry and peptide sequencing 
Three to four biological replicates of 4x108 exponentially growing B-LCLs were 
prepared from each subject. MIPs were released by mild acid treatment and 
separated by strong cation exchange chromatography (SCX) using an off-line 
1100 series binary LC system (Agilent Technologies) as previously described.16 
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MIP fractions were analyzed by LC-MS/MS using an Eksigent LC system cou-
pled to a LTQ-Orbitrap mass spectrometer (Thermo Electron).16-18 Additional 
details are provided as supplemental methods. MS/MS of all peptide identifi-
cations are available through ProteoConnections24 at http://www.thibault.iric.
ca/proteoconnections. 
3.4.3 MIPs selection, predicted binding affinity and identification of MIP 
source proteins
We filtered peptides by their length and kept those peptides with the canoni-
cal MIP length (8-11mers) and predicted binding affinity (IC50)<500 nM. Also, 
only MIPs detected in at least 3 replicates of both siblings per sibship (i.e. MIPs 
detected in 6-8 samples derived from 2 different HLA-identical siblings) were 
considered for further analyses. The predicted binding affinity of peptides to 
the allelic products was obtained using NetMHC version 3.2 (http://www.cbs.
dtu.dk/services/NetMHC/)21 for the frequent alleles HLA-A*0101/*0301/*2902 
and HLA-B*0801/*1501/*4403) or NetMHCpan version 2.2 (http://www.cbs.
dtu.dk/services/NetMHCpan-2.2/)22 for the rare alleles HLA-A*0205 and HLA-
B*5001. MIPs were further inspected for mass accuracy and MS/MS spectra 
were validated manually. The list of MIPs reported in the present work has 
been provided to The Immune Epitope Database and Analysis Resource (IEDB) 
(http://www.immuneepitope.org/)23 under the reference ID 1022782. MIP 
source proteins were identified using the Sidekick resource (http://www.bio-
info.iric.ca/sidekick/) and only MIPs unambiguously assigned to one source 
gene were further analyzed.
3.4.4 Analysis of enriched pathways and functional categories
The Ingenuity Pathway Analysis software (Ingenuity Systems, http://www.in-
genuity.com/) was used to identify overrepresented canonical pathways and 
functional categories for MIP source proteins. The right-tailed Fisher’s exact 
test was used to calculate a p-value determining the probability that each over-
represented pathway or biological function was due to chance alone.
3.4.5 Functional connectivity score
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An in-house developed all-pairs-shortest-path matrix18 was used to calculate 
the functional association between two lists of nodes (transcripts or proteins), 
in this case: i) MIP source proteins of sibship 1 and MIPs source proteins of 
sibship 2 and ii) all MIP source proteins and all protein-coding transcripts ex-
pressed in B-LCLs. The functional association corresponds to a connectivity 
score. Details on the calculation of the score are provided as supplemental 
methods. A bootstrapping procedure was used as a statistical sampling meth-
od to calculate control connectivity scores from 105 sets of randomly selected 
human protein coding transcripts (1,165 transcripts in Figure 2C and 12,384 
in Figure 4B). The P value corresponds to the number of times that the score 
of the bootstrap is smaller than the score of the sample/number of bootstrap 
iterations (105).
3.4.6 Analysis of transcripts containing miRNA-binding sites 
Transcripts containing MREs were obtained from 2 sources: i) TargetScan v5.1 
(http://www.targetscan.org/)27, which includes both validated and predicted 
miRNA targets and ii) the Molecular Signature Database v3.0 (MSigDB) (http://
www.broadinstitute.org/gsea/msigdb/index.jsp)28, which includes gene sets 
with a known 3’-UTR miRNA binding motif. The MIP datasets used in the anal-
yses were obtained from MS-based studies by our group16, 17, by others19, 29 
or were available at IEDB (http://www.immuneepitope.org/, accessed on May 
2011)23. The human and mouse proteome were downloaded from NCBI by ex-
cluding entries with a gene type for non-coding RNA, ‘transposon’ or ‘pseudo-
gene’. The proportion of transcripts containing MREs in the different datasets 
was compared with the two-tailed Fisher’s exact test.
3.4.7 miRNA enrichment analysis
The miRNA target analysis module of the Web-based Gene Set Analysis Toolkit 
(WebGestalt) (http://bioinfo.vanderbilt.edu/webgestalt/)30 was used to iden-
tify transcripts containing MREs that are overrepresented among MIP source 
transcripts in B-LCLs. This tool also allowed us to predict miRNAs recognizing 
MREs found in enriched MIP source transcripts. A hypergeometric test and a 
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Benjamini and Hochberg correction were used to identify enriched miRNAs 
and target transcripts. 
3.4.8 RNA extraction and cell sorting
5 x 106 PBMCs were labeled with FITC-conjugated anti CD19 (clone HIB19), 
APC-conjugated anti CD20 (clone 2H7) and propidium iodide to exclude cells 
in later apoptotic stages (all from BD Biosciences). CD19+CD20+ B cells were 
sorted on a FACSAria cell sorter (BD Biosciences) before RNA extraction. 0.5-
1.0 x 106 cells were lysed in Qiazol (Qiagen) and total RNA was isolated of with 
the miRNeasy mini kit including DNase I treatment (Qiagen) according to the 
manufacturer’s instructions. Total RNA was quantified using the NanoDrop 
2000 (Thermo Scientific) and RNA quality was assessed with the 2100 Bioana-
lyzer (Agilent Technologies). 
3.4.9 miRNA profiling
miRNA labeling, hybridization and washing steps were carried out with the 
miRNA complete labeling and hybridization kit (Agilent Technologies) accord-
ing to the manufacturer’s instructions. 100 ng of each RNA sample were hy-
bridized to Agilent Human miRNA Microarray Release 16.0 (G4872A-031181 
Agilent Technologies) containing 60K probes for 1,205 human and 144 human 
viral miRNAs (including 25 specific for EBV). Images were acquired with a Ge-
nePix 4000B scanner (Molecular Devices) at a 5 uM/pixel resolution and fea-
tures were extracted with the GenePix 6.1 software. Analyses were performed 
using BRB-ArrayTools Version 4.2.0 Stable Release developed by Dr. Richard 
Simon and BRB-ArrayTools Development Team (http://en.bio-soft.net/chip/
BRBArrayTools.html). The data were background-subtracted and quantile nor-
malized. To estimate a single intensity measure for each miRNA we calcu-
lated the mean of its different probes. We applied the Self-Organizing Maps 
(SOM) method followed by hierarchical clustering analysis using the average 
linkage method and uncentered correlation as similarity metric. Clustering 
analyses were carried out with the Cluster v3.0 program (http://bonsai.hgc.
jp/~mdehoon/software/cluster/)31 and visualized with Java TreeView (http://
jtreeview.sourceforge.net/).32 The miRNA array data have been deposited into 
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the GEO database under accession number GSE35319. 
 
3.5 Results
3.5.1 High-throughput MS-based identification of the MIP repertoire of B-
LCLs
To characterize the MIP repertoire of B-LCLs, we performed mild acid elution 
of peptides from 4 B-LCLs derived from PBMCs of 4 different subjects. The 
4 subjects belonged to 2 HLA-disparate sibships, each composed of one pair 
of HLA-identical siblings. Eluted peptides were fractionated by ion exchange 
chromatography and analyzed by nanoLC-MS/MS.16-18 To identify MIPs con-
sistently expressed by B-LCLs we selected those MIPs detected in at least 3 
replicates of both siblings in each sibship (i.e. MIPs constantly detected in 6-8 
samples derived from 2 different HLA-identical siblings). We further filtered 
peptides according to the canonical MIP length (8-11mers) and kept only those 
that were predicted to bind to their corresponding HLA-A and B allelic prod-
ucts for further analysis. In order to evaluate the HLA binding affinity of our 
peptides, we used NetMHC and NetMHCpan,21, 22 which are the best-performing 
MHC-binding predictors.33, 34 HLA-C-associated peptides were not included in 
this study because predictors for HLA-C allomorphs are not fully developed. 
We identified a total of 2375 unique 8-11mers associated to 8 HLA-
A and B allelic products: HLA-A*0101/*0205/*0301/*2902 and HLA-
B*0801/*1501/*4403/*5001 (Table S1). Of the identified MIPs, 29 are listed 
in the IEDB and have been previously identified by various techniques includ-
ing MHC ligand elution, MHC binding and T-cell response assays. Most of the 
peptides identified here are therefore novel and significantly enlarge the list 
of MIPs associated to MHC allomorphs, especially those for which less than 10 
human peptides are currently known (HLA-A*0205 and HLA-B*0801/*5001). 
We found that a large proportion of MIPs were specific to one HLA (Figure 1A). 
Less than 10% of MIPs were predicted to bind to more than one HLA (Figure 
1A), though a stronger binding preference was found for a single HLA allelic 
product (Table S1). Accordingly, the overlap between MIPs from HLA-disparate 
subjects was minimal (0.4%) (Figure 1C). Of note, we observed locus-dependent 
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differences in the predicted binding affinity of our MIPs. On average, HLA-A-
associated peptides had a significantly stronger binding affinity than HLA-
B-associated peptides (Figure 1B and Figure S1). We conclude that HLA allo-
morphs present essentially distinct MIP repertoires and that at the organismal 
level, the HLA genotype ultimately defines the MIP repertoire of an individual. 
Figure 1. General features of MIPs eluted from B-LCLs from 2 HLA-dispa-
rate sibships
There were 2 HLA-identical siblings per sibship and each MIP included in the 
analysis was found in both siblings. A) Proportion of MIPs associated to 1, 2 
or more different HLA allelic products, based on bioinformatic predictions 
with NetMHC/NetMHCpan. Most MIPs are associated to a single allelic prod-
uct (HLA type). B) Predicted MHC I binding affinity (IC50) of eluted peptides 
shows that HLA-B-associated peptides are weaker binders than HLA-A-as-
sociated peptides (*P < 0.0001; 2-tailed Mann Whitney test). Each dot repre-
sents a peptide and the red line corresponds to the mean binding affinity. C) 
Venn diagram showing minimal overlap between MIPs from HLA-disparate 
sibships. Peptide numbers and percentages are depicted for each category. 
Total number of MIPs for each sibship are shown in colors.
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3.5.2 MIPs of HLA-disparate individuals derive from different sets of source 
proteins that are functionally interconnected and implicated in similar bi-
ological pathways
We unambiguously identified 1,750 proteins source of 2,290 peptides (Table 
S1), indicating that most MIP source proteins are represented by a single MIP. 
We asked whether distinct sets of MIPs associated to non-overlapping sets of 
HLA molecules originated from the same or from different sets of proteins. 
We found that the overlap between MIP source proteins of sibships 1 and 2 
was minimal (7.5%) (Figure 2A). We then performed an enrichment analysis 
to identify pathways overrepresented in the proteins source of MIPs in each 
sibship. This analysis revealed that most of the overrepresented pathways 
were common to both sibships (Fisher’s exact test, P < 0.05) (Figure 2B). Thus, 
despite the fact that MIPs of HLA-disparate subjects originated mostly from 
different proteins, a significant number of those proteins are implicated in 
the same biological pathways. We further confirmed this result by analyzing 
the functional connectivity between the sets of proteins giving rise to MIPs in 
sibships 1 and 2 using an in-house developed all-pairs-shortest-path matrix 
(Figure 2C). This analysis is based on the fact that proteins acting in the same 
biological pathway are closer in an interaction network, i.e. more function-
ally connected. Functional association was measured as a connectivity score, 
which corresponds to the mean of the shortest path distance between every 
pair of proteins (one protein from each sibship) in an interaction network. We 
found that the set of MIP source proteins of sibship 1 is highly connected to 
the set of proteins of sibship 2. A bootstrap procedure (100,000 iterations) 
failed to reveal a single randomly selected set of proteins in the human pro-
teome that was so tightly connected to the MIP source proteins of our subjects 
(P < 0.0001). Collectively, these results show that B-LCLs from subjects with no 
shared HLA alleles present different immunopeptidomes that originate from 
different sets of proteins that are nevertheless functionally interconnected 
and implicated in the same biological pathways. 
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Figure 2. MIP source proteins are very different in the two sibships, but are impli-
cated in similar biological pathways and are functionally interconnected
A) Venn diagram showing the minimal overlap between MIP source proteins from sib-
ships 1 vs. 2. Protein numbers and percentages are depicted for each category. Total 
number of MIP source proteins for each sibship are shown in colors. B) The Ingenuity 
Pathway Analysis resource was used to identify overrepresented biological pathways 
for MIPs source proteins in sibships 1 and 2. Pathways are sorted by their statistical 
significance [-log(p value, calculated with the right-tailed Fisher’s exact test)]. Higher 
scores indicate increased association between the MIP source proteins and a given 
pathway. The dotted line represents the threshold for statistical significance (P < 
0.05). Immune-associated pathways are highlighted in red. C) MIP source proteins 
from HLA-disparate sibships are functionally interconnected. An all-pairs-shortest-
path matrix was used to calculate the functional association between MIP source pro-
teins of sibship 1 and MIPs source proteins of sibship 2 (see material and methods 
for details). The functional association was measured as a connectivity score, which 
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corresponds to the mean of the shortest path distance between every pair of proteins 
(one protein from each sibship) in an interaction network. Lower scores indicate in-
creased connectivity. The red line represents the connectivity score between the MIP 
source proteins of sibship 1 and the MIP source proteins of sibship 2. A bootstrap 
procedure, represented by the Gaussian distribution, was used to calculate control 
connectivity scores between MIPs source proteins (of sibships 1 or 2) and random 
sets of proteins from the human proteome (*P < 0.0001, calculated as the number of 
times that the score of the bootstrap is smaller than the score of the sample/ number 
of bootstraps). 
3.5.3 MIPs encoded by conserved and polymorphic genomic sequences
One interesting, yet unexplored question is whether MIPs preferentially de-
rive from conserved vs. polymorphic genomic regions. Polymorphic MIPs, 
commonly referred to as minor histocompatibility antigens, are important in 
hematology because they elicit graft-vs.-host disease and graft-vs.-leukemia 
effect following allogeneic hematopoietic cell transplantation.35-38 The most 
common form of polymorphism is single nucleotide polymorphism (SNP). We 
used an in-house developed software (pyGeno) to estimate the frequency of 
SNPs (SNPs/base pairs) in the MIP coding DNA sequences and compared it to 
the SNP frequency in the human exome (Table 1). Our analysis took into ac-
count all validated synonymous and non-synonymous SNPs reported in dbSNP. 
We found no significant differences between the frequency of synonymous or 
non-synonymous SNPs within MIP-coding sequences vs. the rest of the human 
exome. This result suggests that the MIP repertoire shows no bias toward poly-
morphic or invariant genomic sequences. 
Table 1. SNP frequency (SNPs/bp) in MIPs and in the human exome
MIPs correspond to 2,282 unique peptides eluted from B-LCLs. The human exome 
corresponds to 26,4401 CDS extracted from Ensembl (GRCh37.65). dbSNP (Build 135) 
was used to calculate SNP frequency (SNPs/bp). SNP: single-nucleotide polymorphism, 
bp: base pair.
Dataset Length 
(bp)
Non-synonymous 
SNPs
Synonymous 
SNPs
Total
SNPs
Number SNPs/
bpa
Number SNPs/
bpb
Number SNPs/bpc
MIPs 59994 230 0.0038 216 0.0036 446 0.0074
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Exome 35201356 150158 0.0043 115376 0.0033 265534 0.0075
aP = 0.12, bP =0.16 , cP =0.50 , two-tailed Fisher’s exact test when comparing MIP coding se-
quences to the exome not encoding MIPs.
3.5.4 MIPs derive preferentially from abundant transcripts
We previously reported that in primary mouse thymocytes, MIPs derived pref-
erentially from highly abundant mRNAs.16 However, studies on human cells 
have casted some doubts on the correlation between the immunopeptidome 
and the transcriptome.9 To directly evaluate this relationship, we compared the 
expression level of 15,737 protein-coding transcripts expressed by B-LCLs26 
with the expression level of 1,707 MIP coding transcripts (Figure 3A-B). We set 
4 expression categories based on Toung et al.26: very low, low, medium and 
high, and compared the proportion of transcripts belonging to each category 
in the 2 sets of transcripts. We found that MIP coding transcripts were skewed 
toward higher expression categories (Figure 3B). While 54% of all transcripts 
were expressed at a medium to high levels, 87% of those coding for MIPs did 
so. Furthermore, the proportion of highly abundant transcripts was enriched 
by 3.5 times in MIP-coding transcripts relative to the whole protein coding 
transcriptome. Consistent with this, while 46% of transcripts are expressed at 
low or very low levels, only 13% of MIP coding transcripts fell into these cate-
gories (Figure 3B). We further demonstrated that changing the thresholds that 
defined the various categories did not affect the differential expression of MIP 
coding transcripts relative to all transcripts expressed in B-LCLs (Figure S2). 
Since MIPs preferentially derived from abundant transcripts, we next asked 
whether the proportion of MIP-coding transcripts was increased in a region 
with high transcriptional activity. The 6p21 chromosomal region contain-
ing the extended human MHC is recognized as a canonical transcriptional 
hotspot.7 We first confirmed that this region generates increased proportion 
of highly abundant transcripts and further calculated the average expression 
of transcripts derived from 6p21 vs. the whole transcriptome of B-LCLs (Figure 
3C). We found that the average gene expression level measured in FPKM (frag-
ments per kilobase of exon per million fragments mapped) was 2 times greater 
for 6p21 than for all expressed protein-coding transcripts. We then compared 
the proportion of MIP-coding transcripts located in 6p21 vs. in the rest of the 
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genome (Figure 3D). We found that the proportion of MIP-coding transcripts 
was significantly higher for transcripts located in 6p21 than elsewhere in the 
Figure 3. MIPs derive preferentially from abundant transcripts
A) MIP source transcripts are expressed at a wide range of levels. Expression levels were ob-
tained from Toung et al.26 and measured in FPKM by RNA-sequencing. Frequency distribution 
of expression levels of 15,737 protein-coding transcripts expressed by B-LCLs (black bars) and 
1,707 (out of 1,750) transcripts source of MIPs (red line) for which an entry was found in the 
RNA-seq data. The frequencies of mRNAs and of MIPs source mRNAs are displayed on the left 
and right y-axis, respectively. Frequencies were calculated for 0.2 FPKM-bin increments. Ex-
pression categories (very low, low, medium and high) were set based on Toung et al.26 and con-
firmed to be unbiased (Figure S2). B) Proportion of transcripts belonging to the expression cat-
egories shown in A among the two sets of transcripts indicate that MIPS derive preferentially 
from transcripts expressed at moderate to high levels as opposed to transcripts expressed at 
very low to low levels (*P < 2.2 x 10-6, Fisher’s exact test). C) The 6p21 chromosomal region is a 
transcriptional hotspot in B-LCLs. Graph shows the proportion of transcripts belonging to the 
expression categories shown in A among 316 protein-coding transcripts located in the 6p21 
chromosomal region and the protein-coding transcriptome of B-LCLs (*P < 0.008, **P < 2.05 
x 10-7, Fisher’s exact test). The average expression level (FPKM per gene) is shown on the top 
for both datasets. The 6p21 region analyzed was comprised between positions 30400001 and 
46200000 (UCSC genome browser and NCBI Map viewer). D) The 6p21 transcriptional hotspot 
is a preferential source of MIPs. Comparison of the proportion of MIP-coding transcripts locat-
ed in 6p21 (6p21+) and in the rest of the genome (6p21-) (*P = 0.013 x 10-6, Fisher’s exact test). 
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genome. This results show that the 6p21 transcriptional hotspot is a preferen-
tial source of MIPs.
3.5.5 The MIP repertoire is functionally connected to the transcriptome
In mouse thymocytes and dendritic cells, we found that the MIP repertoire 
conceals a cell type-specific signature.16, 17 To test whether this is also true in 
human cells, we first used the Ingenuity Pathway Analysis resource to identify 
major functional categories that were overrepresented in the set of proteins 
encoding MIPs in B-LCLs (Figure 4A). Some overrepresented categories were 
associated to basic cellular biological processes such as cell cycle, protein syn-
thesis and gene expression, reflecting intracellular events occurring in any 
proliferating cell. The salient finding is that several immune-specific function-
al categories were also overrepresented, including hematopoiesis, lymphoid 
tissue structure and development, and humoral and cell-mediated immune re-
sponses (Figure 4A, categories in red). Furthermore, these major immune cat-
egories included B cell-specific functions such as proliferation, development 
and differentiation of B lymphocytes, class switching and development of pre-
B and pro-B lymphocytes (Table S2). Moreover, the MIP repertoire reflected im-
mune-associated, as well as intracellular pathways important for B cell biology 
(Figure 2B, pathways in red). Among the overrepresented pathways, we found 
antigen presentation, IL-6 signaling (required for B cell maturation), PI3K sig-
naling in B lymphocytes (crucial in B-cell development) and JAK2 in cytokine 
signaling (very active in stimulated B cells). 
If the MIP repertoire is molded by the cell type-specific transcriptome, then 
the set of MIP-encoding proteins in B-LCLs should be functionally connected to 
the B-LCLs’ transcriptome. To test this hypothesis, we used our shortest path 
matrix method18 to evaluate the functional connectivity between the set of MIP 
source proteins and the protein-coding transcriptome of B-LCLs and compare 
this connectivity to the connectivity scores of 105 random human transcrip-
tome sets (Figure 4B). The functional connectivity found between MIP coding 
transcripts and the transcriptome of B-LCLs was significantly greater than the 
MIP connectivity to control transcriptomes (bootstrapping, P < 0.0001). Inter-
estingly, the MIP-transcriptome connectivity increased as a function of the ex-
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pression level of MIP coding transcripts (Figure S3). Thus, the connectivity 
of MIP-encoding transcripts to the transcriptome reached its maximum value 
when only highly abundant transcripts were considered. We conclude that the 
MIP repertoire of human cells is functionally connected to the cells’ transcrip-
tome in a transcript level-dependent manner. 
Figure 4. The MIP repertoire is functionally connected to the transcriptome
A) Graph showing the major functional categories that are overrepresented in the 
MIP repertoire of B-LCLs. Overrepresented functional categories were identified with 
the Ingenuity Pathway Analysis resource and are sorted by their statistical signifi-
cance [-log(p value), calculated with the right-tailed Fisher’s exact test]. Higher val-
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ues indicate increased association between the MIP source proteins and a given cat-
egory. The dotted line represents the threshold for statistical significance (P < 0.05). 
Immune-associated categories are highlighted in red. More details on functional an-
notations represented in immune-associated categories are provided in Table S2. B) 
The immunopeptidome of B-LCLs is functionally connected to the transcriptome of 
B-LCLs. An all-pairs-shortest-path matrix was used to calculate the functional asso-
ciation between MIP source proteins and the protein-coding transcriptome of B-LCLs 
(see material and methods for details). The functional association was measured as 
a connectivity score, which corresponds to the mean of the shortest path distance 
between every pair of proteins in an interaction network, i.e. one MIP-source protein 
and one expressed transcript of B-LCLs. The red line represents the connectivity score 
between MIP source proteins and transcripts expressed by B-LCLs. A bootstrap proce-
dure, represented by the Gaussian distribution, was used to calculate control connec-
tivity scores between MIPs source proteins and random sets of the human transcripts. 
3.5.6 MIPs preferentially derive from transcripts containing miRNA-bind-
ing sites
According to the dominant paradigm, MIPs derive primarily from DRiPs gen-
erated by yet elusive biochemical processes.10, 13 Theoretically, the amount of 
MIPs generated by a transcript should therefore be dictated by two factors: the 
transcript abundance and the transcript DRiP rate. In accordance with this as-
sumption, medium and highly abundant transcripts were a preferential source 
of MIPs (Figure 3A), However, some MIPs derived from transcripts expressed at 
low or very low levels (Figure 3A). We therefore speculated that low abundance 
transcripts/proteins that generate MIPs, do so because they have a high DRiP 
rate. miRNAs are a class of non-protein-coding RNAs that bind to MREs on tar-
get transcripts causing destabilization of the target transcript or inhibition of 
its translation.39 Destabilization of target mRNAs by miRNAs could constitute 
a possible mechanism by which DRiPs are generated. To test whether miRNA 
targets are a preferential source of MIPs, we first calculated the proportion 
of transcripts containing MREs in 3 datasets: transcripts source of MIPs in 
our B-LCLs, all human protein-coding transcripts (Figures 5A and S4A), and 
protein-coding transcripts expressed in our B-LCLs (Figures S4C-D). We used 
2 different databases to identify validated and predicted transcripts recog-
nized by miRNAs, TargetScan v5.127 and the Molecular Signature Database v3.0 
(MSigDB)28, and performed independent analyses with both databases (Figures 
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5A and S4). These analyses revealed that when compared to the B-LCL tran-
scriptome (Figures S4C and D) or to the human protein-coding transcriptome 
(Figure 5A), the set of transcripts encoding MIPs identified in B-LCLs from each 
sibship was significantly enriched in transcripts containing MREs.
Figure 5. The MIP-coding transcriptome is enriched in transcripts containing miR-
NA-binding sites
A) Human transcripts containing miRNA-binding sites are a preferential source of 
MIPs. The proportion of MIPs that derive from miRNA targets was calculated for vari-
ous datasets: B-LCLs from sibships 1 and 2 (this study), B-LCLs19, renal cell carcino-
mas29 and all human peptides listed in the IEDB23. A list of 8,725 human protein-
coding miRNA targets was extracted from TargetScan.27 Numbers on the bottom 
indicate the number of entries for each dataset. The proportion of MIPs that derive 
from miRNA targets for all datasets was significantly higher than the proportion of 
miRNA targets in the human protein coding transcriptome (PCT) a) P < 2.2 x 10-16, b) 
P < 3.3 x 10-9, c) P < 0.01, d) P < 2.12 x 10-9, e) P < 1.38 x 10-4, Fisher’s exact test). B) 
Mouse transcripts containing MREs are preferential sources of MIPs. The proportion 
of MIPs that derive from miRNA targets was calculated for various datasets: dendritic 
cells (DCs)17, thymocytes16 and all mouse peptides listed in the IEDB23. A list of 504 
mouse protein-coding miRNA targets was extracted from TargetScan.27 Numbers on 
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the bottom indicate the number of entries for each dataset. The proportion of MIPs 
that derive from miRNA targets for all MIP datasets was significantly higher than the 
proportion of miRNA targets in the mouse protein coding transcriptome (PCT) (a) P < 
1.0 x 10-11, b,c) P < 2.2 x 10-16,Fisher’s exact test).  
To determine whether this feature of the MIP-coding transcriptome was cell 
type-specific, we carried out the same analysis on publicly available datasets 
of human MIPs: B-LCLs expressing HLA-B*180119, renal cell carcinomas29 and 
a list of all human peptides identified in at least 20 different cell types and 
extracted from the IEDB.23 In all cases, the proportion of MIP source transcripts 
bearing MREs was higher than expected (Figures 5A and S4A). We then tested 
whether this was also true for mouse MIPs (Figures 5B and S4B). Analysis of 
mouse MIPs previously identified by our group in DCs17 and thymocytes16, 
as well as MIPs from different cell lines listed in the IEDB23, showed that the 
mouse MIP-encoding transcriptome was also significantly enriched in miRNA 
targets. In summary, these results show that irrespective of cell type, both 
mouse and human MIP-coding transcripts are enriched in miRNA targets.
3.5.7 MIPs from HLA-disparate sibships derive from different sets of tran-
scripts regulated by similar miRNomes
We used the WebGestalt analysis program30 to identify the specific MREs en-
riched in the 3’-UTR of MIP coding transcripts identified in B-LCLs from our 2 
HLA-disparate sibships (Figure 6A). A representative set of enriched MREs is 
shown in Table 2 and the complete list can be found in Table S3. 
Table 2. Representative set of enriched miRNA binding sites present in transcripts 
that are source of MIPs in B-LCLs from both sibships
The WebGestalt analysis tool was used to calculate the enrichment. N: number of tran-
scripts source of MIPs that contain the 3’-UTR binding site recognized by the specified 
miRNAs. RE: Ratio of enrichment (observed/expected number of transcripts). P value: 
calculated from the hypergeometric test.
3’-UTR 
binding 
site
miRNA sibship 1 sibship 2
N RE P value N RE P value
TGCACTT MIR-519C 
MIR-519B 
MIR-519A
51 4.21 5.93E-18 9 2.23 2.15E-02
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ACATTCC MIR-1     
MIR-206
40 4.94 8.63E-17 11 4.07 9.95E-05
TGCCTTA MIR-124A 53 3.53 2.87E-15 11 5.02 1.31E-02
CTTGTAT MIR-381 30 5.64 1.66E-14 5 2.81 3.36E-02
ACCAAAG MIR-9 48 3.48 9.38E-14 16 3.48 2.01E-05
TAGCTTT MIR-9 48 3.48 9.38E-14 16 3.48 1.95E-02
TGAATGT MIR-181A 
MIR-181B 
MIR-181C 
MIR-181D
47 3.51 1.23E-13 9 2.01 3.72E-02
GTGCCTT MIR-506 57 2.93 7.65E-13 20 3.08 1.16E-05
ACTTTAT MIR-142-5P 34 4.28 1.18E-12 11 4.15 8.38E-05
TTTGCAC MIR-19A 
MIR-19B
46 3.28 2.41E-12 14 2.99 3.00E-04
TTTGTAG MIR-520D 35 3.93 6.75E-12 7 2.36 3.08E-02
GTATTAT MIR-369-3P 25 4.51 3.62E-10 6 3.24 1.11E-02
GTTTGTT MIR-495 27 4.05 8.41E-10 8 3.6 1.90E-03
TTTGCAG MIR-518A-2 24 4.33 1.88E-09 7 3.79 2.70E-03
CTTTGTA MIR-524 36 3.01 5.82E-09 13 3.26 2.00E-04
CAGTGTT MIR-141 
MIR-200A
28 3.33 3.32E-08 10 3.57 6.00E-04
TATTATA MIR-374 26 3.44 5.41E-08 8 3.17 4.10E-03
TTTTGAG MIR-373 23 3.77 5.75E-08 8 3.93 1.10E-03
CTCAGGG MIR-125B  
MIR-125A
28 3.20 7.76E-08 7 2.4 2.84E-02
TGTTTAC MIR-30A-5P 
MIR-30C 
MIR-30D 
MIR-30B 
MIR-30E-5P
40 2.54 9.80E-08 11 2.09 1.78E-02
TGGTGCT MIR-29A 
MIR-29B 
MIR-29C
37 2.65 9.83E-08 12 2.58 2.80E-03
GCAAAAA MIR-129 20 4.09 1.07E-07 6 3.68 6.20E-03
ATTCTTT MIR-186 25 3.35 1.63E-07 6 2.41 4.03E-02
ATACTGT MIR-144 21 3.81 1.77E-07 10 5.44 1.83E-05
We then asked whether the MIP repertoire would reflect the miRNome. In ac-
cordance to the observation that MIPs of HLA-disparate sibships derive from 
different sets of proteins (Figure 2A), the sets of MIP source transcripts bear-
ing enriched MREs in the two sibships displayed minimal overlap (7%; Figure 
6A). Having compared miRNA targets, we next compared the miRNAs recog-
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nizing MREs in MIP source transcripts. Enriched miRNA targets were classified 
according to their specific 3’-UTR MREs. We then compared the miRNAs that 
were predicted to regulate MIP source transcripts in the 2 sibships. Notably, 
we found a 57% overlap among enriched miRNAs regulating MIP source tran-
scripts in the two sibships (Figure 6B). Collectively, these results suggest that 
MIPs from HLA-disparate subjects derive from different sets of transcripts 
regulated by mostly similar miRNAs.
Figure 6. MIPs from HLA-disparate sibships derive from different sets of tran-
scripts regulated by similar miRNomes
A) Venn diagram shows that MIPs of HLA-disparate sibships derive from different 
sets of miRNA targets. The WebGestalt analysis program30 was used to identify tran-
scripts significantly enriched in 3’-UTR binding sites of specific miRNAs among all 
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MIP source transcripts identified in sibships 1 and 2 (P < 0.05, hypergeometric test). 
Total number of MIP source transcripts that are miRNA targets for each sibship are 
shown in colors. B) Different sets of MIP source transcripts are predicted to be reg-
ulated by mostly the same miRNAs. The WebGestalt analysis program30 was used 
to identify miRNAs that recognize the 3’-UTR binding site present in enriched MIP 
source transcripts. Numbers and percentages of miRNAs are depicted for each cat-
egory. Total number of miRNAs that target MIP source transcripts in each sibship are 
shown in colors. C) miRNA profiling shows that B-LCLs from HLA-disparate sibships 
have similar miRNA expression profiles. Human miRNA microarrays were used to as-
sess the expression of 1,205 human and 144 viral miRNAs, in B-LCLs (2 subjects from 
each sibship), CD19+CD20+ cells isolated from PBMCs of one member of sibship 2, and 
two non-lymphoid cell lines (HEK293 and HeLa). Hierarchical clustering was used to 
calculate the correlation between various profiles (represented by a dendrogram). D) 
miRNAs that target MIP source transcripts in B-LCLs are expressed at higher levels 
in B-LCLs than in other cell types. All miRNAs studied were ranked from high to low 
according to their expression level in each cell line. Among them, the ranking of each 
of the 133 miRNAs predicted to regulate MIP source transcripts in B-LCLs was deter-
mined in B-LCLs, primary CD19+CD20+ cells, HEK293 cells and HeLa cells. Each dot 
corresponds to one miRNA. The median rank is shown for each cell population (red 
line and values). In average, miRNAs predicted to recognize MIP source transcripts 
are ranked significantly higher (i.e. more expressed) in B-LCLs than in non-lymphoid 
cell lines (*P < 0.05, one-way ANOVA and Bonferroni’s multiple comparison test). B-
LCL-1.1: from subject 1 of sibship 1, B-LCL-1.2: from subject 2 of sibship 1, B-LCL-2.1: 
from subject 1 of sibship 2, B-LCL-2.2: from subject 2 of sibship 2.
To confirm that the miRNome of our 2 sibships was indeed similar, we per-
formed genome-wide miRNA profiling in 8 different cell lines: B-LCLs from the 
4 subjects (2 siblings from each sibship), primary CD19+CD20+ B cells from 
one of the subjects and 2 non-lymphoid human cell lines, HEK293 and HeLa 
(Figure 6C). Hierarchical clustering analysis revealed that the highest similarity 
was found between B-LCLs from the 2 sibships, which formed a separate clus-
ter. Hence, as expected, B-LCLs express a cell type-specific miRNome that is 
independent of the HLA genotype or other interindividual genetic differences. 
We then asked whether enriched miRNAs that were predicted to regulate MIP 
source transcripts in the 2 sibships (Tables 2 and S3) were indeed expressed in 
the B-LCLs of our four subjects and if so, at what level. All 1,349 profiled miR-
NAs were ranked from high to low according to their expression level in each 
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cell line. Among them, the ranking of each of the 133 miRNAs predicted to 
regulate MIP source transcripts in B-LCLs was determined in B-LCLs, primary 
CD19+CD20+ cells, HEK293 cells and HeLa cells (Figure 6D). Importantly, en-
riched MREs can be recognized by more than one miRNA (Table 2), and we can-
not assign which of the predicted miRNAs was indeed acting on the transcript 
source of MIPs. Despite this source of uncertainty, we found that in average, 
miRNAs predicted to recognize MIP source transcripts ranked significantly 
higher in B-LCLs than in control cell lines. Thus, miRNAs predicted to recog-
nize MIP source transcripts in B-LCLs were expressed at higher levels in B-LCLs 
than in other cell types. This supports the concept that the immunopeptidome 
of a cell is molded by its miRNome. 
3.6 Discussion
Self MIPs regulate all key events in the life of CD8 T cells. Indeed, CD8 T cells 
are selected on self MIPs, sustained by self MIPs, and activated in the presence 
of self MIPs.40 Moreover, MIPs are the targets of several immune processes in-
cluding autoimmunity, graft rejection, graft-.vs.-host disease and the graft-vs.
leukemia effect.5, 6, 37 Estimates suggest that the immunopeptidome comprises 
about 0.1% of the nonapeptide sequences (the typical length of MIPs) found 
in the proteome.5 Despite the important role of MIPs in health and disease, 
we know little about their biogenesis except for the fact that they derive from 
DRiPs whose physical nature remains ill-defined.13 In this study, we aimed to 
characterize the global landscape of MIPs on human cells and to gain insights 
in the biogenesis of the human immunopeptidome. We used B-LCLs as they can 
be obtained from practically any subject, they proliferate extensively in vitro, 
express high levels of MHC I molecules at the surface and have been shown to 
be a reliable tool for high-throughput genomic studies.41 We found that most 
MIPs bind one unique HLA among all available MHC allelic products, and they 
do so with different predicted binding affinities. In general, HLA-A-associated 
peptides had a significantly higher binding affinity than HLA-B-associated pep-
tides. This probably results from differences in the permissiveness of the HLA 
binding motifs. We also observed that subjects with no shared HLA-A and -B 
alleles present different MIP repertoires, showing that the immunopeptidome 
of an individual is ultimately determined by the combination of its HLA allelic 
products. This result was expected based on the specificities of the various 
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HLA binding motifs9 and is in accordance with a recent MS-based study that 
showed minimal overlap in the identity of soluble plasma MIPs found in two 
HLA-different individuals. 
Three salient findings emerged from the present work. Firstly, even though 
HLA-different subjects present different MIPs derived from different proteins, 
these MIPs originate from proteins that are functionally interconnected and 
implicated in the same biological pathways. In our B-LCLs, many MIP source 
proteins were associated to functional categories or involved in signaling path-
ways characteristic of the immune system or specific to B cell biology. Ac-
cordingly, we found that the MIP repertoire of B-LCLs was intimately linked 
to the transcriptome of B-LCLs. This further supports our previous results on 
mouse MIPs identified on thymocytes and DCs showing that the MIP repertoire 
conceals a tissue/cell-specific signature.16, 17 This means that the immunopep-
tidome is not monopolized by MIPs derived from ubiquitous housekeeping 
genes. The notion that the MIP repertoire is cell type-specific has to be taken 
into account in immunotherapeutic interventions such as leukemia immuno-
therapy.42 
Secondly, our results show that under basal conditions, the MIP repertoire 
of human B-LCLs derived preferentially from abundant transcripts. This was 
true when taking into consideration the whole exome (Figure 3 A-B) or a single 
transcriptional hotspot (the 6p21 chromosomal region; Figure 3 C-D). Notably, 
we used as a reference the average mRNA expression estimated by RNA-seq 
in B-LCLs from 20 unrelated individuals26, which provides an accurate esti-
mation of transcript abundance in this cell type. A correlation between tran-
script abundance and MIP presentation was also observed in MS studies on 
primary mouse thymocytes.16 However, this correlation was absent in studies 
analyzing changes in MIP abundance induced by neoplastic transformation or 
metabolic stress.16, 18, 29 All of these reports can be reconciled with a parsimoni-
ous explanation: i) in healthy normal cells, MIPs preferentially derive from the 
most abundant transcripts, and ii) in stressed cells, changes in MIP abundance 
result to a large extent from co- or post-translational processes that regulate 
the DRiP rate.
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Finally, perhaps the most exciting finding reported herein is that MIPs derive 
preferentially from transcripts bearing MREs. miRNA profiling experiments re-
vealed that the miRNAs which recognize MIP source transcripts in our B-LCLs 
were expressed at higher levels in B-LCLs than in other cell types. Furthermore, 
even though MIPs from HLA-disparate subjects derived from different tran-
scripts, miRNA profiling experiments confirmed that these sets of transcripts 
are regulated by similar miRNomes as predicted by bioinformatic analysis. 
Notably, we found that transcripts containing MREs were a preferential source 
of MIPs not only in our B-LCLs but also in various mouse and human cell types 
analyzed by our group and others. The relation between MREs and MIPs is 
therefore very robust as it holds true across species and cell types. Though we 
still have to investigate how miRNAs could enhance the generation of MIPs, 
our working hypothesis is that destabilization of mRNAs by miRNAs gener-
ates DRiPs. Consistent with this idea, studies on cells transfected with shRNA 
or mRNAs carrying premature stop codons have revealed that the nonsense-
mediated decay pathway can generate MIPs, presumably as a result of DRiP 
formation.43, 44 Indeed, miRNAs can decrease the levels of the targeted protein 
via various mechanisms including slowing of elongation, ribosome drop-off 
and nascent polypeptides degradation.45, 46 We therefore postulate that miR-
NAs are major regulators of the DRiP rate. Given the pervasive influence of 
miRNAs on all cellular processes including normal and neoplastic lympho-
hematopoiesis,47-50 further studies are warranted to understand how miRNA 
may mold the immunopeptidome of normal and neoplastic cells. In addition 
we propose that the engineering of the MIP repertoire via the miRNome might 
be relevant in immunotherapy. 
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3.11 Supplemental methods
3.11.1 Mass spectrometry and peptide sequencing 
MIPs were released by mild acid treatment and separated by ion exchange 
chromatography using an off-line 1100 series binary LC system (Agilent Tech-
nologies) as previously described.16 Peptides were loaded at 8 uL/min on a 
homemade strong cation exchange (SCX) column (0.3 mm internal diameter × 
50 mm length) packed with SCX bulk material (Polysulfoethyl ATM, PolyLC). 
Peptides were separated into five fractions using a linear gradient of 0–25% B 
in 25 min (solvent A: 5 mM ammonium formate, 15% acetonitrile, ACN, pH 3.0; 
solvent B: 2 M ammonium formate, 15% ACN, pH 3.0) and brought to dryness 
using a speedvac. MIP fractions were resuspended in 2% aqueous ACN (0.2% 
formic acid) and analyzed by LC-MS/MS using an Eksigent LC system coupled 
to a LTQ-Orbitrap mass spectrometer (Thermo Electron).16-18 Peptides were 
separated in a custom C12 reversed phase column (150 μm i.d. X 100 mm, 
Jupiter Proteo 4 μm, Phenomenex) at a flow rate of 600 nL/min using a linear 
gradient of 3-60% aqueous ACN (0.2% formic acid) in 69 mins. Full mass spec-
tra were acquired with the Orbitrap analyzer operated at a resolving power of 
60 000 (at m/z 400) and collision-activated dissociation tandem mass spec-
tra were acquired in data-dependent mode with the linear ion trap analyzer. 
Mass calibration used an internal lock mass (protonated (Si(CH3)2O))6; m/z 
445.120029) and mass accuracy of peptide measurements was within 5 ppm.
3.11.2 MS/MS sequencing and peptide clustering 
Mass spectra were analyzed using Xcalibur software and peak lists were gener-
ated using Mascot distiller version 2.1.1 (http://www.matrixscience.com). Da-
tabase searches were performed against a non-redundant IPI human database 
containing 150,858 sequences (version 3.54, released January 2009) using 
Mascot (version 2.2, Matrix Science). A Mascot search against a concatenated 
target/decoy database consisting of combined forward and reverse versions 
of the IPI human database was performed to establish a cutoff score threshold 
of typically 25. Non-redundant peptide sequences with a Mascot score higher 
than 25 were selected. The tolerance for precursor and fragment mass values 
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were set to 0.02 and 0.5 Da, respectively. Searches were performed without 
enzyme specificity and a variable modification for oxidation (Met) and deami-
dation (Asn, Gln). Raw data files were converted to peptide maps comprising 
m/z values, charge state, retention time and intensity for all detected ions 
above a threshold of 15000 counts using in-house software (Mass Sense).16-18 
Peptide maps were aligned and clustered together to profile the abundance 
of Mascot identified peptides using hierarchical clustering with criteria based 
on m/z and time tolerance (±0.02 m/z and ±1 min). This resulted in a list of 
non-redundant peptide clusters for all replicates of all samples. MS/MS of all 
peptide identifications are available through ProteoConnections24 at http://
www.thibault.iric.ca/proteoconnections under the project 111. 
3.11.3 Functional connectivity score
To calculate the score, we first computed a distance (D) between each pair of 
neighbor nodes in an interaction network, D = –log2(P), where P is the prob-
ability that an interaction exists between 2 nodes given by the STRING data-
base 9.0 (http://string-db.org/)25. STRING is a database of both known and pre-
dicted protein-protein interactions. It includes direct (physical) and indirect 
(functional) associations, which are derived from different sources: genomic 
context, high-throughput experiments, coexpression, and prior knowledge. 
Procedures to compute experimental scores are described in http://string-
stitch.blogspot.com/2008_06_01_archive.html. We then summed the distanc-
es between nodes composing the shortest path between each pair of proteins 
in the matrix (one protein from each list). The connectivity score was then 
obtained by calculating the mean of the shortest path distance between every 
pair of nodes in a given matrix.
3.11.4 Analysis of SNP frequency
We have used the in-house developed software pyGeno to estimate the fre-
quency of single nucleotide polymorphisms (SNPs) in the MIP coding genomic 
sequences and in the human exome. PyGeno is a Python module that inte-
grates Ensembl GTF files (GRCh37.65) for gene annotations, the reference hu-
man genome (GRCh37.p2) and the reference database of SNPs dbSNP (Build 
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135). We first located exomic sequences corresponding to each MIP and then 
searched for validated SNPs in the peptide-coding region. Similarly, validat-
ed SNPs were located in the whole human exome corresponding to 264,401 
coding sequences (CDS) extracted from Ensembl. We then classified SNPs as 
synonymous (nucleotide variation not leading to an amino acid change) or 
non-synonynous (nucleotide variation leading to an amino acid change). Syn-
onymous SNPs correspond to the dbSNP function class ‘synonymous-codon’ 
and non-synonymous SNPs comprise the dbSNP function classes ‘stop-gained’, 
‘missense’, ‘stop-lost’, ‘cds-indel’ and ‘frameshift-variant’. The number of SNPs 
inside all MIP-coding regions where summed and divided by the total length 
in base pairs (bp) of all MIP-coding regions to determine the SNP frequency 
(SNP/bp). The same approach was applied to estimate the SNP frequency in the 
exome, considering all CDS instead of MIP coding regions. The SNP frequency 
in MIP coding sequences and in the exome not encoding MIPs was compared 
with a two-tailed Fisher’s exact test. 
3.11.5 Transcriptome of B-LCLs 
We used reported gene expression profile data of B-LCLs from 20 unrelated in-
dividuals performed by RNA-seq26 and available at the GEO repository (http://
www.ncbi.nlm.nih.gov/geo/, GSE29158). RNA expression levels are given in 
fragments per kilobase of exon model per million mapped reads (FPKM) and 
the expression level for a gene is the sum of the FPKM values of its isoforms. 
For each coding transcript we calculated the average expression (AE) of the 
20 B-LCLs. Non-protein coding and not-expressed transcripts were excluded. 
A total of 15,737 protein-coding transcripts expressed in B-LCLs were classi-
fied into four expression categories based on Toung et al.26: very low (AE>0), 
low	 (0.05<AE≤	 2.3),	medium	 (2.3<AE≤163)	 and	 high	 (163<AE).	We	 used	 the	
UCSC genome browser to map the 6p21 chromosomal region between posi-
tions 30400001 and 46200000 bp and the NCBI Map viewer to obtain the list of 
genes comprised in that region. Of those, we considered only genes classified 
as ‘protein-coding’ and with a RefSeq status ‘validated’, ‘reviewed’ or ‘model’. 
The average expression level (FPKM per gene) was calculated for all protein-
coding genes in 6p21 and all protein-coding genes expressed in B-LCLs.
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3.12 Supplemental Figures
Figure S1. Comparison of the predicted MHC I binding affinity (IC50) of MIPs
Predicted MHC I binding affinity (IC
50
) of eluted peptides to different HLA allelic prod-
ucts, based on bioinformatic predictions with NetMHC/NetMHCpan. 
Figure S2. Random changes of mRNA expression thresholds set to define expres-
sion categories do not affect the differences in expression between transcripts 
encoding MIPs and all the transcripts expressed in B-LCLs
Random thresholds of mRNA expression level were set. For each threshold, a Fisher’s 
exact T test was performed to compare the frequency of mRNA expression levels 
above and below a given threshold in MIP source transcripts vs. the transcriptome. 
The P value obtained by this test is shown for each random threshold of mRNA ex-
pression level analyzed (black line). The dotted blue lines represent the thresholds 
used to define expression categories in Figure 3. The red line indicates the limit P 
value for significance. Each significant P-value indicates that the proportions on both 
sides of the threshold in the 2 datasets are significantly different. Thus, this analysis 
shows that after setting the expression categories thresholds anywhere between -10 
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and 10, the comparison of the proportion of transcripts in each category is signifi-
cantly different between MIP source transcripts and the transcriptome of B-LCLs.
Figure S3. The MIP-transcriptome connectivity correlates with the level of expres-
sion of the transcripts in the transcriptome
The connectivity scores between MIP source proteins and 3 different sets of the pro-
tein-coding transcriptome of B-LCLs were calculated with the all-pairs-shortest-path 
matrix as described (Figure 4B). The 3 sets of transcripts analyzed were as follows: i) 
high, medium and low (H+M+L) (top), ii) high and medium (H+M) (middle) and iii) low 
(L) (bottom). The scores are indicated in red and represented by red lines. A bootstrap 
procedure, represented by the Gaussian distribution, was used to calculate control 
connectivity scores between MIPs source proteins and random sets of the human pro-
tein coding transcriptome. (*P < 0.0001, calculated as the number of times that the 
score of the bootstrap is smaller than the score of the sample/ number of bootstraps). 
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Figure S4. MIPs coded by miRNA targets are overrepresented in the mouse and 
human immunopetidomes
The same approach as the one described in Figure 5 A and B was used. In this case, 
the list of A) 5,887 human and B) 3,803 mouse protein-coding miRNA targets was 
extracted from MSigDB.28 Numbers on the bottom indicate the number of entries for 
each dataset. A) The proportion of MIPs that derive from miRNA targets for all human 
datasets was significantly higher than the proportion of miRNA targets in the human 
protein coding transcriptome (PCT) (a) P < 2.2 x 10-16, b) P < 2.43 x 10-11, c) P < 2.35 x 
10-3, d) P < 3.3 x 10-8, e) P < 1.38 x 10-6, Fisher’s exact test). B) The proportion of MIPs 
that derive from miRNA targets for all mouse datasets was significantly higher than 
the proportion of miRNA targets in the mouse protein coding transcriptome (PCT) 
(a,c) P < 2.2 x 10-16, b) P < 3.52 x 10-8, Fisher’s exact test). C) and D) Proportion of 
miRNA targets in MIP source transcripts vs. the protein coding transcriptome of B-
LCLs. A list of C) 5,813 and D) 8,621 human protein-coding miRNA targets extracted 
from MSigDb28 and TargetScan27, respectively, was used to calculate the proportion 
of targets in 15,730 protein-coding transcripts expressed by B-LCLs26 and 1,577 tran-
scripts source of peptides eluted from B-LCLs of both sibships. The proportion of 
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miRNA targets is significantly higher in MIP coding transcripts than in the proteincod-
ing transcriptome of B-LCLs (a) P < 1.96 x 10-10, bP < 1.25 x 10-7, Fisher’s exact test).
3.13 Supplemental Tables
Supplemental tables S1-S3 are available on http://bloodjournal.hematologyli-
brary.org/content/119/26/e181/suppl/DC1.
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4 Minor histocompatibility antigens
Minor histocompatibility antigens (MiHAs) are a particular type of MHC I or 
MHC II-associated peptides that were originally discovered in a transplanta-
tion context, where they play a role in modulating immune reactions between 
donor and recipient cells [1,2]. In a transplantation setting between two per-
fectly HLA-matched (i.e. MHC-identical) individuals, recipient cells present a 
repertoire of MHC I-peptides that is not perfectly identical to the repertoire of 
peptides presented on donor cells [3]. Those MHC peptides that differ between 
patient and donor and that result from donor/recipient genetic disparity out-
side the MHC are known as MiHAs [4]. Hence, in the context of two HLA-identi-
cal subjects, MiHAs represent non-self peptides and therefore are not subject 
to tolerance mechanisms [5]. Consequently, MiHAs can induce and modulate T 
cell allo-responses in the recipient-to-donor or donor-to-recipient direction [5]. 
4.1 Origin of MiHAs
MiHAs result from any type of genetic variation in genes outside the MHC al-
tering the amino acid sequence of the peptide or the expression of the protein 
source of peptide [6]. Most MiHAs discovered to date are caused by one or 
more nonsynonymous single nucleotide polymorphisms (ns-SNPs) in protein 
coding sequences that give rise to single or several amino acid substitutions in 
the polymorphic peptide [3]. Moreover, MiHAs can result from insertions, de-
letions, copy number variations (CNVs), frame-shift mutations and nonsense 
mutations [3,7-9]. The type and location of the genomic polymorphism can 
either affect the generation [9,10], the processing [11,12], the presentation 
[13-16] or the recognition of the peptides by the TCR [13,14,17,18] (Figure 1). 
Since in most human cases the alternative potential MiHA variant never reach 
the cell surface or is not immunogenic, most MiHAs possess only one immu-
nogenic allele and only unidirectional recognition is seen [5].
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In various instances genetic variation impedes the generation of the protein 
source of peptides leading to MiHAs. The first MiHA was discovered following 
rejection of transplanted HLA-matched bone marrow cells from a male donor 
by his female recipient sibling [1]. The cause of rejection was the recognition 
of a male antigen derived from a gene on the Y- chromosome by the female T 
cells. Hence, the absence of Y chromosome-encoded proteins in female cells 
due to a “sex-mismatch” can lead to a particular type of MiHAs, referred to as 
HY MiHAs. The genes KDM5D and UTY located in the Y chromosome encode 
more than 6 distinct HY MiHAs [19]. Another example is the non-deleterious 
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Figure 1. Mechanisms of generation of MiHA disparities
Genomic polymorphisms can affect multiple steps in the MHC I antigen 
processing and presentation pathway. Examples of human MiHAs are given 
in each step.
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homozygous deletion of the UGT2B17 gene that is responsible for the genera-
tion of at least 2 known MiHAs [10,20,21]. Additionally, the PANE1 MiHA re-
sults from an nonsense SNP that generates a premature termination codon in 
the MiHA negative (variant) allele [9]. Similarly, the P2X5 MiHA results from a 
single nucleotide insertion/deletion (indel) that causes a frameshift and leads 
to a different protein sequence and thus the absence of peptide [8].
MiHAs can also result from SNPs in non-coding regions, such as 3’ or 5’ UTRs 
of protein-coding genes [22-24]. The HY-A33 MiHA results from a SNP present 
in the 5’ UTR of the TMSB4Y gene leading to the expression of a protein vari-
ant in an alternative reading frame that is absent in the TMSB4Y homologue 
on chromosome X [23]. MiHAs can also be created by intronic SNPs in splicing 
sites leading to different splicing variants and thus the presence of a MiHA in 
some subjects and its absence in others [25,26]. This is the case of the ACC-
6 MiHA, which derives from an alternative splice variant of the HSMD gene 
[25]. Likewise, MiHAs can be generated by SNPs in cryptic, noncanonical open 
reading frames in “genes” that are otherwise not known to generate a protein 
product. This is the case of the HB-1 MiHA encoded by a short 41 amino acids 
sequence whose function is unknown and that results from translation start-
ing at a CUG codon [27]. 
Ns-SNPs have also been shown to affect the processing of the peptide [11,12,28-
31]. For example, the methionine residue in the sequence of the HA-3T MiHA 
allelic variant (named HA-3M) causes the destruction of the precursor peptide 
by proteasomal cleavage C-terminal to the methionine residue [12]. Also, the 
ns-SNP in the coding region of HA-8 leads to inefficient translocation of pep-
tide precursors into the ER by TAP and thus the corresponding variant peptide 
is absent on the cell surface [11]. A more peculiar example is the SP110 MiHA, 
produced by an exonic ns-SNP that causes the natural splicing of two non-con-
tiguous peptide fragments in the reverse order by the proteasome resulting in 
a novel MiHA whose sequence is not encoded by the genome [30]. 
Finally, MiHAs can result from amino acid substitutions that affect the bind-
ing to MHC molecules or the recognition by the TCR [14,27]. In the first case, 
ns-SNPs that lead to changes in residues at anchor positions of the peptide 
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frequently affect the stability and binding of the peptide to MHC molecules. In 
the second scenario, the MiHA and its allelic counterpart are highly discrimi-
nated by T cells due to the fine specificity of the TCR in distinguishing non-self 
from self [32]. This situation is exemplified by the HA-1H MiHA variant (HA-
1R) that do bind the HLA molecule but is not recognized by the TCR [14]. Since 
both MiHA variants are presented at the cell surface, these type of MiHAs can 
exhibit reciprocal antigenicity, such that both allelic peptide variants can elicit 
a T cell response [32,33]. Notably, posttranslational modifications can also 
lead to discrimination by the TCR [34-36]. For instance, the murine MiHA H4b 
contains a phosphorylated threonine residue that distinguishes it from the not 
immunogenic variant that contains an isoleucine residue instead [34]. Analo-
gously, the cysteinylation of the cysteine residue contained in the HY-A2 MiHA 
can augment the recognition by a T cell clone, despite the fact that it slightly 
reduces the binding affinity for HLA-A*0201 [35]
4.2 MiHAs and allo-recognition
In an HLA-matched transplantation setting, MiHAs encoded by biallelic genes 
can differ between patient and donor due to genomic polymorphisms and trig-
ger 3 types of bidirectional immune responses between donor and recipient 
cells: graft rejection, graft-versus-host disease (GvHD) and graft-versus-tumor 
(GvT) or graft-versus-leukemia (GvL) reactions. Graft rejection occurs when 
recipient T cells respond and target immunogenic peptides on the graft itself 
[37]. Inversely, donor T-cell responses directed against MiHAs of the recipient 
that are not present on donor cells, can cause the detrimental GvHD, but also 
elicit the curative GvT or GvL reactions [38]. The cell and tissue expression of 
the MiHAs determine in some extent the direction and type of reaction [39]. 
For instance, an HLA-matched donor who is homozygous for the MiHA ‘nega-
tive’ allele may have T cells that recognize recipient cells that are heterozygous 
or homozygous for the MiHA ‘positive’ allele [32,40]. In this donor-to-recipient 
scenario, MiHAs restrictively expressed in hematopoietic cells or tissue (in-
cluding leukemic cells) induce specific allo-immune responses of donor T cells 
against recipient hematopoietic/leukemic cells that can lead to destruction 
of cancer cells (GvT/GvL reactions). On the contrary, MiHAs ubiquitously ex-
pressed in the recipient participate not only in GvL but also in GvHD [41,42], in 
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which donor T cells damage recipient target organs including the skin, gastro-
intestinal tract, liver and lung [43]. 
HY MiHA-specific T cells can be readily isolated from male recipients of MHC-
matched female grafts [44]. Accordingly, the rate of relapse after transplanta-
tion is decreased in male recipients of MHC-matched female grafts owing to 
alloreactivity against male-specific HY MiHAs that contribute to GvL activity 
[45-48]. Paradoxically, male recipients of female donors do not necessarily ex-
perience increased survival due to increased morbidity and mortality caused 
by a higher risk of acute GVHD in these patients [41,45,46,49,50]. 
Apart from their central role in mediating transplantation outcomes, MiHAs 
are also important in “natural” allo-recognition conditions such as pregnancy. 
The role of MiHAs in pregnancy was first considered following the observation 
that parous female donors were more likely to elicit GvHD in transplant recipi-
ent than non-parous female or male donors [45]. Several studies have shown 
that the maternal immune system can recognize and respond to fetal MiHAs 
(reviewed in [51]).  For instance, T cells specific for the MiHAs HA-1, HA-2 
and HY have been found in maternal blood following pregnancy of mothers 
lacking the corresponding immunogenic alleles [51-53]. Indirect evidence sug-
gests that fetal MiHAs might play a role in pregnancy complications. Increased 
expression of the MiHA HA-1 has been measured in preeclamptic placentas. 
Also, epidemiologic evidence suggests that recognition of fetal MiHAs might 
be implicated in secondary recurrent miscarriage, specially in women who 
have previously given birth to a male baby [51].  
4.3 MiHA-based immunotherapy
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an estab-
lished potentially immunotherapeutic approach for several hematological 
malignancies [54]. Originally, the role of allo-HSCT was to reconstitute the 
patient hematopoietic compartment after sublethal chemoradiotherapy with 
the engrafted immune system from the donor. Nevertheless, it shortly became 
evident that donor lymphocytes could mediate the curative GvT/GvL effect 
after allo-HSCT, which could be exploited in cancer immunotherapy [54,55]. 
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To reduce the development of GvHD following allo-HSCT, donor T cells can be 
depleted from the stem cell graft and re-administered after allo-HSCT in case 
of relapse in a process termed donor lymphocyte infusion (DLI). Compelling 
direct and indirect evidence suggest that the curative capacity of allo-HSCT 
results from a potent GvL/GvT effect mediated by donor lymphocytes [56]. 
First, it has been shown that following allo-HSCT, both CD8+ and CD4+ T cells 
specific for MiHAs on recipient cells are activated in vivo and can be isolated 
in vitro [2,57]. Second, human MiHA-specific CD8+ T cells have been shown 
to lyse primary leukemic cells in vitro [57-60]. Third, an increased incidence 
of leukemic relapse has been observed after autologous, syngeneic (identical 
twin) or T-cell depleted allo-HSCT [54]. Lastly, donor lymphocyte infusion is 
very effective to treat patients who relapsed after allo-HSCT [54]. Unfortunate-
ly, the successful application of the GvL/GvT effect in allo-HSCT is masked by 
the considerable morbidity and mortality of GvHD [56]. Currently, one of the 
main focus of research in the field is strategies to augment the GvL effect to 
prevent and treat relapse, while diminishing or avoiding GvHD [5].
The association of transplantation outcome and donor/recipient mismatching 
at loci encoding MiHAs has been evaluated by numerous retrospective studies 
yielding conflicting results even when analyzing the same MiHA [3,49,50,61-
63]. Some studies have associated MiHA mismatch with GvL effect and long 
term survival in patients who received donor lymphocyte infusion to treat 
post-transplant relapse [14,60,64,65]. For instance a retrospective study has 
shown that one or more MiHA mismatches between HLA-matched donor and 
recipients in a large cohort of patients, who underwent T cell-depleted allo-SCT, 
resulted in improved relapse-free survival [49]. Other studies have not found 
a significant correlation between specific MiHA disparities and allo-HSCT out-
come [61-63,66]. In opposition, some studies have shown that certain (but not 
all) MiHA mismatches between donor and recipient can increase the incidence 
and severity of GvHD [39,67,68], suggesting that some MiHAs might be pre-
ferred in allo-SCT. Despite the need of more systematic and comparable stud-
ies to establish the relation of allo-HSCT outcome and each MiHA mismatch, 
collectively these results suggest that early identification of MiHA mismatches 
between recipient and potential donors may help improving donor selection, 
improve allo-HSCT outcome, while minimizing GvHD [67].
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The concept of targeting hematopoietic tissue-restricted MiHAs for immuno-
therapy of hematological malignancies was introduced in the mid-nineties. Var-
ious studies have shown that MiHA-based immunotherapy can very effectively 
destroy tumor cells in mouse models [69-72]. Moreover, it has been shown 
that adoptive transfer of CD8+ cytotoxic T cells directed at a single MiHA can 
effectively eradicate leukemia and melanoma without GvHD in mouse models 
[73,74]. Several strategies have been developed for using MiHAs to elicit GvL 
and GvT effects in humans [75]. Examples include in vitro isolation and expan-
sion MiHA-specific T cells, vaccination of patients and donors with dendritic 
cells pulsed with MiHA or modified to present MiHA source proteins, mRNA 
or DNA and redirection of T cell specificity by gene transfer of MiHA-specific 
TCR [32,54]. An alternative approach is to isolate MiHA-specific T cells directly 
from the donor before allo-HSCT and administer them as part of the graft or 
shortly after transplant (reviewed in [5]).
Currently, the hematopoietic-restricted HA-1 [28] and HA-2 MiHAs are the 
most extensively explored MiHAs in immunotherapy. HA-1 is probably the 
most therapeutically-relevant MiHA, that could be applied in 6-12% of patients, 
depending on the transplantation setting (HLA-matched sibling vs. unrelated 
donor transplantation) [76]. Recently, Warren and coworkers have proposed 
the modulation of T cells specific for MiHAs to augment GvL and GvT effects, 
while reducing the need of immunosuppressive drugs [77]. In this approach, 
donor T cells specific for a particular MiHA expressed exclusively in leuke-
mic/tumor cells are isolated from the recipient’s blood following transplanta-
tion and expanded ex vivo [77]. The expanded T cells are re-infused into the 
recipient following a disease relapse. A preliminary clinical trial of adoptive 
immunotherapy using MiHA-specific T cells (although poorly characterized), 
showed some success in treating relapse but also pulmonary toxicity at high 
T-cell doses which correlated with MiHA expression in pulmonary endothelial 
cells [77]. 
The limited number of identified human MiHAs has been one major barrier for 
the broad clinical application of MiHAs in immunotherapy [5]. Ideally, a large 
panel of MiHAs would facilitate the selection of the best target as the tissue ex-
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pression of the MiHA, the HLA-restricting molecule and the correct directional 
disparity between donor and recipient, reduce the real number of usable MiHA 
for each particular transplantation case. Preferably, MiHAs need to fulfill vari-
ous characteristics for broad application in immunotherapy of leukemia. First, 
a restricted expression of MiHAs to hematopoietic cells would maximize the 
GvT effect without causing GvHD [55]. Second, MiHAs presented by common 
HLA molecules and that display an equally balance phenotype population fre-
quency (to increase the chance of MiHA-mismatch) would have a broader ap-
plication [78]. Additionally, the genetic nature of the MiHA could increase its 
potency.  It has been suggested that MiHAs resulting from gene deletions (such 
as UGT2B17) could have more impact than MiHAs resulting from SNPs, as this 
will increase the potential of multiple antigenic epitopes associated to differ-
ent HLA molecules to trigger an immune response [67,68].
4.4 The arduous identification of MiHA 
Since the discovery of the first MiHA almost 4 decades ago [1], new MiHAs have 
been identified at a very slow rate. A summary of all currently known MiHAs 
associated to MHC I and MHC II is presented in table 1. There are currently 59 
MiHAs reported in the literature, of which 12 are associated to MHC II and 47 
to MHC I molecules. They derive from 44 autosomal and 6 Y-chromosome-en-
coded genes of broad or restricted expression. Notably, 33 of them (56 %) have 
been identified in the last 5 years, illustrating how recent advances in human 
genomics and bioinformatics have accelerated the pace of MiHA discovery. 
Several techniques including both forward and reverse immunology approach-
es have been developed to identify MiHAs. Classically, the identification of 
MiHAs starts with a MiHA-reactive T cell clone obtained from a patient show-
ing a clinical response to DLI after allo-HSCT, followed by elucidation of the 
antigens that are recognized. These T-cell based approaches are referred to as 
forward immunology approaches. The T cell clone is used to investigate the 
MiHA specificity, the HLA allele that presents it and the basis of its immunoge-
nicity, using techniques such as cDNA-expression cloning [10,17,22,25,27,79-
82], high performance liquid chromatography (HPLC) and mass spectrometry 
(MS) [13,18,28,35,36,83-85], genetic linkage analysis [8,11-13,28,29,86,87] or 
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whole genome association scanning [21,22,81,88,89]. 
The first MiHAs were discovered using T-cell based immunology approaches 
combined with HPLC and MS. In this strategy, peptides are extracted directly 
from the recipient cell and fractionated by HPLC to identify fractions that 
contain the epitope recognized by cytotoxic T cells. Positive fractions are then 
analyzed by MS [13,28,35,36,84]. Alternatively, T cell-based approaches have 
been combined with cDNA expression cloning. Here, MiHA-specific cytotoxic 
T cells are screened against COS7 or 293T cells cotransfected with pools of 
plasmid cDNA library prepared from MiHA-positive cells and with a plasmid 
encoding the HLA-restricting allele [17,24,25,27,30,33,90]. Positive cells are 
subcloned to identify those that express the cDNA encoding the MiHA, which 
is then localized by transfecting truncated versions of the gene or by predic-
tion algorithms for HLA binding [6]. This technique has been more recently 
adapted for the identification of MHC II-associated MiHAs by expressing the 
cDNA library in bacteria and then loading the modified bacteria into MHC II-
positive B-LCLs [82,91]. 
Alternatively, MiHAs have been discovered by testing the reactive T cell clones 
against a panel of B-LCLs from large pedigrees such as the Centre d’Etude Poly-
morphism Humain (CEPH) families that have been mapped for genetic mark-
ers, followed by genetic linkage analysis to identify the chromosomal region 
underlying the MiHA [8,81,92].
Important development in the field are genome-based strategies for MiHA 
identification such as genome-wide-association studies, HapMap screening, 
whole genome association scanning and genome-wide zygosity-genotype cor-
relation analysis [21,22,88,89,92,93]. Basically, these approaches analyze the 
relationship between patterns of expression of the MiHA phenotype of B-cell 
lymphoblastoid cell lines (B-LCLs), measured by in vitro cytotoxicity or cyto-
kine secretion assays, and their pattern of SNPs genotype obtained from pub-
licly available B-LCLs of known genotypes or from databases such as HapMap 
[94]. In contrast to genetic linkage analysis, these approaches are more rapid 
and powerful because the genome-wide analysis is performed simultaneously 
for all SNPs across the whole genome.
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The genome-wide zygosity-genotype correlation analysis allows to precisely 
map the genomic locus of MiHAs and identify the MiHA amino acid sequence 
[89,92]. This method starts with the isolation of CTLs from allo-SCT recipi-
ents with a strong GvT response. The CTLs are tested in vitro for recognition 
of recipient’s but not donor’s APCs. Selected CTLs are then screened using 
a panel of B-LCLs with different combinations of HLA molecules to identify 
the specific HLA molecule presenting the MiHA. Then, B-LCLs from multiple 
individuals carrying the specific HLA and from different father-mother-child 
trios are tested against the CTL.  Using a Mendelian segregation pattern of the 
father-mother-child trios the MiHA zygosities are deduced for various indi-
viduals and a genome-wide zygosity-genotype correlation analysis allows the 
identification of candidate SNPs, of which only non-synonymous coding SNPs 
are retained. Lastly the SNP disparity in donor and recipient cells is confirmed 
and all possible nonameric sequences including the SNP are synthesized and 
tested in vitro with the CTL (IFN-γ response). This approach allowed the recent 
identification of the UTA2-1 MiHA, among others [76].
Alternative approaches not requiring father-mother-child trios are those based 
on whole-genome association scanning (WGAs) [21,22,81,88]. In this strategy, 
a panel of SNP-genotyped B-LCLs (either expressing the patient’s HLA mol-
ecules or retrovirally transduced with the HLA genes of the patients) are test-
ed for recognition by the CD8+ T cells isolated from patients with leukemia 
who responded to DLI with minor GvHD. The genetic origin of MiHAs is then 
identified based on an analysis of association between T cell recognition of 
each B-LCL and individual SNP genotypes. The precise identity of the MiHA is 
determined using synthetic peptides. Recently, a similar approach combining 
microarray-based SNP genotyping followed by peptide prediction and in vitro 
peptide binding assays has been used for the identification of MiHAs associat-
ed to MHC II [93]. Genome-based approaches represent one of the most prom-
ising methods currently available for high-throughput identification of MiHAs.
Forward approaches based on cytotoxic T cell clones have the advantage of 
identifying clinically relevant MiHAs, as frequently MiHA specific- T cells cor-
relate with clinical responses [60]. However, one of the major constraints of 
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T cell-based approaches is the relative scarcity of CD8+ T cells in peripheral 
blood and target sites. Furthermore, MiHA-specific T-cell responses may go 
undetected, especially when analyzed directly ex vivo in clinical specimens 
that are not obtained during the peak GVL response. In addition, T cells be-
ing extremely cross-reactive, T-cell based antigen discovery (in the absence of 
MS) is associated with a high rate of false positives [95,96]. Hence, it is often 
necessary to fish a target population with MHC multimers and expand the T 
cells ex vivo using cytokines and antigen, potentially altering their functional-
ity [97,98]. Novel alternative approaches have been proposed to facilitate the 
cumbersome task of isolating T cell clones from blood of allo-HSCT recipients. 
Bleakley and coworkers have successfully applied the in vitro stimulation of 
naive CD8+ T cells from unprimed donors with monocyte-derived dendritic 
cells from the HLA-identical sibling for the identification of novel MiHAs [40]. 
Hombrink and coworkers also developed an highthroughput approach to si-
multaneously isolate different reactive T cells from peripheral blood mono-
nuclear cells (PBMCs) by using a large collection peptide-MHC tetramers and 
then expanding the cells in vitro prior to analysis by flow cytometry [99].
Because T cell are not always available, reverse immunology approaches 
based on bioinformatic predictions of MiHA have been developed [19,93,99-
101]. These approaches start with prediction of candidate peptides and subse-
quently in vitro screening using proteasome digestion, HLA-binding, and test-
ing for their ability to activate T cells. An example of this strategy is the recent 
work by Mortensen and coworkers, who predicted all possible 8-11mer pep-
tides derived from the UTY gene located on the Y-chromosome that could bind 
the 15 most common HLA-A and HLA-B molecules [102]. The predicted pep-
tides were ranked, synthesized and tested for induction of cytokine response 
upon contact with PBMCs from a lymphoma patient who was in remission after 
allo-HSCT. Subsequently, the candidate MiHA was confirmed with HLA-peptide 
binding assays and tetramer staining. Another example is a recent reverse im-
munology approach proposed by Robins and coworkers, in which candidate 
MHC-binding nonamers are generated in silico based on single mutations iden-
tified by exome sequencing of melanoma cell lines obtained from patients and 
tested for recognition by autologous tumor-infiltrating lymphocytes [103].
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Although reverse immunology strategies are less laborious than forward ap-
proaches, they often fail to confirm the processing and immunogenicity of the 
candidate MiHAs under natural conditions because they suffer from a high 
false discovery rate that can represent 95% of candidate peptides [103]. Cur-
rently, reverse immunology approaches reflect the limited knowledge and un-
predictability of the antigen processing pathway, in which only 0.1 % of the 
produced peptides are indeed presented on the cell surface [104].  To improve 
discovery, novel approaches have combined bioinformatics predictions with 
experimental identification of HLA-presented MIPs and MiHAs by mass spec-
trometry without the need of T cell clones [105]. For example, van Veelen and 
coworkers have developed a database of all possible polymorphic proteins 
generated from all reported ns-SNPs that can be used for identification of 
polymorphic MIPs and potential MiHAs by mass spectrometry [106]. Although 
this strategy relying on naturally presented peptides, instead of predicted pep-
tides, has allowed the identification of the LB-NISCH-1A MiHA [107], the use of 
a generalized database for MS-based peptide identification introduced another 
type of bias leading to 25% of false positive peptide identifications [105,107].
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5.3 Abstract
We developed a novel approach combining next-generation sequencing, bioin-
formatics and mass spectrometry to assess the impact of non-MHC polymor-
phisms on the repertoire of MHC I-associated peptides (MIPs). We compared 
the genomic landscape of MIPs eluted from B lymphoblasts of two non-twin 
MHC-identical siblings and discovered that 0.5% of non-synonymous single 
nucleotide variations were represented in the MIP repertoire. We identified 34 
polymorphic MIPs which were encoded by biallelic loci and behaved as domi-
nant or recessive traits. We determined that, at the population level, at least 
536 polymorphic MIPs can be presented by the five HLA class I allotypes ex-
pressed by our subjects and that 12% of the MIP-coding exome is polymorphic. 
Our method provides fundamental insights into the relation between the ge-
nomic self and the immune self and accelerates the discovery of polymorphic 
MIPs (also known as minor histocompatibility antigens), which play a major 
role in allorecognition.
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5.4 Introduction
Multicellular organisms distinguish self and genetically distinct members of 
the same species (nonself) based on recognition of polymorphic cell surface 
molecules referred to as “histocompatibility antigens”1. The capacity to dis-
tinguish self from allogeneic histo-incompatible “nonself” (allorecognition) is 
critical for multicellular life2-4. In Botryllus schlosseri, a member of the urochor-
dates (the closest living sister group of vertebrates), self is defined by a single 
polymorphic gene, BHF5. The definition of self is more complex in vertebrates. 
Thus, the TCR of classic adaptive CD8 T cells recognizes MHC class I-associat-
ed peptides (MIPs), and the ensemble of MIPs presented on the surface of a cell 
(the “immunopeptidome”) establishes its immunologic identity6. CD8 T cells 
are eminently self-referential and highly discriminant: they are selected on 
self-MIPs, sustained by self-MIPs, and must swiftly react when confronted with 
nonself MIPs interspersed in a sea of self-MIPs7, 8. Understanding the molecular 
definition of self for CD8 T cells has been made possible by high-throughput 
mass spectrometry (MS) analyses of MIPs9-15. Progress in this field has been 
heralded by the development of MS instruments whose sensitivity, dynamic 
range and mass accuracy are orders of magnitude superior to those of analyz-
ers available a decade ago16. The immunopeptidome is shaped by numerous 
co- and post-translational events9, 17, 18. Accordingly, high-throughput MS stud-
ies have revealed that the immunopeptidome is highly complex and that its 
composition (i.e., the source of MIPs) cannot be inferred solely from transcript 
or protein abundance10, 12, 15, 19-21. 
The MHC I region contains two major classes of genes: modern classical MHC 
Ia genes (e.g., HLA-A, HLA-B and HLA-C in humans) and more ancient MHC 
Ib genes (e.g., HLA-E and HLA-G). MHC Ia molecules play a dominant role in 
adaptive immunity. They bind MIPs and are encoded by the most polymorphic 
genes known22, 23. Since MHC Ia allotypes display distinct peptide binding mo-
tifs, the HLA genotype has a major impact on the MIP repertoire24. Notably, 
almost all genetic polymorphisms in HLA Ia alleles are located in exons 2 and 
3, which encode the MIP-binding pocket. These exons contain less than one 
millionth of the 3.3 × 109 bases in the haploid human genome25. Besides, the 
1000 Genomes Project Consortium has identified 38 million single nucleotide 
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polymorphisms (SNP), 1.4 million short insertions and deletions, after com-
prehensive studies on 1,092 subjects23. This raises the fundamental question: 
what might be the impact of the numerous polymorphisms outside of the MHC 
on the MIP repertoire? In other words, to what extent do genomic polymor-
phisms translate into differences in the immunopeptidome? 
Several MIPs have been found to derive from polymorphic genomic regions26, 
27. For historical reasons, these polymorphic MIPs are referred to as minor his-
tocompatibility antigens (MiHAs). MiHAs are a consequence of genetic varia-
tions that hinder MIP generation (e.g., gene deletion) or the structure of a MIP 
[e.g., high frequency non-synonymous SNPs (ns-SNPs) or less-well character-
ized non-synonymous single nucleotide variations (ns-SNVs)]25, 28, 29. MiHAs are 
generally defined according to three criteria: they are present in some but not 
in all subjects bearing a given HLA allele, their presence/absence is linked to 
a well-defined genetic polymorphism, and they can elicit allo-immune T-cell 
responses25, 28, 29. Three decades of research have led to the discovery of about 
35 human MiHAs encoded by autosomes and presented by HLA class I mol-
ecules25, 29. The discovery of each MiHA has been a major endeavor, if not a 
technical tour de force30-35. However, due to the lack of a suitable systems level 
approach, we ignore the global impact of non-MHC genomic polymorphisms 
on the immunopeptidome (i.e., what proportion of MIPs are MiHAs). Based on 
various theoretical premises, it has been speculated that the number of Mi-
HAs expressed by an individual might be very low (less than ten) or very high 
(greater than 1,000)25, 27. In addition to its conceptual importance, the impact 
of genetic polymorphisms on the immunopeptidome is of considerable medi-
cal relevance because MiHAs are the targets of three allo-immune processes: 
graft rejection, graft-versus-host disease and graft-versus-tumor reaction25, 36-
41. 
Systems-level molecular definition of the immunopeptidome can be achieved 
only by MS studies. However, since current MS approaches cannot reliably de-
tect polymorphic peptides, they are inadequate for MiHA discovery42. Further-
more, since several steps of MIP processing cannot be modeled with available 
algorithms [e.g., formation of defective ribosomal products43], MiHA identifica-
tion using prediction tools is a daunting task fraught with high false discov-
ery rates42. To resolve this conundrum, we have developed a genoproteomic 
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strategy that hinges on a combination of next-generation sequencing and high-
throughput MS peptide identification. Our personalized platform provides un-
precedented insights into the genomic landscape of human MIPs and enables 
high-throughput identification of MiHAs and of their underlying genomic 
polymorphisms.
 
5.5 Results
5.5.1 Development of a combined MS, next-generation sequencing and bio-
informatics approach for the identification of MIPs
To evaluate the impact of non-HLA genetic polymorphisms on the MIP reper-
toire, we analyzed the immunopeptidome of Epstein-Barr virus-transformed 
B lymphoblastoid cell lines (B-LCLs) from two non-twin HLA-identical siblings 
(Fig. 1a). The success of our endeavor hinged on two factors: the need to reli-
ably identify MIPs encoded by polymorphic genomic regions and to maximize 
the coverage of the immunopeptidome (the number of unique MIPs identified).
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Figure 1. High-throughput genoproteomic strategy used for the identification of 
polymorphic MIPs on B-LCLs from 2 HLA-identical siblings
(a) General overview of the personalized approach, which combines next-generation 
sequencing, MS and bioinformatics. (b) Schematic representation of the combinatorial 
method used to translate in silico polymorphic regions containing ns-SNVs. (c) Com-
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bining the predicted MHC binding affinity and Mascot score enables to discriminate 
between MIPs and contaminant peptides. The dataset of peptides identified with an 
FDR	≤	5%	was	filtered	according	the	Mascot	score	(which	represents	the	confidence	
level of a peptide assignation), and the predicted MHC binding affinity. The red rect-
angle	and	lines	indicate	the	combination	of	values	(IC50	≤	1,250	nM	and	Mascot	score	
≥	21)	that	allowed	identifying	the	maximum	number	of	MIPs	with	a	5%	FDR	threshold.
5.5.2 Detection of MIPs encoded by polymorphic genomic sequences using 
personalized proteomic databases 
Large-scale MS-based analyses represent the sole approach enabling compre-
hensive molecular definition of the MIP repertoire6, 15, 44. However, standard 
high-throughput MS is blind to a whole universe of polymorphic peptides. 
Indeed, sequencing (or assignation) of peptides by tandem MS is done using 
engines (e.g., Mascot) that attempt to correlate tandem MS fragment ions from 
a sample under study with those predicted from available protein databas-
es (e.g. UniProt). Unfortunately, most polymorphic peptides are absent from 
these databases and tandem MS spectra from unlisted polymorphic peptides 
will inevitably remain unassigned or misassigned. We reasoned that the most 
straightforward solution to this conundrum would be to use next generation se-
quencing data to create subject-specific proteomic databases that would serve 
as a reference for MS sequencing. We therefore sequenced both the exome and 
the transcriptome of B-LCLs from each subject in order to combine the ben-
efits of both sequencing technologies and to cover as much as possible each 
individual’s coding genome45 (Fig. 1a). Next-generation sequencing data were 
then used to build in silico the proteome of B-LCLs from our subjects using the 
in-house developed python module pyGeno24 (Fig. 1b). Following integration 
of exome and transcriptome sequencing, similar number of base pairs and 
proportions of the human exome were covered in both siblings (Fig. 2 track 3 
blue vs. orange and Supplementary Data 1 available online). Exome and tran-
scriptome sequencing data of each subject were used to identify SNVs with 
respect to the reference genome (GRCh37.p2, NCBI). SNVs were then filtered 
according to their quality, combined into a single set and integrated at their 
respective position on the reference human genome to obtain two “personal-
ized genomes”, from which we extracted and translated every transcript (see 
“In silico generated proteomes”). The translations were then compiled in two 
168
“personalized protein databases”, one for each subject.
Figure 2. Integrative view of the genomic landscape of the MIP repertoire of HLA-
identical siblings
Circos plot showing similar proportions of sequenced genomic and transcriptomic 
10 50 100
15
0
20
0
2
0
50
10
0
15
0
200
3
0
50
100
150
4
0
50
100
150
5
0
50
100
150
6
0
50
100
150
7
0
50
100150
8
0
50100
9
0
5010
010 0
50
10
0
11
0
50
10
0
12
0
50
100
13
0
50
100
14
0
50
100
15
0
50
100
16
0
50
17
0
50
18
0
50
19
0
50
20
0
50
21
0
22
0
50
X
0
50
100
150
s
s
s
s
s
s
s
s
s
s
s
s
s
s s
s
s s
s
s
s
MiHAs
Outermost to inermost tracks: 
1. Chromosomal position
2. Genes per 500 Kb
3a. Exome- and RNA-seq coverage per 500 Kb subj.1
3b. Exome- and RNA-seq coverage per 500 Kb subj.2
4. Ns-SNVs between subjects 1 and 2
5. Ns heterozygous loci 
6. All identified MIPs
7. MiHAs detected in subj.1, subj.2 or both (different or identical genotypes)
169
regions in both siblings and the relatively small number of regions that give rise to 
MS-detected MIPs including polymorphic MiHAs among all sequenced genes. From 
outermost to innermost tracks: 1) ideogram indicating chromosomal positions for 
each chromosome, 2) histogram depicting the number of genes for 500-Kb windows, 
3) heat map showing the fraction of bases of 500-Kb windows covered by exome 
(outer circle) or transcriptome (inner circle) sequencing of subjects 1 (orange) and 2 
(blue), 4) tile graph of 4,833 ns-SNV between siblings (purple), 5) tile graph of 3,774 
heterozygous loci where both alleles are shared by the two subjects and lead to non-
synonymous amino acid changes (green), 6) tile graph representing genomic regions 
that give rise to 4,468 MIPs, 7) Each dot represents one single gene-encoded MiHA 
deriving from regions containing ns-SNVs and detected by MS in subjects 1 (orange), 
2 (blue) or both (green).
5.5.3 Maximizing the level of coverage of the immunopeptidome 
MIPs were eluted from the cell surface by mild acid elution performed on 4 
biological replicates of 500 million cells for each subject. Eluted peptides were 
desalted and separated on strong cation exchange chromatography prior to 
LC-MS/MS analyses using high resolution precursor and product ion spectra. 
Compared to other methods such as MHC I immunoprecipitation, acid elution 
has the advantage of harvesting almost all MIPs, irrespective of their MHC 
binding affinity46. However, direct acid elution can increase the amount of 
non-MHC contaminant peptides that are recovered11. In order to maximize 
the sensitivity and specificity of MIP detection, we have therefore developed an 
analysis pipeline that relies on a combination of four parameters: i) the canoni-
cal MIP length of 8 to 11 amino acids, (ii) the predicted MHC binding affinity 
given by the NetMHCcons algorithm47, (iii) the Mascot score, which reflects the 
quality of peptide assignation, and (iv) the false discovery rate (FDR), which 
indicates the proportion of decoy (false) vs. target (true) identifications (see 
Materials and methods). We found that for an FDR of 5%, the best coverage of 
the	immunopeptidome	was	obtained	by	combining	a	Mascot	score	≥	21	and	an	
MHC	binding	affinity	≤	1,250	nM	(Fig.	1c	and	Supplementary	Fig.	S1-S2).
Next, we compared the number of peptide identifications obtained by Mascot 
using the regular human protein database (UniProt) and personalized databas-
es based on exome and transcriptome sequencing (Supplementary Fig. S3A). 
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We identified 4,468 unique MIPs from the 2 personalized databases (Supple-
mentary Data 2). The numbers of MIPs identified with the reference database 
vs. personalized databases were similar with a 96% overlap (Supplementary 
Fig. S3A). Notably, replacement of reference with the personalized databases 
had no impact on the quality (Mascot score) of identified peptides (Supplemen-
tary Fig. S3B). 
5.5.4 The MIP repertoire of HLA-identical siblings is similar but not identi-
cal
We have previously shown that the HLA genotype has a major impact on the 
MIP repertoire of MHC-mismatched individuals24. Here, we compared the MIP 
repertoire of HLA-identical siblings to evaluate the impact of non-HLA genetic 
polymorphisms on the immunopeptidome. In addition to having identical HLA 
genotypes, the two siblings showed similar expression levels of the HLA-A, 
HLA-B and HLA-C genes (Supplementary Data 3) and of the total amount of 
MHC class I molecules at the cell surface (Supplementary Fig. S4). Following 
mild acid elution of peptides of comparable efficacy between subjects (Supple-
mentary Fig. S4), we identified a total of 4,468 MIPs encoded by genes from 
all chromosomes (Fig. 2 track 6 and Supplementary Data 2), detected in a vari-
able number of biological replicates (Fig. 3A) and associated to HLA-A*0301, 
-A*2902, -B*0801, -B*4403 or –C*1601. Similar numbers of MIPs were identi-
fied from the two subjects (4,114 in subject 1 and 4,186 in subject 2). As ex-
pected, the majority of the MIPs (86%) were detected in both subjects (Fig. 3a). 
Most MIPs (75%) had a predicted binding affinity < 500 nM (Fig. 3b). We found 
no significant difference in the average binding affinity of 282 peptides exclu-
sively detected in subject 1 vs. 351 peptides exclusively detected in subject 2 
(Fig. 3b). Furthermore, the number of peptides predicted to bind each of the 
HLA molecules was similar between the 2 subjects, suggesting that both sib-
lings have comparable surface expression of each of the 5 HLA allelic products 
tested (Fig. 3c). Collectively, these results show that the MIP repertoire of HLA-
identical subjects is similar yet not identical. 
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Figure 3. HLA-identical siblings present similar but not identical MIP repertoires
(a) Venn diagram showing that 86% of MIPs from HLA-identical siblings were detected 
in both subjects. A total of 4,468 MIPs were identified in the siblings after analysis of 
8 biological samples (4 biological replicates per sibling). MIPs were detected in vari-
able number of biological replicates. For peptides exclusively detected in one subject, 
the number of replicates in which the peptide was found is shown. The total numbers 
of MIPs exclusively detected in subject 1 or 2 are shown in red and blue, respectively. 
(b) Scatter plot showing that 75% of identified MIPs are predicted to bind their respec-
tive HLA molecules with an IC50 < 500 nM. The IC
50
 for 5 HLA alleles was calculated 
with the NetMHCcons algorithm. For each peptide (represented by dots), the best 
binding score for a specific allele was kept. The yellow boxes highlights 75% of all 
peptides. The black lines and values indicate the average binding affinity of all pep-
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tides identified in each sibling. Red and blue lines and numbers represent the average 
binding affinity of 282 and 351 unshared peptides exclusively detected in subject 1 
or 2, respectively. The predicted binding affinity of the two sets of unshared MIPs 
was statistically indistinguishable (P = 8.5 x 106 by 2-tailed Mann-Whitney test). (c) 
The number of peptides associated to each HLA molecule was similar between the 2 
subjects. 
5.5.5 Identification of MiHAs among unshared MIPs 
MiHAs are typically encoded by bi-allelic loci28, 29. For each locus where two al-
leles are present in our subjects, three genotypes are possible: AA, AB and BB. 
At the peptidomic level, each allele can be dominant (generate a MIP) or reces-
sive (a null allele that generates no MIP). Moreover, by comparing MIPs eluted 
from two HLA-identical individuals, dominant MiHAs can be separated into 
two groups: unshared MIPs (genotypes AA vs. BB, AB vs. AA or BB), or shared 
MIPs (AB vs. AB). If one allele is recessive (e.g., B), subjects can be similar at the 
peptidomic level (express the A MiHA) even though they have different geno-
types (AA vs. AB) (Fig. 4).
In our search for MiHAs, we first performed in-depth analyses of MIPs detected 
in only one subject (unshared MIPs; Fig. 3a). Here the key finding was that out 
of 633 unshared MIPs, only 13 (2%) were encoded by genomic regions harbor-
ing ns-SNVs between the two subjects (Fig. 4 and Supplementary Data 2). The 
origin of 3 of these 13 MIPs was ambiguous (they could derive from several 
Type and number of identified MiHAs
AA vs. BB
AB vs. AA
AB vs. AA
(Table 1A)
AB vs. AA
(Table 1B)
AB vs. AB
AB vs. AB  
(Table 1B)
MiHA-encoding 
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22
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Figure 4. Overview of MiHAs identified following analy-
sis of genomic and peptidomic data from our two sub-
jects
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genes), whereas the other ten MiHAs were assigned to a single gene (Fig. 4 
and Table 1A). The genetic polymorphisms responsible for almost all MiHAs 
corresponded to SNPs reported in the dbSNP database48 (Table 1A). Consis-
tent with previous findings on human MiHAs29, only one of the two possible 
variants was detected by MS for each MiHA locus (Table 1A). In other words, 
at the peptide level, one allele was dominant (generated a MIP) and one was 
recessive (generated no MIP) (Table 1A). In 4 out of 10 cases, absence of the 
variant MiHA at the cell surface could be explained by a decreased binding af-
finity of the variant for the corresponding HLA molecule (IC
50
	difference	≥	2x).	
Nine of our best characterized MiHAs are novel, while one (KEFEDGIINW) has 
been previously reported49. Four MiHAs were detected by MS in the subject 
homozygous for the corresponding allele but not in the heterozygous subject 
(Table 1A, rows 7-10). This suggests that zygosity influences MiHA abundance 
and that low abundance MiHAs may fall below the MS detection threshold in 
heterozygous subjects. Consistent with this, the MS intensity for these four 
MiHAs was low in homozygous subjects (Supplementary Data 2). Six MiHAs 
were coded by an allele present only in one subject (Table 1A, rows 1-6), and 
were thus potentially immunogenic for the other sibling. We further validated 
the presence of the ns-SNV in the corresponding DNA and/or cDNA regions 
of these six MiHAs in both subjects by Sanger sequencing to discard errors in 
base calling or mapping (Supplementary Fig. S5). Then, we assessed the im-
munogenicity of four of these MiHAs by cytotoxicity assays. In all cases, in 
vitro generated MiHA-specific CTLs selectively killed allogeneic MiHA-positive 
B-LCLs (to similar levels as autologous B-LCLs pulsed with the MiHA) but not 
autologous MiHA-negative unpulsed B-LCLs (Fig. 5a). 
Table 1. MiHAs resulting from ns-SNVs in the MIP-coding region and detected in 
(A) one of the two subjects or in (B) both subjects
Selected features of the MiHAs are shown, including the amino acid sequence, the 
subject (S) in which the MiHA was detected, the source gene, the HLA molecule for 
which the MiHA has the best predicted binding affinity (IC
50
), the translated genotype 
shown in amino acids (AA), the alternative MiHA variant and its predicted HLA bind-
ing affinity (IC
50
), and the dbSNP identification when the ns-SNV corresponds to a 
known SNP. The MS-detected and non-detected polymorphic residues are highlighted 
in bold underlined and bold italics, respectively. IC
50
 values of the non-detected MiHA 
variants	are	shown	in	italics	when	they	show	a	fold	difference	≥	2	relative	to	the	de-
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Figure 5. Unshared MIPs encoded by polymorphic loci are immunogenic
Frozen PBMCs from the MIP-negative subject were thawed and stimulated with au-
tologous dendritic cells pulsed with an unshared MIP detected in the other individual. 
Primed cells were restimulated with irradiated autologous B-LCLs pulsed with the 
same peptide for another 7 days. Restimulated cells were tested for in vitro cytotox-
icity activity against autologous B-LCLs pulsed with the relevant peptide (positive 
control, black), unpulsed autologous B-LCLs (negative control, white), or MIP-positive 
allogeneic B-LCLs (test, grey) at various effector-to-target (E:T) ratios. The minimal 
cytotoxic activity against unpulsed autologous B-LCLs is most likely due to recogni-
tion of EBV epitopes. Average and S.D. of three or four independent experiments 
are shown. Significant differences are indicated by * P < 0.05 or ** P < 0.01, 2-tailed 
Student t-test. (a) Unshared MIPs encoded by polymorphic loci. (b) Unshared MIPs en-
coded by non polymorphic loci.
What is the significance of the unshared MIPs derived from non-polymorphic 
regions but detected by MS in only one subject (n = 633-13 = 620; Fig. 3a)? 
100:1 50:1 25:1 12:1 6:1 3:10
20
40
60
100:1 50:1 25:1 12:1 6:1 3:10
20
40
60
100:1 50:1 25:1 12:1 6:1 3:10
20
40
60
ITGAL-1T
NQO1-1R
C13Orf18-1R IGLV2-11-1HH
QIYSTCVSK
LLYATQQGQAK
50:1 25:1 12:1 6:1 3:1
Effector: CTL against subj.2-specific peptide
Sp
ec
ific
 ly
sis
 (%
)
B-LCLs (subj.1) + peptide
B-LCLs (subj.2)
B-LCLs (subj.1)
Target:
Effector: CTL against subj.1-specific peptide
B-LCLs (subj.2) + peptide
B-LCLs (subj.1)
B-LCLs (subj.2)
Target:
E:T ratio
Sp
ec
ific
 ly
sis
 (%
)
50:1 25:1 12:1 6:1 3:10
20
40
50:1 25:1 12:1 6:1 3:10
20
40
Effector: CTL against subj.1-specific peptide
B-LCLs (subj.2) + peptide
B-LCLs (subj.1)
B-LCLs (subj.2)
Target:
b
E:T ratio
*
*
**
**
**
**
** **
50:1 25:1 12:1 6:1 3:10
20
40 KTVYPASYR
Sp
ec
ifi
c 
ly
si
s 
(%
)
E:T ratio
Effector: CTL against subj.2-specific peptide
B-LCLs (subj.1) + peptide
B-LCLs (subj.2)
B-LCLs (subj.1)
Target:
E:T ratio
**
**
Sp
ec
ific
 ly
sis
 (%
)
a
176
Could they be MiHAs whose presence is regulated by cis- or trans- acting poly-
morphisms (outside of the MIP-coding genomic sequence) that would affect 
MIP processing25, 28? The MS/MS spectra of each of these MIPs were manually 
validated and to further confirm the absence of these MIPs in one of the two 
subjects, we searched these MIPs in two additional biological replicates from 
each cell line. Most non polymorphic unshared MIPs were detected in only one 
or two replicates (Fig. 3a). This suggests that the presence of these MIPs was 
inconsistent, perhaps because of the shotgun nature of MS. Another possible 
explanation is that these MIPs derive from proteins expressed only in specific 
stages of the cell cycle11, and that they are not genuine MiHAs. However, 41 
unshared MIPs could not be discarded so easily because they were detected 
in 3-6 replicates of one sibling and absent in 6 replicates of the other sibling. 
Except for 2 cases, exclusive detection of these MIPs in one of the siblings was 
not caused by differences in abundance of the MIP-source transcript (Supple-
mentary Fig. S6a) or in the expression of the MIP-coding exon between sub-
jects (Supplementary Fig. S6b), nor by differences in the expression of genes 
involved in the antigen processing and presentation pathway (Supplementary 
Data 3). We therefore evaluated the immunogenicity of the three most entic-
ing unshared MIPs coded by non-polymorphic regions, i.e., those showing the 
highest MS intensity and reproducibility (Fig. 5b and Supplementary Data 2). 
We reasoned that if these MIPs were MiHAs, they should be immunogenic, 
even if their presence was dictated by unidentified polymorphisms outside of 
the MIP-coding genomic sequence25, 28. None of the tested MIPs could elicit the 
generation of cytotoxic T cells in the MIP-negative sibling. We therefore failed 
to discover a single MiHA among unshared MIPs coded by non-polymorphic 
regions. The most parsimonious explanation is that these MIPs were simply 
differentially expressed peptides whose abundance was below the MS detec-
tion threshold in B-LCLs from one subject. Though further studies may be war-
ranted to understand interindividual differences in the abundance of specific 
MIPs, we predict that in most if not all cases, differentially expressed peptides 
coded by non-polymorphic regions are irrelevant as regards alloreactivity. Ac-
cordingly, we conclude that identification of MiHAs absolutely requires a com-
bination of MS and genomic data. Reliance solely on MS detection of unshared 
MIPs would overestimate the number of MiHAs. In contrast, the use of person-
alized databases based on whole exome and transcriptome sequencing allows 
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to rapidly identifying genuine MiHAs coded by polymorphic loci. 
5.5.6 The global imprint of ns-SNVs on the MIP repertoire
In order to assess the global imprint of ns-SNVs on the MIP repertoire, we 
asked the question: what proportion of ns-SNVs between our two subjects 
were located in MIP coding exomic sequences? By comparing the whole exome 
and RNA-seq data from our two HLA-identical siblings, we found a total of 
4,833 ns-SNVs (Fig. 2, track 4). Overall, 26 of these ns-SNVs were located in 
regions coding for 22 MiHAs identified by MS, of which 14 originated from a 
single gene and are depicted in the Circos plot (Fig. 2 track 4 vs. 7 blue, orange 
and pink) and 8 have an ambiguous origin (e.g., immunoglobulin genes) (Fig. 
4, n=3+5 and Supplementary Data 2). The 14 unambiguously assigned MiHAs 
were unshared (Table 1A) or shared (Table 1B rows 1-4) at the peptidomic 
level. Thus, from a genomic perspective, only 0.5% of all ns-SNVs (26/4,833) 
found between our subjects were represented in their MIP repertoire. 
5.5.7 Identification of MiHAs among shared MIPs
Among 3,835 shared MIPs, 21 were encoded by bi-allelic loci and therefore rep-
resent MiHAs (Fig. 4, n=9+12). These shared MIPs would not be immunogenic 
for our subjects but would be immunogenic for subjects homozygous for the 
alternative allele. In 9 cases, one subject was homozygous for a dominant 
MiHA allele (AA) and the other subject was heterozygous for the dominant and 
a recessive allele (AB) (Fig. 4). The origin of five of these 9 MiHAs was ambigu-
ous (they could derive from several genes), whereas the other four MiHAs were 
assigned to a single gene (Table 1B, rows 1-4 and Fig. 4). The exome of our 
subjects shared 3,774 heterozygous loci (Fig. 2, track 5). Twelve MiHAs derived 
from such bi-allelic loci for which our subjects shared the same heterozygous 
genotype (AB). Eight of these twelve MiHAs could be unambiguously assigned 
to a single gene (Fig. 2 track 7 in green, Fig. 4 and Table 1B rows 5-11). The two 
alleles were co-dominant in one case, whereas only one allele was dominant 
(identified by MS) in all other cases. MIP dominance did not reflect allelic im-
balance at the transcript level (data not shown). Nonetheless, in four cases of 
shared MiHAs, the product of the recessive allele was predicted to have a lower 
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MHC binding affinity than the product of the dominant allele (Table 1B). 
5.5.8 Overall differences in the MIP repertoire of HLA-identical siblings
Comparison of genomic and proteomic data from our subjects led to the dis-
covery of 34 MiHAs (Fig. 4), of which 22 were unambiguously assigned to a 
specific gene (Fig. 2, track 7 and Table 1). Out of 34 MiHAs, 13 were found in 
only one of the two subjects whereas 21 MiHAs were shared MIPs (Fig. 4). This 
means that out of 4,468 MIPs only 13 (0.3%) would be immunogenic for one of 
our subjects. If all unshared non-polymorphic MIPs are not immunogenic, as 
we observed with the 3 MIPs tested (Fig. 5b), this would mean that each sub-
ject would be tolerant to about 99.7% of the MIPs found on the B-LCLs of this 
sibling. The use of personalized databases for tandem MS sequencing was in-
strumental in the discovery of many MiHAs. Taking into account only the best 
characterized MiHAs, 6 out of the ten listed in Table 1A (unshared MIPs) and 
5 out of the 12 listed in Table 1B (shared MIPs) would have been missed in the 
absence of personalized databases, because these 11 peptides were absent in 
the Uniprot database. 
5.5.9 What proportion of MIP coding regions is polymorphic at the popula-
tion level? 
To address this question, we searched in the dbSNP database for validated ns-
SNPs in the genomic sequences coding our 4,468 MIPs. We found that at the 
population level, 88% of our MIP coding sequences were invariant whereas 12% 
contained at least one ns-SNP: 670 ns-SNPs were found in the genomic region 
coding for 536 MIPs (Fig. 6a-b and Supplementary Data 4). Hence, at the popu-
lation level, 536 MiHAs can be presented by the five HLA class I molecules 
studied herein: HLA-A*0301, -A*2902, -B*0801, -B*4403 and –C*1601. Further 
studies will be required to determine the number of dominant and recessive 
peptide variants encoded by these 536 MiHA loci.
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Figure 6. Frequency of ns-SNPs in the MIP coding exome
(a) Circos plot illustrates the relative proportion of polymorphic MIPs (n = 536) in 
the immunopeptidome and the genomic location of their coding loci. (b) Histogram 
showing the number and percentages of MIP coding regions containing ns-SNPs in 
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the global population. We used dbSNP to find validated ns-SNPs in the exomic se-
quences encoding the 4,468 MIPs identified in our subjects. In the case of MIPs de-
riving from multiple source regions, the average number of ns-SNPs of all possible 
MIP source regions was calculated. (c) The 4,468 MIPs of our subjects were encoded 
by 13,404 nucleotides. We performed 10,000 random samplings of 4,468 exomic se-
quences (containing a total of 13,404 nucleotides) from the human reference exome 
(Ensemble GRCh37.65). In all samplings, the frequency of exomic sequences coding 
for 8-,9-,10- and 11-mers was identical to the frequency found in the 4,468 MIP cod-
ing sequences from our subjects. The histogram depicts the distribution of validated 
ns-SNPs (dbSNP) in exomic sequences from the global population found in 10,000 
random samplings of the whole exome. The average number of ns-SNPs of all random 
samplings was 708 (s.d. 30.4, 95% confidence interval: 650-768 shown in orange). The 
blue dotted line shows the number of ns-SNPs (n = 670) in the exomic sequences cod-
ing for the MIPs detected in our subjects.
5.5.10 Is there a bias in favor or against ns-SNPs in MIP coding regions? 
To address this question, we wished to compare, in the global population, the 
frequency of ns-SNPs in the whole exome vs. the frequency in the 4,468 exomic 
sequences coding for the MIPs identified herein. To this end, we designed a 
bootstrap procedure (10,000 iterations) based on random samplings of 4,468 
peptide-coding regions (13,404 base pairs/sampling) from the human refer-
ence exome (Ensemble GRCh37.65). For each sampling, we then calculated the 
number of validated ns-SNPs reported in dbSNP (Fig. 6c). In all samplings, the 
frequency of exomic sequences coding for 8-,9-,10- and 11-mers was identical 
to the frequency found in the 4,468 MIP coding sequences from our subjects. 
The number of ns-SNPs in the MIP coding exome (n = 670) fell in the range 
of ns-SNPs found in 10,000 random samplings of the whole exome (average 
= 708; 95% confidence interval 650-768). We therefore conclude that the MIP 
coding exome reflects the frequency of ns-SNPs in the human genome. 
 
5.6 Discussion
MS is the sole method that enables direct identification of MIPs and large scale 
analyses of the MIP repertoire6, 20. Indirect predictions based on reverse immu-
nology approaches are fraught with false discovery rates that may reach 95%50, 
51. Currently, MS sequencing has been largely limited to peptides represented 
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in the reference UniProt database. Our work demonstrates that the universe of 
peptides identified by MS can be expanded and refined by using personalized 
databases that include whole exome and transcriptome sequencing data. 
As well stated by J. Yewdell et al. “Despite the fact that quantitative aspects 
of systems are critical to their understanding, they are frequently ignored”52. 
In line with this concept, our data provide the answer to a longstanding ques-
tion: what is the proportion of invariant vs. polymorphic MIPs presented by 
MHC molecules? In other words, to what extent do non-MHC genomic poly-
morphisms enhance the interindividual variability of the immunopeptidome? 
We found that, at the population level, at least one ns-SNP is found in 12% of 
exomic sequences coding the MIPs presented by five common HLA class I al-
lotypes. That about 88% of the immunopeptidome of HLA-identical siblings 
is invariant in the global population illustrates the overwhelming importance 
of the HLA genotype in defining the content of the MHC class I immunopepti-
dome. 
In depth analyses of genomic and proteomic data revealed that about 0.5% 
of ns-SNVs between the exome of our subjects were represented in their MIP 
repertoire. Consequently, 13 MIPs were unique to one subject and might elicit 
allogeneic T-cell responses from his sibling, as demonstrated for four of them. 
Integration of personalized genomic and proteomic data was absolutely es-
sential for identification of these rare polymorphic MIPs interspersed among 
thousands of non-polymorphic MIPs. Since the MIP repertoire is molded by the 
transcriptome, some MIPs are ubiquitous and others are cell lineage-specific11, 
53. Accordingly, various cell types present non-identical MIP repertoires. MIPs 
derive mostly from transcripts expressed at medium to high levels (as op-
posed to very low or low levels), and about 8,500 transcripts are expressed at 
medium to high levels in B-LCLs24. We therefore posit that, at the organismal 
level, the total number of unshared MiHAs between two HLA-identical siblings 
would be about 2.5-fold the number found in B cells, assuming a total number 
of 21,000 human transcripts (i.e., 13 x (21,000/8,500) = 32). Unrelated indi-
viduals share fewer gene sequences than siblings. As a consequence, it has 
been calculated that the frequency of unshared MiHAs is increased by about 
1.8-fold in unrelated (HLA-matched) subjects relative to siblings29. Thus, two 
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unrelated HLA-identical subjects would display about 58 unshared MiHAs. Of 
note, these numbers might increase with more sensitive MS instruments and 
better sequencing coverage of difficult regions (e.g. GC-rich). 
All MHC antigens are dominant. Our data show that this is not the case for Mi-
HAs. Out of 21 MiHA loci (Table 1), 20 had one dominant (MIP generating) and 
one recessive (no MIP generated) allele. This observation is clearly consistent 
with population analyses of ten well characterized autosomal MiHA loci: only 
one locus had two dominant alleles29. The absence of MIP could be explained 
by a decreased MHC binding affinity of peptides coded by eight of our 21 
recessive alleles. We infer that for the other 13 recessive alleles, the absence 
of MIP must be due to interference of the polymorphism with some step in 
MIP processing that precedes MHC binding (e.g., cleavage by the proteasome 
or other proteases)18, 43. With tens of thousands of proteins, mammalian cells 
are the most complex entity in the antigenic universe faced by our immune 
system54. Theoretical estimates suggest that the immunopeptidome contains 
0.1% of the 9-mer sequences present in the proteome6. Few peptides win the 
fierce competition for inclusion in the immunopeptidome. Thus, if we con-
sider MiHAs coded by dominant alleles, as winners, it follows that in 20 out of 
21 cases (the recessive alleles), a single amino acid substitution transformed 
winners into losers. This is an eloquent reminder that we cannot predict the 
molecular composition of the immunopeptidome based on our limited under-
standing of the complexity of the MIP processing pathway.
Allogeneic hematopoietic cell transplantation has led to the discovery of the 
allogeneic graft-versus-leukemia (GVL) effect, which remains the most wide-
ly effective strategy for cancer immunotherapy in humans. GVL is mediated 
mainly, if not exclusively, by donor T cells that recognize host MiHAs. In line 
with recent progress in the field of cell therapy, MiHAs are therefore attractive 
targets for adoptive T-cell immunotherapy of cancer, particularly hematologic 
cancers36-41. However, because of the low number of molecularly defined hu-
man MiHAs, less than 30% of patients would currently be eligible for immu-
notherapy targeted to specific MiHAs55. Our report reveals a strategy for high-
throughput MiHA discovery that could greatly accelerate the development of 
MiHA-targeted immunotherapy. 
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Our genoproteomic method combining next generation sequencing and MS 
shows how it is possible to accurately identify by MS any peptide, provided 
that its source DNA or RNA has been sequenced. This notion opens new av-
enues in systems immunology and should be invaluable for exploration of 
several “black holes” in the immunopeptidome. One particularly important 
black hole is the “cancer immunome”56. Compelling evidence suggests that 
the most immunogenic antigens present on cancer cells are mutant peptides 
derived from the numerous mutations found in neoplastic cells57-59. However, 
tumor-specific mutant peptides (alike MiHAs) are not detected by standard 
large scale MS approaches. We posit that our method should enable discovery 
of tumor-specific peptides (the product of somatic mutations) with the same 
accuracy as MiHAs (the product of germline genetic polymorphisms). Accord-
ingly, our next priority will be to use this method to explore the impact of the 
cancer mutations on the immunopeptidome of cancer cells. 
 
5.7 Methods
5.7.1 Cell culture and HLA typing
This study was approved by the Comité d’Éthique de la Recherche de l’Hôpital 
Maisonneuve-Rosemont and all subjects provided written informed consent. 
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples 
of 2 non-twin HLA-identical Caucasian female siblings. B-LCLs were derived 
from PBMCs with Ficoll-Paque Plus (Amersham) as described60. High-reso-
lution HLA genotyping was performed at the Maisonneuve-Rosemont Hospi-
tal. The two siblings are HLA-A*03:01,*29:02; B*08:01,*44:03; C*07:01,*16:01; 
DRB1*03:01,*07:01. 
5.7.2 RNA extraction and preparation of transcriptome libraries
Total RNA was isolated from 5 million B-LCLs using RNeasy mini kit including 
DNase I treatment (Qiagen) according to the manufacturer’s instructions. Total 
RNA was quantified using the NanoDrop 2000 (Thermo Scientific) and RNA 
quality was assessed with the 2100 Bioanalyzer (Agilent Technologies). Tran-
scriptome libraries were generated from 1 μg of total RNA using the TruSeq 
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RNA Sample Prep Kit (v2) (Illumina) following the manufacturer’s protocol. 
Briefly, poly-A mRNA was purified using poly-T oligo-attached magnetic beads 
using two rounds of purification. During the second elution of the poly-A RNA, 
the RNA was fragmented and primed for cDNA synthesis. Reverse transcrip-
tion of the first strand was performed using random primers and SuperScript 
II (InvitroGene). A second round of reverse transcription was done to generate 
a double-stranded cDNA, which was then purified using Agencourt AMpure XP 
PCR purification system (Beckman Coulter). End repair of fragmented cDNA, 
adenylation of the 3’ ends and ligation of adaptors were completed following 
the manufacturer’s protocol. Enrichment of DNA fragments containing adapt-
er molecules on both ends was done using 15 cycles of PCR amplification and 
the Illumina PCR mix and primers cocktail.
5.7.3 DNA extraction, preparation of genomic DNA libraries and exome 
enrichment
Genomic DNA was extracted from 5 million B-LCLs using the PureLink Genom-
ic DNA Mini Kit (Invitrogen) according to the manufacturer’s instructions. DNA 
was quantified and quality-assessed using the NanoDrop 2000 (Thermo Scien-
tific). Genomic libraries were constructed from 1μg of genomic DNA using the 
TruSeq DNA Sample Preparation Kit (v2) (Illumina) following the manufactur-
er’s protocol. We used 500 ng of DNA-Seq libraries for hybrid selection-based 
exome enrichment with the TruSeq exome enrichment kit (Illumina) according 
to the manufacturer’s instructions.
5.7.4 Whole transcriptome sequencing (RNA-Seq) and exome sequencing
Paired-end (2 x 100 bp) sequencing was performed using the Illumina HiSeq2000 
machine running TruSeq v3 chemistry. Cluster density was targeted at around 
600-800k clusters/mm2. Two RNA-Seq or four exomes libraries were sequenced 
per lane (8 lanes per slide). More than 53 and 50 million of mega bases (Mb) 
of	annotated	exons	were	covered	(≥	5	reads)	in	subjects	1	and	2,	representing	
76-81% of the human annotated exome (Supplementary Data 1). Sequence data 
were mapped to the human reference genome (hg19) using the Casava 1.8.1 
and the Eland v2e mapping softwares (Illumina). First, the *.bcl files were con-
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verted into compressed FASTQ files, following by demultiplexing of separate 
multiplexed sequence runs by index. Single reads were aligned to the human 
reference genome using the multiseed and gapped alignment method. Multi-
seed alignment works by aligning the first seed of 32 bases and consecutive 
seeds separately. Gapped alignment extends each candidate alignment to the 
full length of the read and allows for gaps up to 10 bases. The following criteria 
were applied: i) a read contains at least one seed that matches with at most 2 
mismatches without gaps and ii) gaps were allowed for the whole read, as long 
as they correct at least five mismatches downstream. For each candidate align-
ment a probability score, which is based on the sequencing base quality values 
and the positions of the mismatches, was calculated. The alignment score of 
a read, which is expressed on the Phred scale, was computed from the prob-
ability scores of the candidate alignments. The best alignment for a given read 
corresponded to the candidate alignment with the highest probability score 
and was kept if the alignment score exceeded a threshold. Reads that mapped 
at 2 or more locations (multireads) were not included in further analyses. For 
the exome paired-end libraries, the best scoring alignments for each half of 
the pair were computed and compared to find the best paired-read alignments 
according to the estimated insert size distribution. In the case of RNAseq li-
braries, an additional alignment was performed against splice junctions and 
contaminants (mitochondrial and ribosomal RNA). Sequences mapping to con-
taminants were discarded whereas reads uniquely mapping to splice junctions 
were kept and converted back to genome coordinates. The Integrative Genom-
ics Viewer v2.0 (http://www.broadinstitute.org/igv/)61 was used to visualize 
the mapped reads. 
5.7.5 Quantification of transcript expression
We used two methods to estimate and compare transcript expression between 
subjects. In the first method, the Casava 1.8.1 software (Illumina) was used 
to estimate gene or exon expression levels (RNA-seq) measured as RPKM (i.e. 
Read Per Kilobases of exon model per Million mapped reads) using the follow-
ing formula: Gene or exon RPKM = 109 x Cb/Nb L, where Cb is the number of 
bases that fall on the feature, Nb is the total number of mapped bases and L 
is the length of the feature in base pairs. We also used the DESeq package62, 
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which is based on raw counts, to compare transcript expression.
5.7.6 Identification of single nucleotide variations and read counting
Variant call, indel detection and read counting were done using the Casava 
1.8.1 software (Illumina). Reads were re-aligned around candidate indels to im-
prove the quality of variant calls and site coverage summaries. Casava was also 
used to retrieve all SNVs observed between the reference genome (GRCh37.p2, 
NCBI) and the sequenced transcriptome and exome of our subjects. For each 
called SNV, Casava retrieves and calculates various statistics including its po-
sition, the reference base, the number of base calls for each nucleotide, the 
most probable genotype (max_gt), and a Q-value expressing the probability 
of the most probable genotype (Qmax_gt). The Q-value is a quality score that 
measures the probability that a base is called incorrectly. This information was 
loaded into an in-house python module, pyGeno24, for further processing and 
filtering (see “In silico generated proteomes” section).
5.7.7 In silico generated proteomes (personalized databases)
As the transcriptome is functionally closer to the proteome than the genome, 
we used the transcriptome sequencing data as the main information to con-
struct personalized databases. To further increase the sequencing coverage of 
our subjects and thus improve the personalized databases, we integrated the 
exome sequencing data to the transcriptome sequencing data. For every SNV 
found by transcriptome sequencing, we retained the most probable genotype 
if	 the	Q-value	 (Qmax_gt)	was	 ≥20,	which	 corresponds	 to	 a	 1%	 error	 rate	 (a	
higher quality score indicates a smaller probability of error). We also included 
the genotypes of SNVs that were only found by exome sequencing and that 
had	a	Q-value	≥20.	Lastly,	we	 included	all	bases	of	SNVs	called	by	both	the	
transcriptome and exome sequencing, regardless of the Q-Value. The retained 
genotypes of all SNVs were then integrated in the reference genome (GRCh37.
p2) at their right position to construct a “personalized genome” for each sub-
ject. These personalized genomes were used to extract all transcripts reported 
in the Ensembl gene set (GRCh37.65) for all chromosomes except for the Y 
chromosome and mitochondrial DNA. These transcripts were then in silico 
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translated into proteins using the reading frame specified in the Ensembl gene 
set. Considering that the vast majority of MIPs have a maximum length of 11 
amino acids, we established a window of 21 amino acids centered at each het-
erozygous ns-SNV. When a window contained more than one SNV, we trans-
lated in silico all possible combinations and included them in the personalized 
databases (Fig. 1b). Finally, we compiled all translation products into two data-
bases (one for each subject) that were used for the identification of MIPs (see 
“MS/MS sequencing and peptide clustering” section). Both resulting databases 
had a similar size, in terms of number of residues (36,007,210 in subject 1 and 
36,010,026 in subject 2) and number of entries (95,806 in subject 1 and 95,687 
in subject 2). Moreover their size is comparable to the size of the reference 
UniProt human database used (43,384,120 residues and 75,530 entries).
5.7.7 MS/MS sequencing and peptide clustering
Based on our previous studies on MS data reproducibility across technical and 
biological replicates11, we prepared four biological replicates of 5 x 108 expo-
nentially growing B-LCLs from each subject. MIPs were released by mild acid 
treatment, desalted on an HLB cartridge 30cc, filtered with a 3000Da cut-off 
membrane and separated into seven fractions by cation exchange chromatog-
raphy using an off-line 1100 series binary LC system (Agilent Technologies) 
as previously described11, 12. Fractions containing MIPs were resuspended 
in 0.2% formic acid and analyzed by LC-MS/MS using an Eksigent LC system 
coupled to a LTQ-Orbitrap ELITE mass spectrometer (Thermo Electron). Pep-
tides were separated on a custom C18 reversed phase column (150 μm i.d. X 
100 mm, Jupiter Proteo 4 μm, Phenomenex) using a flow rate of 600 nL/min 
and a linear gradient of 3-60% aqueous ACN (0.2% formic acid) in 120 mins. 
Full mass spectra were acquired with the Orbitrap analyzer operated at a re-
solving power of 30 000 (at m/z 400). Mass calibration used an internal lock 
mass (protonated (Si(CH3)2O))6; m/z 445.120029) and mass accuracy of pep-
tide measurements was within 5 ppm. MS/MS spectra were acquired at higher 
energy collisional dissociation (HCD) with a normalized collision energy of 
35%. Up to 6 precursor ions were accumulated to a target value of 50000 with 
a maximum injection time of 300 ms and fragment ions were transferred to 
the Orbitrap analyzer operating at a resolution of 15000 at m/z 400. 
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Mass spectra were analyzed using Xcalibur software and peak lists were gener-
ated using Mascot distiller Version 2.3.2 (http://www.matrixscience.com). Da-
tabase searches were performed against UniProt Human database (43,384,120 
residues, released on April 2, 2013), databases specific to subjects 1 and 2 
(34,976,580 and 34,990,381 residues, respectively, see “in silico generated 
proteome” section) and EBV_B95.8 database (40,946 residues), using Mascot 
(Version 2.3.2, Matrix Science). To calculate the false discovery rate (FDR), we 
performed a Mascot search against a concatenated target/decoy database us-
ing the human UniProt or subject-specific databases. The target represents the 
forward sequences and the decoy its reverse counterparts. Mass tolerances 
for precursor and fragment ions were set to 5 ppm and 0.02 Da, respectively. 
Searches were performed without enzyme specificity with variable modifica-
tions for cysteinylation (Cys), phosphorylation (Ser, Thr and Tyr), oxidation 
(Met) and deamidation (Asn, Gln). Raw data files were converted to peptide 
maps comprising m/z values, charge state, retention time and intensity for all 
detected ions above a threshold of 8,000 counts using in-house software (Pro-
teoprofile)12. Peptide maps corresponding to all identified peptide ions were 
aligned together to correlate their abundances across sample sets and repli-
cates. The MS/MS spectra of unshared MIPs were validated manually.
5.7.8 Identification of MIPs
MIP identification was based on four criteria: i) the canonical MIP length of 8 to 
11 amino acids, (ii) the predicted MHC binding affinity given by the NetMHC-
cons algorithm47, (iii) the Mascot score, which reflects the quality of peptide as-
signation, and (iv) the false discovery rate (FDR), which indicates the proportion 
of decoy (false) vs. target (true) identifications. First, we evaluated the correla-
tion between these parameters. We found a strong correlation (0.88) between 
FDR	values	<60%	and	MHC	binding	affinity	values	≤	1,750	nM	for	all	8-11mers	
(Supplementary Fig. S1). Indeed, the proportion of peptides with an MHC bind-
ing	affinity	≤	1,750	nM	 increases	as	 the	FDR	decreases	 (Supplementary	Fig.	
S2a). This correlation was specific to MIPs, since no correlation was found for 
random peptides (Supplementary Fig. S1 and S2b). These results show that low 
FDR	values	allow	enrichment	of	high	affinity	peptides	(MHC	binding	affinity	≤	
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1,750 nM) and thus of MIPs. However, the drawback of using a stringent low 
FDR as the main filter is that the total number of identifications considerably 
decreases (Supplementary Fig. S2a) as well as the proportion of small pep-
tides (8-9 mers) identified (Supplementary Fig. S2c). Accordingly, the relative 
proportion of peptides found in target vs. decoy decreased with increasing 
peptide length63, in accordance with the notion that short peptides such as 
MIPs generally require higher Mascot scores to achieve a low FDR. Moreover, 
the tandem MS fragment ions of MIPs are less predictable and evenly distrib-
uted than those of tryptic peptides which further complicate their assignment 
by database search engines such as Mascot. To set a more suitable Mascot 
score threshold for high-throughput MIP detection, we evaluated the relation 
between the Mascot score and the predicted binding affinity for all 8-11 mer 
peptides	identified	with	an	FDR	≤	5%	(Fig.	1c).	Then,	we	calculated	the	number	
of MIPs identified with all combinations of Mascot score and predicted binding 
affinity. We found that the highest number of MIP identifications was obtained 
by	combining	a	Mascot	score	≥	21	and	an	MHC	binding	affinity	≤1,250	nM	at	a	
5% FDR (Fig. 1c). 
5.7.9 ns-SNPs found in MIP coding genomic regions in the population
For each MIP, we retrieved the coordinates of the peptide-coding DNA region. 
These coordinates were then used to extract both the corresponding reference 
sequence and all non-synonymous validated SNPs reported by dbSNP (Build 
137) for that region. For MIPs deriving from multiple source regions, the num-
ber of ns-SNPs reported, corresponds to that of the MIP source region possess-
ing the maximal number of ns-SNPs.
5.7.10 Random peptide sampling
We constructed a genome-wide index. To do so, we indexed every coding se-
quences reported in the Ensembl gene set (GRCh37.65), except for those lo-
cated in the Y chromosome or the mitochondrial DNA, into a segment tree. 
Next, we kept only the first layer of the tree and removed the gaps between the 
indexed regions, effectively transforming the tree into a coding DNA sequence 
list, which was used for the random peptide sampling. For each of the 4,468 
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identified peptides, a random peptide of the same length and that fell en-
tirely into a single coding DNA sequence, was chosen. Next, for each randomly 
selected peptide, we counted the number of ns-SNPs reported in dbSNP137 
(validated and missense). The distribution was obtained after repeating the 
sampling of 4,468 random peptides 10,000 times. 
5.7.11 PCR and Sanger sequencing
PCR amplification of the MiHA-encoding DNA and cDNA regions was per-
formed with the Phusion ® High-Fidelity PCR kit (New England BioLabs). For 
each candidate, 1-2 pairs of sequencing primers were designed manually and 
with the PrimerQuest software (Integrated DNA Technologies) (Supplemen-
tary Table S1), and were synthesized by Sigma. PCR products were purified 
with the PureLink Quick Gel Extraction Kit (Invitrogen). Sanger sequencing 
was performed on candidate DNA and cDNA at the IRIC’s Genomics Platform. 
Sequencing results were visualized with the Sequencher software v4.7 (Gene 
Codes Corporation).
5.7.12 Cytotoxicity assays
Dendritic cells (DCs) were generated from frozen PBMCs, as previously de-
scribed64. To generate cytotoxic T cells, autologous DCs were irradiated 
(4,000 cGy), loaded with 2 μM of peptide and cultured for 7 days with freshly 
thawed autologous PBMCs at a DC:T cell ratio of 1:10. From day 7, responder 
T cells were restimulated for 7 additional days with irradiated autologous B-
LCLs pulsed with the same peptide (B-LCL:T cell ratio 1:5). Expanding T cells 
were cultured in RPMI 1640 (Invitrogen) containing 10% human serum (Sigma-
Aldrich) and L-glutamine. IL-2 (50 U/ml) was added for the last 5 days of the 
culture. Cytotoxicity assays were performed as described12, with minor modi-
fications. Briefly, B-LCLs were labeled with carboxyfluorescein succinimidyl 
ester (CFSE) (Invitrogen), extensively washed, irradiated (4,000 cGy) and then 
used as targets in cytotoxicity assays. Target cells were plated in 96-well U-bot-
tom plates at 5,000 cells/well. Effector cells were added at different effector-
to-target ratios in a final volume of 200 µl/well. Plates were centrifuged and 
incubated for 18h-20h at 37°C. Flow cytometry analysis was performed using 
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a LSRII cytometer with a high throughput sampler device (BD Biosciences). 
The percentage of specific lysis was calculated as follows: [(number of CFSE+ 
cells remaining after incubation with unpulsed target cells – number of CFSE+ 
cells remaining after incubation with peptide-pulsed target cells) / number of 
CFSE+ cells remaining after incubation with unpulsed target cells] x100. 
5.7.13 Statistical analysis and data visualization
The 2-tailed Student t-test was used to identify differentially expressed MIPs 
and MiHAs that induced cytotoxicity. The 2-tailed Mann-Whitney test was used 
to compare the MHC binding affinity of unshared MIPs. Differentially expressed 
transcripts were identified with the DESeq package that uses a model based on 
the negative binomial distribution62. The Spearman correlation was used to 
evaluate the relation between differences in MIP abundance and differences in 
MIP-coding gene or exon expression. The genomic location of identified MIPs 
including MiHAs and the RNA-seq and exome sequencing coverage were visu-
alized with the Circos software65 .
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Supplementary Figure S1. Global false discovery rate (FDR) and predicted binding 
affinity allow discrimination between MIPs and contaminant (non-MIP) peptides
Predicted binding affinity to the relevant HLA molecules of 20,380 eluted peptides 
(black) and 20,380 random peptides generated from the personalized protein data-
bases of subjects 1 and 2 (grey) was calculated using NetMHCcons. Binding score cat-
egories were generated by intervals of 500 nM (IC50). Each dot represents the mean 
predicted binding affinity for peptides in a given bin. For each category, the level 
of accuracy in the peptide identification is shown as the FDR. The FDR (database of 
20,319 target/12,011 decoy peptides identified by Mascot and defined by the cluster-
ing) was calculated for the eluted and the random peptides. The inset shows a high 
correlation between FDR values < 60% and PBA values < 1,750 nM. The distribution 
of random peptides shows no correlation between the predicted binding affinity and 
the FDR. 
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Supplementary Figure S2. The global false discovery rate (FDR) allows enrich-
ment of MIPs and affects the proportion of small (8-9mers) and long peptides (10-
11mers) identified
a) We calculated the predicted binding affinity (IC50) for the 8-11mer peptides ob-
tained after applying different FDR thresholds. FDR values were calculated from a 
dataset of 20,319 eluted peptides (target) and 12,011 reverse peptide versions (de-
coy). Without filtering any 8-11mer peptide identified by Mascot, the FDR value cor-
responds to 59% (maximal FDR). Bars show the number of peptides with a predicted 
binding	affinity	≤	1,750	nM	(blue)	or	>	1,750	nM	(red).	The	second	y-axis	shows	the	
enrichment in MHC I-peptides calculated as the ratio of peptides with a predicted 
binding	affinity	≤1,750	/	>1,750	nM.	b)	We	performed	the	same	analysis	by	randomly	
generating the same amount of peptides for each FDR threshold. The figure shows 
that lower FDR thresholds increase the proportion of eluted peptides with high pre-
dicted binding affinity (a) but have no impact on random peptides (b). c) Proportion 
of 8 – 11mers identified by applying different FDR thresholds. Low FDR values favor 
the identification of long peptides and disfavor the identification of short peptides. 
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Supplementary Figure S3. Comparison of MIPs identified using UniProt vs. person-
alized databases built with next generation sequencing data
(a) Venn diagram comparing the number and percentage of unique and common MIP 
sequences found using UniProt vs. personalized databases. (b) Mascot score of MIPs 
identified with each database.
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Supplementary Figure S4. Quantification of surface HLA-ABC before and after pep-
tide elution
B-LCLs from subjects 1 and 2 were stained with PE anti human HLA-ABC monoclonal 
antibody or the corresponding isotypic control and the mean fluorescence intensity 
(MFI) was analyzed by flow cytometry before or after mild acid elution of peptides. 
The histogram shows similar levels of HLA-ABC surface expression before and after 
peptide elution in representative samples of subjects 1 and 2.
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Supplementary Figure S5. Validation of 6 MiHA-coding sequences by Sanger se-
quencing
Chromatograms obtained after Sanger sequencing of PCR-amplified DNA or cDNA 
encoding 6 MiHAs. The primers used are shown in Supplementary Table S1. Polymor-
phic loci are highlighted in grey. The IGLV2-11-1HH MiHA results from 2 nucleotide 
changes at the transcript level in subject 2.
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Supplementary Figure S6. Differential expression of non-polymorphic MIPs does 
not correlate with differences in MIP-coding genes or exons between subjects
For 41 non-polymorphic MIPs that were exclusively detected in one sibling, we calcu-
lated the fold difference in intensity of the MIP and the fold difference in expression 
of the underlying MIP-coding gene (a) or exon (b) measured in Reads Per Kilobase per 
Million mapped Reads (RPKM). In only 2 cases, MIP abundance differences reflect MIP-
coding transcript differences (dots in red and blue). The calculated Spearman r value 
(rs2) shows no correlation.
5.15 Supplementary Data 
Supplementary data 1-4 are available upon request.
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6 Discussion
6.1 The influence of specific HLA allelic products on the MHC I immu-
nopeptidome 
A subject who is heterozygous for HLA-A, HLA-B and HLA-C genes would ex-
press 6 different types of MHC I molecules on the cell surface. Our analyses 
of the MHC I immunopeptidome of B-LCLs from HLA-disparate families con-
firmed that the HLA genotype ultimately defines the immunopeptidome of a 
cell. This result was expected based on the specificities of the various binding 
motifs [1] and is in accordance with a recent MS-based study of soluble plasma 
MIPs showing that two individuals with no shared HLA alleles present little 
more than 10% of the same peptides [2]. 
Different MHC I molecules not only possess distinct binding motifs, but also 
interact in different ways with various components of the PLC and TAP [3-5] 
and this probably influences in some extent the set of peptides that bind each 
MHC I allelic product. Accordingly, it has been reported that 2 different HLA 
allelic products can compete in the ER for the presentation of a viral peptide 
[6]. In line with this, ~9% of MHC I peptides identified in our studies showed 
predicted promiscuous binding to two or more HLA allotypes of the same 
subject. Since we elute all the peptides from the cell surface, our method does 
not enable to determine whether promiscuous peptides were bound to one 
or all predicted HLA molecules. Nevertheless, we found that most promiscu-
ous MHC I peptides were predicted to bind strongly to one HLA and weakly 
to another HLA allelic product. We also remarked the presence of overlapping 
peptides deriving from the same or from different proteins. Based on these 
observations, one can expect some level of “competition” in the ER between 
the HLA allotypes for the pool of peptides. For example, let’s suppose that the 
same N-terminal extended precursor peptide “ABCDEFGHIJ” binds “HLA#1” 
(weakly) and “HLA#2” (strongly) in the ER and that both HLA molecules are 
expressed at the same level, then the binding affinity and/or other unknown 
factors should determine whether “HLA#1”, “HLA#2” or both HLA molecules 
will bind and present the peptide and how much of it. Moreover, the presented 
peptide could be the same or slightly different (e.g. CDEFGHIJ or ABCDEF-
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GHIJ) depending on the peptide optimization done in the ER which is adapted 
according to the HLA molecule [7-9], similar to what was found for a viral 
peptide [6]. The scenario should be probably different for a subject who only 
possesses “HLA#2” and lacks “HLA#1”. Would the peptide be less or more 
abundant? I presume that the repertoire and quantity of peptides presented 
by a given MHC I molecule will be influenced in some extent by the other HLA 
alleles expressed by the individual. To test this hypothesis, the immunopep-
tidome of various individuals who share only 1 HLA allelic product could be 
compared. Notably, this type of analysis is only possible with high-throughput 
studies as the one presented here. If this concept is true, then we should not 
only analyze the peptide coding region and its predicted binding affinity for 
one given MHC to predict whether a peptide will be presented by a subject, but 
take into account possible interactions with all other MHC allelic products of 
the individual. 
6.2 The MHC I immunopeptidome is cell-specific and subject–specific 
Since the HLA genotype is the most determinant factor in defining the im-
munopeptidome of a person, one would expect to find very similar immuno-
peptidomes in HLA-identical subjects. Accordingly, our analyses of the im-
munopeptidome of HLA-identical siblings showed that 86% of the identified 
peptides were shared. The shotgun nature of the MS [10] or inter-replicate 
variations in gene expression could explain the exclusive detection of certain 
peptides in only one subject. However, 41 out of 4,468 (0.9%) peptides were 
constantly present in one subject and absent across 6 replicates of the other 
subject, suggesting that those peptides represent real differences in the im-
munopeptidomes of these siblings. Of note, the exclusive detection of 13 out 
of 41 unshared peptides in one of the siblings could be explained by ns-SNVs 
in the peptide-coding region affecting the peptide binding or perhaps its pro-
cessing. We ignore the mechanism underlying the exclusive expression of the 
remaining peptides but it could be due to genomic polymorphisms elsewhere 
than in the peptide-coding region or to posttranslational or epigenetic mecha-
nisms. Our results show that non-HLA inter-individual differences account for 
at least 0.9% differences in the repertoire of MHC I peptides of HLA-identical 
siblings. Hence, our results show that the MHC I immunopeptidome of an in-
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dividual is shaped by its genome and ultimately defined by the HLA genotype. 
In line with this, we found that the MHC I-peptide repertoires and transcripts 
source of peptides were different in HLA-disparate families. However, these 
different sets of transcripts/proteins were functionally interconnected and 
implicated in the same biologic pathways. Moreover, several immune-specific 
and B cell-specific functional categories were overrepresented in the set of 
proteins encoding MHC I peptides in B-LCLs. In contrast, comparison of the 
immunopeptidome of two different mouse cell types (DCs and thymocytes) 
showed that their peptide repertoires originated from transcripts with distinct 
biologic functions that were specific to each cell type (appendix 2) [11]. Hence, 
collectively these results show that the immunopeptidome is subject-specific 
regarding the nature of the peptides and cell-specific regarding the functional 
origin of those peptides. 
The identification of the source proteins from which the peptides originate 
can give us some cues about the factors that govern peptide processing. More-
over, it can stimulate new questions about how the immune system is able to 
distinguish self from non-self. For instance, it would be very interesting to ana-
lyze proteins that generate many different peptides and proteins that gener-
ate many copies of the same peptide. Which biological or chemical properties 
make of them a preferential or efficient source of MHC I peptides? Previous 
independent studies have found that for specific proteins, some properties 
such as the degree of hydrophobicity [12,13], the presence of transmembrane 
domains [12], the presence of degradation signals [14,15], the tendency to mis-
fold [14,16] and the intracellular localization [14,17,18], can enhance peptide 
presentation. However, other studies have found that some of these features 
do not affect antigen presentation from other proteins [15]. These studies have 
been done in particular cellular models and have been observed for specific 
proteins. We can now explore big datasets such as the ones presented here to 
determine whether these observations can be generalized to other proteins 
source of peptides and discover other features that are common to source 
proteins. 
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6.3 Influence of the transcriptome on the MHC I immunopeptidome
Our study in human cells helped resolve previous contradicting results regard-
ing the relationship between the transcriptome and the immunopeptidome 
[19-22]. We found that the MHC I immunopeptidome derived preferentially 
from abundant transcripts, although transcripts expressed at low levels gener-
ated MHC I peptides. This result confirms previous results from our laboratory 
in mouse thymocytes [21] and is in a agreement with bioinformatic analysis 
of the expression profile of transcripts coding for MHC I peptides [22]. On 
the contrary, the transcriptome-immunopeptidome correlation was absent in 
studies comparing changes in peptide and transcript abundance induced by 
neoplastic transformation or metabolic stress [20,21,23]. This suggest that un-
der steady-state conditions, the MHC I immunopeptidome is biased toward 
peptides that derive from abundant transcripts, but that this tendency is ab-
sent in stressed cells. Accordingly, we have previously shown that ER stress 
and the unfolded protein response impaired the presentation of MHC I-associ-
ated peptides owing to post-transcriptional mechanisms: inhibition of overall 
protein synthesis and reduced supply of peptides (appendix 1). Moreover, we 
showed that the impact was more severe when a model protein source of pep-
tides was localized in the cytosol than in the ER, suggesting that stress could 
affect in different extents proteins source of peptides depending on their loca-
tion. Another study from our laboratory has shown that changes in the immu-
nopeptidome induced by metabolic stress (inhibition of the mTOR pathway) 
were mainly caused by co- and/or post-translational mechanisms [23]. The 
plasticity of the immunopeptidome could reflect not only metabolic changes 
but also changes in the mechanisms responsible for the generation of peptides 
under particular conditions. This could be further investigated in other types 
of cells and under other types of stresses. 
In a related observation, among the functional categories and pathways that 
were enriched in transcripts source of MIPs, we found terms associated to 
protein synthesis and transcription. Notably, Toung and coworkers found an 
enrichment of equivalent GO-term categories in medium and high-expressing 
genes in an RNA-sequencing analysis of human B-LCLs [24]. Thus, the over-
representation of some functional categories such as protein synthesis and 
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transcription in the immunopeptidome of B-LCLs could be reflecting those 
transcripts source of peptides that are abundant.
Since transcript abundance is the net result of ongoing transcription and tran-
script degradation [25], it would be necessary to dissociate the effect of active 
transcription vs. low rate of degradation of transcripts source peptides on 
the immunopeptidome. We showed that the enrichment for highly abundant 
transcripts as a source of MHC I peptides is accentuated in the transcriptional 
hotspot comprised in the 6p21 chromosomal region. This results points to-
wards transcription rate as the major player but further studies are needed to 
prove this hypothesis (see perspectives). In line with this, it would be of great 
interest to test whether other transcriptional hotspots would be a preferential 
source of MHC I peptides or whether this is a unique property of the 6p21 
region. A high transcription rate comes with an increased number of errors 
during transcription and perhaps our results reflect a selective mechanism for 
choosing RNAs for translation into DRiPs based on quality and not quantity. 
6.4 The immunopeptidome preferentially derives from transcripts 
bearing microRNA response elements (MREs)
We discovered that MIPs derive preferentially from transcripts bearing MREs. 
This relationship was observed in different cell types of mouse and human 
origin and hence it appears to be a generalized phenomenon. We further con-
firmed that the microRNAs (miRNAs) that were predicted to target transcripts 
source of MHC I peptides were indeed expressed at higher levels in our cells 
compared to non-lymphoid cell lines.
miRNAs regulate gene expression posttranscriptionally by base-pairing to the 
mRNA 3’-UTR leading to mRNA decay and/or repression of protein synthesis 
by mechanisms that are not fully understood [26]. Although we did not explore 
how mRNA targeting by miRNAs could favor MHC I-peptide presentation, we 
hypothesize that miRNAs could represent major regulators of the DRiP rate 
via destabilization of mRNAs. miRNAs could generate DRiPs during the tar-
geted mRNA degradation step and/or during translation inhibition. This idea 
is supported by previous studies implicating RNA regulation in DRiP genera-
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tion [27]. It was reported that a small interfering RNA (siRNA) targeted down-
stream of a reporter peptide results in production of 5’mRNA products in the 
absence of full-length mRNA. These products were translated into truncated 
proteins resulting in enhanced antigen presentation in vitro and increased tu-
mor destruction in vivo [27]. miRNAs can also repress translation in different 
ways: inhibition of translation initiation, slow down or inhibition of translation 
elongation, ribosome drop-off leading to premature termination of transla-
tion and co-translational degradation of the nascent polypeptide [26,28-30]. 
All these events can potentially generate DRiPs. In fact, it has been shown 
that mRNAs carrying premature stop codons that prevent the production of 
full-length proteins via the nonsense-mediated decay pathway can produce 
MHC I peptides by a noncanonical mRNA translation process [31,32]. Similarly, 
miRNA targeting could increase the number of pioneer translation products 
produced during translation initiation.
One could argue that if the ribosomes would pre-terminate before reaching 
the 3’ of the ORF or if 5’mRNA products are produced, there should be enrich-
ment for peptides from the N-terminus of the protein (i.e. the 5’ of the mRNA 
coding sequence) in the immunopeptidome. Yewdell and coworkers have re-
cently analyzed the locations of a large set of known viral epitopes within their 
proteins and found a significant bias in the central region of the proteins [33]. 
On the contrary, recent bioinformatics analyses made in our laboratory show 
that the C-terminal portion of proteins are underrepresented in the immuno-
peptidome of B-LCLs (T. Daouda, unpublished data), which would be in line 
with our results. Of note, viral infection induce a variety of metabolic changes 
including ER stress leading to global attenuation of protein synthesis [34,35]. 
In response, viruses often use internal ribosomal entry sites (IRES) allowing 
translation initiation in the middle of the mRNA [36]. Therefore, the location 
of the peptide in the protein source could be different for viral antigens than 
for self-peptides and this could explain the discrepancies in the location bias 
found between Yewdell’s work and our laboratory. 
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6.5 Which factors determine the number of MHC I peptides generated 
by a transcript?
Our results show that the number of MHC I peptides generated by a source 
transcript can be influenced by at least two factors: the transcript abundance 
and the presence of MREs in the transcript. 
A priori our results seem contradictory, since recognition by miRNAs can lead 
to translation inhibition and/or to the degradation of the targeted mRNA and 
probably to decreased transcript abundance. However, it is important to con-
sider that transcript abundance reflects the net effect of ongoing transcription 
and mRNA degradation. For instance, increased mRNA degradation will be 
masked by a high transcription rate. Moreover, some mRNA targets of miRNAs 
can be translationally repressed with little if not change in mRNA abundance 
[29]. 
One possibility is that transcript abundance and the presence of MREs in the 
transcript are related factors. In this scenario, lowly abundant mRNAs that 
generate MHC I peptides could do so because they are highly targeted by miR-
NAs (and presumably resulting in a high DRiP rate). If true, we would expect to 
find more miRNA targets among lowly abundant transcripts that give rise to 
peptides. We tested this hypothesis and found similar proportions of miRNA 
targets among low and high abundant transcripts (data not shown). Although 
this preliminary analysis was based on what is predicted to be targeted and 
not what is indeed targeted by miRNAs and thus can be further improved with 
experimental data, it suggests that predicted miRNA targeting cannot explain 
per se how low abundance transcripts generate MHC I peptides. Perhaps, other 
mechanisms, such as nonsense-mediated decay pathway [37-39] could explain 
this observation.
Another possibility is that transcript abundance and miRNA targeting con-
stitute features of a “special” set of transcripts that are a preferred source 
of peptides. This set of transcripts could represent those that are bound by 
“immunoribosomes” [38,40] in a selective mechanism for choosing RNAs for 
translation into DRiPs and rapid peptide generation. 
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6.6 A novel personalized approach for the identification of MHC I-asso-
ciated peptides including MiHAs 
Current high-throughput MS approaches rely on traditional search engines (e.g. 
Mascot) that match tandem mass spectra sequences against hypothetical spec-
tra generated from known protein sequence databases (e.g. UniProt Human da-
tabase) [41-43]. This algorithmic strategy limits peptide identification only to 
reference proteins and is blind to variations in the amino-acid sequence [44]. 
Hence, conventional MS is inadequate for MiHA detection because it cannot 
detect polymorphic peptides. Previous efforts have been made in the develop-
ment of databases suitable for identification of polymorphic peptides [44-46]. 
However, the inclusion of all reported protein variants considerable increases 
database size rendering it impractical and leads to the assignment of peptides 
to sequences that are not necessary present in the analyzed sample (false posi-
tives). To overcome these obstacles, we developed a novel strategy that hinges 
on high-throughput identification of MHC I peptides by tandem MS analyses 
with a personalized proteome database generated from in silico translation of 
combined exome and transcriptome sequencing data. This approach enable 
us to identify 4,468 MHC I peptides including 34 MiHAs. This personalized 
method allows a more precise MS-based identification of any peptide whose 
DNA or RNA coding region has been sequenced. Although the comparison of 
the immunopeptidome identified with a reference database vs. the personal-
ized database showed that the number and nature of identified peptides is 
very similar (96% overlap), we demonstrated that ~50% of identified MiHAs 
would have been missed in the absence of a personalized database. Moreover, 
the use of both exome and transcriptome sequencing allows the validation of 
ns-SNVs in the peptide-coding region with 2 independent approaches.
Both forward and reverse immunology strategies have been used for the iden-
tification of MHC peptides including MiHAs (chapter 4). Previous reverse im-
munology approaches have combined genome sequencing and bioinformatics. 
A recent study compared ns-SNP differences between HLA-identical siblings 
using a microarray-based SNP genotyping assay for 10,000 validated ns-SNPs 
[47]. The protein coding variations unique to one of the siblings were used to 
predict epitopes that could bind HLA-DRB1*0301 and 10 of these candidates 
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were tested in vitro for DRB1*0301 binding and stimulation of CD4+ T cell 
responses. Interestingly, only 2 out of 10 candidates could induce CD4+ T cell 
responses. This means that only 20% of predicted peptide candidates based on 
genomic differences and binding predictions were truly MiHAs. Similarly, Rob-
ins and coworkers synthesized candidate MHC-binding nonamers that were 
predicted in silico based on single mutations identified by exome sequencing 
of patient-derived melanoma cell lines and tested the peptides for recognition 
by autologous tumor-infiltrating lymphocytes [48]. They found that only 5% of 
the predicted peptides were indeed recognized by the tumor infiltrating lym-
phocytes. These two examples illustrate that reverse immunology approaches 
based on genomic sequencing and bioinformatic predictions suffer from a high 
false discovery rate reflecting our limited knowledge and the unpredictability 
of the antigen-processing pathway. We identified 4,833 ns-SNVs between these 
siblings of which only 0.5% (26) were detected in the coding region of 22 Mi-
HAs. Of note, identified MiHAs behave as recessive or dominant traits at the 
cell surface and hence only one of the two possible variants was detected. 
Moreover, we showed that in several cases the amino acid change considerably 
decreased the binding affinity of the peptide for the HLA molecule. Although 
more sensitive MS instruments could enhance MHC I peptide identification, 
these results suggest that only a tiny fraction of all potential MiHAs that could 
be generated from each ns-SNV, reach the cell surface. We further examined 6 
MiHAs that were coded by an allele present only in one subject and found that 
all 6 MiHAs induced selective killing by MiHA-specific CTLs (i.e. were immuno-
genic). Our approach demonstrates the necessity of using not only genomics 
and bioinformatics, but also proteomics data to identify those “winner pep-
tides” that are successfully processed and presented in a given cell type and 
thus decrease the number of false discoveries.
There are currently 47 reported MiHAs (table 1, chapter4). Our method enabled 
the discovery of 34 MiHAs and 536 potential MiHAs in the general population, 
by analyzing one single couple of HLA-identical siblings. Hence, this strategy 
could greatly accelerate the development of MiHA-targeted immunotherapy. 
Importantly, our approach can be further improved at various steps.
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6.7 Proposed improvements to our personalized approach: the data-
base
Our approach focused on the identification of MiHAs caused by ns-SNPs in 
the peptide-coding region. Nevertheless, any genetic polymorphism that quali-
tatively or quantitatively affects the display of self-peptides at the cell sur-
face could in principle give rise to MiHA disparities. Other type of genomic 
polymorphisms such as indels (insertions/deletions), gene deletions and copy 
number variants (CNVs) could be considered. 
Gene deletions can be quite frequent without causing any phenotype, espe-
cially for genes with high degree of homology [49,50]. For example, the fre-
quency of the homozygous deletion of the UGT2B17 gene can be more than 
80% in some populations [51]. Deletion of the UGT2B17 gene is responsible for 
the generation of at least 2 known MiHAs (and probably many other uniden-
tified MiHAs) presented by 3 different HLA molecules. Y chromosome genes 
can also encode many HY MiHAs, as illustrated by KDM5D and UTY genes 
encoding more than 6 distinct HY MiHAs [52]. HY MiHAs could be identified 
in the future by studying sister-brother siblings. Also, CNVs and short indels, 
which are quite frequent in the human genome [53,54], could be detected from 
the exome data using algorithms such as Splitread [50]. Finally, mitochondrial 
DNA could be sequenced and incorporated in the database. Indeed, peptides 
of mitochondrial origin can be presented by MHC I molecules and mitochon-
drial MiHAs have been identified in mice [55,56]. The drawback of including 
all these types of genetic variations is a considerable increase in database size, 
since all possible protein combinations are predicted in silico from genomic 
variation. This combinatorial problem gets bigger in highly polymorphic re-
gions where various SNPs (and perhaps indels and CNVs) are contained in a 
short frame. One alternative would be to search for genetic linkage informa-
tion in order to reduce the number of combinations.
The in silico translation of exome and transcriptome sequences was done ac-
cording to the canonical ORF. However, it is widely known that cryptic MHC 
I peptides including MiHAs can derive from products of ARFs [57,58]. Hence, 
it would be relevant to include all 3 forward and 3 reverse reading frames in 
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the database to discover not only MiHAs but also cryptic peptides in general. 
Of note, MiHAs deriving from ARFs have seldom been described [59,60]. This 
might reflect their scarcity or most probably the difficulty of identification. 
In line with this, MHC I peptides including MiHAs can also arise from transla-
tion of “untranslated” 3’- and 5’-UTRs and from intronic regions [60-62]. In 
our RNA-seq experiments, a significant proportion of sequenced reads (~10%) 
mapped to introns. This information as well as sequences from UTR were not 
analyzed but could be considered in the construction of the database. Inter-
estingly, we identified a set of 700 peptides by MS that the search engine 
(Mascot) couldn’t match to any sequence in our personalized proteomes (data 
not shown). One possibility is that these peptides correspond to erroneous MS 
sequencing or to peptides that do not fragment well in the MS and thus have 
a bad identification quality. Although, a manual inspection of the sequences 
will be needed to discard this possibility, another explanation will be an “atypi-
cal” origin of those peptides. They could represent any type of sequence not 
contained in the reference proteome: 5’ or 3’ UTRs, translation products of 
ARFs or posttranslational protein splicing events [63-66]. The identification of 
this latter category of peptides is currently the most challenging. We currently 
ignore how frequently these events occur and what proportion of the MHC 
I immunopeptidome originates from those non-conventional sources. Their 
existence suggest that the MHC I immunopeptidome is probable more diverse 
and larger than anticipated and that many MHC I peptides including MiHAs 
cannot be predicted merely on genomic polymorphisms. 
6.8 Proposed improvements to our personalized approach: peptide elu-
tion and MS analyses
The identification of MHC I peptides by MS is relatively challenging given the 
complexity of the peptide mixture [19,42,67]. This complexity is even higher in 
samples obtained with mild-acid elution composed of thousands of MHC I and 
non-MHC I peptides, most of them with homogeneous size [67]. Because MHC 
I peptides are relatively short, their fragmentation spectra frequently do not 
allow unambiguous matches to database sequences [43]. Moreover, the fact of 
having mostly only 1 MHC I peptide representative of each protein in one sam-
ple renders protein identification more difficult [42]. Finally, most current MS 
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approaches have been developed to favor the identification of peptides result-
ing from trypsin digestion. Tryptic peptides are characterized by the presence 
of a basic residue (lysine or arginine) at the C-terminus, which favors peptide 
fragmentation and leads to better MS/MS spectra [67]. MHC I peptides do not 
necessarily show these features and are fragmented randomly depending on 
their amino acid composition [67]. 
A quality score such as the Mascot score is commonly used in proteomics to 
estimate the quality of the MS/MS identification. However, the score is directly 
correlated with the peptide length [68], which means that short peptides such 
as MHC I-peptides would tend to have lower scores despite good spectra qual-
ity. We demonstrated that the Mascot score can be combined with the pre-
dicted binding affinity to adapt this MS quality measure to MHC I peptides. 
Our study suggest that the frequently used Mascot score threshold of 35 is 
too stringent for MHC I peptides, as approximately half of the identified MHC 
I peptides including MiHAs had Mascot scores <35. 
These challenges merit further development of MS algorithms that predict the 
characteristics of MHC I peptides to enhance their identification. Also, novel 
MS approaches not relying on proteomic databases such as de novo sequenc-
ing [69] could enable the identification of MHC I peptides not encoded in the 
genome such as peptides resulting from posttranslational protein splicing 
events [66].
We identified four MiHAs in the subject homozygous for the corresponding 
allele but not in the heterozygous subject. This suggests that zygosity influ-
ences MiHA abundance and that low abundance MiHAs may fall below the MS 
detection threshold in heterozygous subjects. Consistent with this, the MS in-
tensity for these four MiHAs was low in homozygous subjects. Similarly, we as-
sessed the immunogenicity of three MHC I peptides that had identical peptide 
coding sequences in both subjects but were detected in one sibling and absent 
in all replicate samples from the other sibling. However, none of these three 
peptides could elicit CTLs in the MHC I-peptide-negative sibling. This suggests 
that these peptides were differentially expressed in both siblings and that its 
abundance was below the MS threshold in one subject. We presently ignore the 
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number of peptides whose abundance at the cell surface is below the MS detec-
tion limit. We believe that we are currently detecting “the top of the iceberg” 
and that many more peptides are probably presented by MHC I molecules, but 
they might escape detection because of low abundance and/or relatively low 
sensitivity in the electrospray ionization process. It becomes necessary to ac-
curately determine the detection threshold of our current MS technique. The 
concentration of peptides in the ER is supposed to be the rate-limiting step 
for MHC I-peptide presentation [70]. With the development of more sensitive 
instruments we will probably be able to precisely answer the question: what 
is the total amount of peptide complexes that is exposed at the cell surface? 
Also, we need to apply absolute quantitative approaches to estimate the total 
number of copies of each specific complex. 
MS also allowed the identification of 652 peptides with post-translational mod-
ifications including oxidation, deamidation, cysteinylation and phosphoryla-
tion that merit further investigation. Although we know that post-translational 
modifications can affect the processing, presentation or recognition of certain 
peptides by CD8 T cells [71], our current knowledge of the biological signifi-
cance of these types of peptides is very limited due to their rarity. In fact, we 
ignore whether post-translationally modified MHC I peptides are indeed rare 
or simply not targeted by current MS protocols. Our method to process eluted 
MHC I peptides could be better adapted to identify post-translationally modi-
fied peptides. In the future, it could be interesting to explore and compare the 
proportion of post-translational modifications in the immunopeptidome and 
in the proteome. Since most (but not all) post-translational modifications oc-
cur post translation, an underrepresentation of posttranslationally modified 
peptides could give some cues about the preferred source of MHC I peptides. 
If DRiPs are the major source of MHC I peptides then one would expect to find 
less post-translational modifications in these peptides in comparison to the 
proportion found in the proteome. However, it would be also necessary to pre-
cisely determine when and where the post-translational modification occurs.
6.9 Impact of genomic polymorphisms on the MHC I immunopeptidome
We studied the effect of non-MHC SNPs on the MHC I immunopeptidome. We 
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concentrated our analyses to ns-SNPs in the peptide-coding region. Neverthe-
less, ns-SNPs in the vicinity of the peptide coding region could produce chang-
es in the MHC I immunopeptidome of HLA-identical subjects. For instance, 
MiHA disparities can be generated by ns-SNPs in the peptide flanking region 
that affect peptide translocation by TAP or its degradation by the proteasome 
[72-74]. In addition, polymorphisms can affect the expression of genes in trans 
[75] and this could quantitatively and qualitatively affect the MHC I-peptide 
repertoire. Polymorphisms in non-coding regions could not only modulate 
gene expression but also affect alternative splicing, RNA editing and generate 
cryptic translation products. For example, polymorphisms in MREs can affect 
recognition by miRNAs with a consequent impact on target transcripts [76].
We concentrated our analyses to SNPs that change the amino acid sequence. 
Nevertheless, synonymous SNPs (s-SNPs) in the mRNA source of peptides or in 
trans could also affect the immunopeptidome. “Silent” or synonymous codon 
positions, define mRNA secondary structure and stability and affect the rate 
of translation, folding and post-translational modifications of nascent poly-
peptides [77,78]. Since the number of s-SNVs that can be found in the peptide-
coding regions of two individuals might lie in the order of thousands, bioin-
formatic tools could be used to filter those s-SNVs that are predicted to affect 
mRNA abundance or the corresponding protein. Further biochemical studies 
will also be needed to understand how s-SNPs affect the immunopeptidome, 
although this would not be an easy task.
Our results suggest that zygosity influences MiHA abundance, as evidenced by 
the detection of four MiHAs in the subject homozygous for the correspond-
ing allele but not in the heterozygous subject. However, we ignore whether 
differences in peptide abundance caused by zygosity could lead to immune 
responses. Neoplastic transformation can provoke differential expression of 
peptides or so called tumor-associated antigens, which can be immunogenic 
[21]. Similarly, it would be of great interest to test whether allelic dosage could 
be sufficient to cause immunogenicity.
We found that at least 41 MHC I peptides were exclusively detected by MS in 
one sibling and constantly absent in the other sibling yet the peptide-coding se-
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quence was identical in the 2 individuals. With the aim of explaining the origin 
of these peptide differences, we analyzed various possible mechanisms. First, 
we did not find any correlation between the exclusive detection of a peptide 
in a subject and an increased expression of the transcript source of peptide 
in the same subject. Second, we compared the level of transcript expression 
of the main known players in the antigen processing pathway between sib-
lings and found no significant differences. Although transcript abundance is 
a very rough estimate of protein levels, our results would discard quantitative 
differences in molecules involved in the antigen processing to explain pep-
tide discrepancies in this sibling. Nevertheless, not only quantitative but also 
qualitative differences in molecules involved in the antigen processing could 
induce changes in the immunopeptidome. As described in the first chapter, 
many proteins participate in the antigen processing and presentation pathway 
and many others are probably unknown. Polymorphisms in one or more of 
these molecules, especially those in active sites or affecting the conformation 
of enzymes could affect their interaction with the peptide or their function. 
For example, ns-SNP in ERAP1 can affect the protein structure, its cleavage ca-
pacity and thus the generation of some peptides [79]. Accordingly, it has been 
shown that some ERAP1 mutants have a ~40% lower peptidase activity in vitro 
[80] and defects in basic enzymatic properties [81]. In another example, An-
drés and coworkers described a polymorphism inducing destruction of ERAP2 
mRNA by nonsense-mediated decay leading to very low ERAP2 protein levels 
and reduction in MHC I surface expression in B-LCLs [82]. Based on these stud-
ies and since ERAP1 and ERAP2 are the main aminopeptidases responsible for 
trimming the N-terminus of peptides, we search for non-synonymous poly-
morphisms between these subjects. We found 2 ns-SNPs that have been shown 
to affect the enzymatic activity of ERAP1 (data not shown) and therefore, I 
presume that polymorphisms in molecules involved in the antigen process-
ing pathway such as ERAP could indirectly change the repertoire of the MHC I 
peptides. 
6.10 MHC I peptides encoded by conserved and polymorphic genomic 
regions
We explored whether MHC I-associated peptides derive preferentially from in-
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variant vs. polymorphic genomics regions. This yet unexplored question is not 
only biologically important but also very pertinent to clinical transplantation: 
can we expect MiHAs to be derived from allogeneic polymorphisms through-
out the human genome, or are person-to-person differences in select proteins 
more subject to presentation? Our results showed that the MHC I immunopep-
tidome is not enriched with polymorphic or invariant peptides. This result was 
supported by two independent analyses: i) a comparison of the frequency of 
SNPs/bp in the peptide-coding DNA sequence and in the human exome (chap-
ter 3) and ii) a bootstrapping procedure to compare the number of ns-SNPs 
(reported in db-SNP) found in 10,000 random samplings of 4,468 hypothetical 
peptide-coding regions from the human reference exome vs. the number of ns-
SNPs found in the regions coding for 4,468 identified peptides (chapter 5). We 
found that at the population level, 88% of peptide-coding sequences identified 
were invariant whereas 12% contained at least one ns-SNP: 670 ns-SNPs were 
found in the genomic region coding for 536 MHC I polymorphic peptides. Our 
results were confirmed by a recent study in which a similar proportion (10%) 
of polymorphic MHC I peptides were identified with a immunoprecipitation-
based mass spectrometry approach [83].
6.11 Identification of potential MiHAs in the general population
Our approach can be used to discover potential MiHAs in the general popula-
tion by identifying MHC I peptides that derive from known polymorphic re-
gions using databases such as dbSNP. To choose the best potential MiHAs, 
one could further select those MHC I peptides whose coding region contains 
ns-SNPs that have balanced allele frequencies in a population to increase the 
chance of observing a disparity between donors and recipients. Moreover, the 
expression of genes source of MiHAs could be verified in different cells and 
tissues to favor those whose expression is restricted to hematopoietic cells 
and cancer cells and thereby favor GvL or GvT effect and avoid GvHD. Gene 
expression could be tested in silico using publicly available databases for dif-
ferent cells and tissues such as BioGPS (http://biogps.org/). Moreover, avail-
able RNA-seq data could be interrogated to have a more precise idea of the ex-
pression of MiHA-encoding transcripts in small subpopulations in each tissue. 
Importantly, lowly expressed transcripts cannot be totally neglected, as our 
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results showed that low abundant transcripts can generate MHC I peptides. 
Thus, although a preliminary in silico inspection can be very informative, pro-
teomic confirmation of the presence or absence of a given MiHA in a specific 
tissue or cell type would be preferable. It would be also important to verify 
whether the potential MiHAs are encoded by a single gene. Lastly, identifica-
tion of MiHAs that are promiscuous binders might have a broader application 
as they could be naturally presented by more than two HLA alleles [84].
6.12 How many human MiHA exist?
The 1000 Genomes Project Consortium has recently reported 38 million SNPs, 
1.4 million short indels and more than 14,000 larger deletions in humans 
[54]. In average, one individual human genome presents 3.6 million SNPs, 344 
thousand indels and 717 large deletions[54]. Because in principle, any genetic 
polymorphism that qualitatively or quantitatively affects the display of self-
peptides at the cell surface could give rise to MiHA disparities, these numbers 
would suggest that a large number of MiHAs mismatches would occur even 
despite selection for identity at the MHC in a clinical setting. Accordingly, 
we compared the exome and transcriptome of two HLA-identical siblings and 
found 4,833 ns-SNVs, most of which corresponded to reported SNPs.  This 
number lies in the range of ns-SNVs found by other groups comparing the 
exomes of 12 unrelated individuals (~3,600-6,400) [47,85]. Since only a frac-
tion of the proteome is sampled in the immunopeptidome owing to HLA bind-
ing selectivity and destruction during antigen processing, only a small fraction 
of the genetic disparities between two HLA-identical individuals is expected 
to be reflected in differences in the MHC I peptide repertoire. Our results re-
flected this selectivity since only 26 (0.5%) were detected in the coding region 
of 22 MiHAs, of which 13 MiHAs were encoded by an unshared allele. 
Theoretical estimates of the number of MiHAs between MHC-identical subjects 
range from 15 to thousands [86-88]. We addressed this issue experimentally 
and identified 13 MiHAs disparities in B-LCLs from two HLA-identical siblings. 
This means that out of 4,468 MHC I peptides present on B-LCLs, 13 (0.3%) 
would be immunogenic for one of these siblings. This number could vary de-
pending on the genes expressed by a given cell type and the genetic similarity 
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of the 2 individuals. The number of MiHAs between HLA-identical subjects 
might be probably much more greater since we restricted our analyses to Mi-
HAs resulting from ns-SNPs in the peptide-coding region. Indels, CNV as well 
as s-SNPs and ns-SNPs inside and outside the peptide-coding region might con-
siderably increase this number. Moreover, more sensitive MS instruments and 
better sequencing coverage could enable identification of more MHC I peptides 
(and thus MiHAs) as well as more polymorphisms, respectively.
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Perspectives
Study of the MHC I immunopeptidome from a systems biology perspec-
tive
Our work illustrates the utility of systems biology approaches to study the 
composition of the MHC I immunopeptidome as well as the “rules” or general 
patterns underlying its biogenesis. In line with this, the Human Immunopep-
tidome Project has been recently proposed with the aim of analyzing the full 
repertoire of HLA-associated peptides in health and disease and understand-
ing the molecular mechanisms involved in its formation [89]. 
In ecological sciences the biodiversity index of an ecosystem is often estimated 
to monitor changes or perturbations in the ecosystem’s functionality [90,91]. 
In immunopeptidomics, an analogous definition of a diversity index would be: 
a quantitative measure that reflects how many different peptides compose 
the immunopeptidome of a given cell under specific conditions, and simul-
taneously takes into account how evenly the number of copies per peptide 
are distributed. The value of a diversity index would increase both when the 
number of peptides increases and when evenness increases. Thus, for a given 
number of peptides, the value of a diversity index would be maximized when 
all peptides are equally abundant. With the development of more quantitative 
MS approaches, it would be feasible to calculate the diversity index of the im-
munopeptidome and compare and study its biological significance (if any) un-
der steady-state conditions and following intrinsic and extrinsic perturbations 
for different cells or tissues.
Since multiple events are involved in the generation of MHCI peptides includ-
ing MiHAs, I personally believe that approaches combining the analysis of vari-
ous functional genomic levels (genomic, transcriptomic, proteomic, degrado-
mic, peptidomic) could be very meaningful. Inclusion of bioinformatics tools 
and methods was crucial in our work and will be indispensable in this kind 
of studies. Although our results contributed to a better understanding of the 
genome-immunopeptidome and transcriptome-immunopeptidome relation-
ships, further experiments are needed to dissociate the contribution of actively 
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transcribed genes vs. that of very stable transcripts to the immunopeptidome. 
For example, RNA Polymerase II CHIP-seq transcription profiling could be used 
to measure transcription rates as a function of RNA Polymerase II occupancy 
across the genome, enabling the measurement of transcription rates without 
the influence of RNA half-life. Similarly, to systematically test the concept that 
the immunopeptidome samples what is being translated as opposed to what 
has been translated, genome-wide measurements of occupancy and density of 
ribosomes on mRNA [92-94] could be performed simultaneously with analysis 
of the immunopeptidome. It would be also of great interest to study the global 
contribution of the degradome to the immunopeptidome using quantitative 
proteomics [95]. Finally, the impact of epigenetic regulation on the MHC I im-
munopeptidome has never been addressed. Studies of the immunopeptidome 
and the “methylolme” of identical twins could reveal some surprises. These 
studies could be well complemented with molecular assays to validate data-
driven hypotheses.
Model to unravel the factors that control which MHC I peptides are dis-
played and in which quantity
Defining the nature of endogenous peptides contributes not only to the un-
derstanding of MHC I antigen presentation but to other central aspects of cell 
biology such as gene expression, protein synthesis and degradation. Our find-
ings can contribute to the optimal design of CD8+ T cell vaccines for tumors 
and pathogens and could be also applied in the autoimmunity field. One inter-
esting model to study the intrinsic factors that promote MHC I peptide gen-
eration are medullary thymic epithelial cells (mTECs). mTECs have the unique 
ability to transcribe otherwise tissue-restricted genes through the action of 
the transcription factor AIRE as well as AIRE-independent factors [96]. Accord-
ingly, RNA-seq experiments performed in our laboratory have recently shown 
that more genes are expressed in medullary thymic epithelial cells leading to 
increased average transcript abundance in comparison to other cell popula-
tions [97]. This promiscuous gene expression leads to presentation of tissue-
restricted antigens by mTECs and is instrumental during negative selection 
of T lymphocytes [96]. One would predict a high “diversity index” in the im-
munopeptidome of mTECs, i.e. the presence of a huge variety of peptides with 
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little variation in the number of copies per peptide. Furthermore, these cells 
would need an efficient mechanism for MHC I peptide generation or a special-
ized DRiP apparatus. This apparatus could be a highly active miRNAome or a 
specific set of miRNAs that efficiently act on transcripts leading to DRiPs for-
mation and facilitating the generation of MHC I peptides. Accordingly, recent 
studies have shown that AIRE can control the expression of miRNAs that char-
acterize mature mTECs [98,99]. These features made of mTECs a very interest-
ing model to study the biogenesis of the immunopeptidome.
MiHAs in personalized therapy
We have shown that the immunopeptidome is subject-specific and cell-specif-
ic. In this context, I envisage personalized therapies, where information of ge-
netic differences between donor and recipients are combined with proteomic 
studies for specific cell types and tissues to predict the outcome of transplan-
tation in different donor-recipient scenarios and thereby facilitate selection of 
the most optimal donor. However, some remaining obstacles need urgently to 
be bypassed before translation to the clinics. The first one is the identification 
of cryptic MiHAs generated by non-conventional processes and not encoded 
in the genome. De novo sequencing MS approaches seem promising in this 
regard [69]. The second challenge is the development of methods to discover 
MHC II-bound MiHAs. To date, very few MHC II-associated MiHAs are known 
despite renewed efforts in their identification. Because MHC II molecules are 
not expressed on most non-hematopoietic tissues under non-inflammatory 
conditions, MHC II-associated MiHAs are less likely to cause GvHD [100]. These 
antigens could be very useful if presented on leukemic or cancer cells express-
ing MHC II. Lastly, MS-based identification still requires huge amount of start-
ing material (500 mill cells for the strategy based on mild acid elution). This 
amount is even higher for cells that express low surface levels of MHC and 
for immunoprecipitation-based MS approaches. We are still far from a very 
sensitive technique that will allow quantification of peptides from small popu-
lations without the need of in vitro expansion and immortalization methods, 
such as infection with EBV. More sensitive approaches will definitely allow the 
characterization of the immunopeptidome in many more cell types and the 
application of approaches such as ours in the clinic. 
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Conclusion
We employed systems biology approaches to unravel the composition and cel-
lular origin of the self MHC I-associated peptide repertoire presented by B-
LCLs derived from 2 pairs of HLA-identical siblings.  
First, we found that HLA-different subjects present different immunopepti-
domes derived from different sets of proteins. These proteins were function-
ally interconnected, implicated in the same biological pathways and conveyed 
to the cell surface a cell type-specific signature. Our results showed that the 
human MHC I immunopeptidome is subject-specific and cell-specific.
Second, our analyses revealed that the MHC I immunopeptidome i) showed no 
bias toward conserved vs. polymorphic genomic sequences, ii) derived prefer-
entially from abundant transcripts and iii) was enriched in transcripts bearing 
MREs. Furthermore, while the MHC I immunopeptidome of HLA-disparate sub-
jects is coded by different sets of transcripts, these transcripts are regulated 
by mostly similar miRNAs. Our data support an emerging model in which the 
generation of MIPs by a transcript depends on its abundance and its regulation 
by miRNAs. 
Finally, we developed a novel personalized approach combining mass-spec-
trometry, next-generation sequencing and bioinformatics for high-throughput 
identification of MHC I peptides including MiHAs caused by ns-SNPs in the 
peptide-coding region. We discovered 34 MiHAs in a pair of HLA-identical sib-
lings and 536 potential MiHAs in the general population. Our results showed 
that MiHAs, which are encoded by biallelic loci, behaved as dominant or re-
cessive traits at the cell surface. Comparison of the genomic landscape of the 
MHC I-peptide repertoires identified in these siblings revealed that i) 0.5% of 
ns-SNVs were represented in the immunopeptidome and ii) 0.3% of the MHC 
I-peptide repertoire would be immunogenic for one of the siblings.
Our results are relevant for the design of peptide-based immunotherapeutics. 
In addition, our MHC I-peptide identification strategy could greatly accelerate 
the development of MiHA-targeted immunotherapy. Finally, our exome, tran-
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scriptome, miRNAome and immunopeptidome datasets of B-LCLs represent a 
new resource for other scientists interested in inter-individual differences and 
therefore is of great valuable for the scientific community. 
 
230
References
1. Lin, H. et al. (2008) Evaluation of MHC class I peptide binding prediction 
servers: Applications for vaccine research. BMC Immunology 9, 8
2. Bassani-Strenberg, M. et al. (2010) Soluble plasma HLA peptidome as a 
potential source for cancer biomarkers. Proc.Natl.Acad.Sci.U.S.A  107, 
18769-18776
3. Zernich, D. (2004) Natural HLA Class I Polymorphism Controls the Path-
way of Antigen Presentation and Susceptibility to Viral Evasion. The 
Journal of Experimental Medicine 200, 13–24
4. Sieker, F. et al. (2008) Differential tapasin dependence of MHC class I 
molecules correlates with conformational changes upon peptide disso-
ciation: A molecular dynamics simulation study. Molecular Immunology 
45, 3714–3722
5. Neefjes, J.J. et al. (1993) Selective and ATP-dependent translocation of 
peptides by the MHC-encoded transporter. Science 261, 769–771
6. Tussey, L.G. et al. (1995) Different MHC class I alleles compete for pre-
sentation of overlapping viral epitopes. Immunity 3, 65–77
7. Turnquist, H.R. et al. (2002) Disparate binding of chaperone proteins by 
HLA-A subtypes. Immunogenetics 53, 830–834
8. Turnquist, H.R. et al. (2000) HLA-B polymorphism affects interactions 
with multiple endoplasmic reticulum proteins. European Journal of Im-
munology  30, 3021–3028
9. H, H.W. et al. (2002) HLA Class I Polymorphism Has a Dual Impact on Li-
gand Binding and Chaperone Interaction. Human Immunology 63, 248–
255
10. Pachl, F. et al. (2013) Characterization of a high field Orbitrap mass spec-
trometer for proteome analysis. Proteomics 13, 2552–2562
11. de Verteuil, D. et al. (2010) Deletion of immunoproteasome subunits 
imprints on the transcriptome and has a broad impact on peptides pre-
sented by major histocompatibility complex I molecules. Molecular and 
Cellular Proteomics 9, 2034–2047
12. Huang, L. et al. (2011) Hydrophobicity as a driver of MHC class I antigen 
processing. The EMBO Journal 30, 1634–1644
13. Istrail, S. et al. (2004) Comparative immunopeptidomics of humans and 
231
their pathogens. Proc.Natl.Acad.Sci.U.S.A 101, 13268–13272
14. Caron, E. et al. (2005) The structure and location of SIMP/STT3B account 
for its prominent imprint on the MHC I immunopeptidome. Internation-
al Immunology  17, 1583–1596
15. Golovina, T.N. et al. (2005) The impact of misfolding versus targeted 
degradation on the efficiency of the MHC class I-restricted antigen pro-
cessing. The.Journal of Immunology 174, 2763–2769
16. Ostankovitch, M. et al. (2005) Regulated Folding of Tyrosinase in the En-
doplasmic Reticulum Demonstrates That Misfolded Full-Length Proteins 
Are Efficient Substrates for Class I Processing and Presentation. The.
Journal of Immunology 174, 2544–2551
17. Kang, T.H. et al. (2006) Enhancement of dendritic cell-based vaccine po-
tency by targeting antigen to endosomal/lysosomal compartments. Im-
munology Letters 106, 126–134
18. Lacaille, V.G. and Androlewicz, M. (2000) Targeting of HIV-1 Nef to the 
Centrosome: Implications for Antigen Processing. Traffic 1, 884–891
19. Mester, G. et al. (2011) Insights into MHC class I antigen processing 
gained from large-scale analysis of class I ligands. Cellular and Molecu-
lar Life Sciences 68, 1521–1532
20. Weinzierl, A.O. et al. (2006) Distorted Relation between mRNA Copy 
Number and Corresponding Major Histocompatibility Complex Ligand 
Density on the Cell Surface. Molecular & Cellular Proteomics 6, 102–112
21. Fortier, M.H. et al. (2008) The MHC class I peptide repertoire is molded 
by the transcriptome. Journal of Experimental Medicine 205, 595–610
22. Juncker, A.S. et al. (2009) Systematic Characterisation of Cellular Lo-
calisation and Expression Profiles of Proteins Containing MHC Ligands. 
PLoS ONE 4, e7448
23. Caron, E. et al. (2011) The MHC I immunopeptidome conveys to the cell 
surface an integrative view of cellular regulation. Molecular Systems Biol-
ogy 7, 533
24. Toung, J.M. et al. (2011) RNA-sequence analysis of human B-cells. Ge-
nome Research 21, 991–998
25. Perez-Ortin, J.E. et al. (2013) Eukaryotic mRNA Decay: Methodologies, 
Pathways, and Links to Other Stages of Gene Expression. Journal of Mo-
lecular Biology 425, 3750–3775
232
26. Fabian, M.R. et al. (2010) Regulation of mRNA translation and stability 
by microRNAs. Annual Review of Biochemestry  79, 351–379
27. Gu, W. et al. (2009) Both treated and untreated tumors are eliminated by 
short hairpin RNA-based induction of target-specific immune respons-
es. Proc.Natl.Acad.Sci.U.S.A 106, 8314–8319
28. Filipowicz, W. et al. (2008) Mechanisms of post-transcriptional regula-
tion by microRNAs: are the answers in sight? Nature Reviews Genetics 
2008, 102–114
29. Hendrickson, D.G. et al. (2009) Concordant Regulation of Translation 
and mRNA Abundance for Hundreds of Targets of a Human microRNA. 
Plos.Biology 7, e1000238
30. Huntzinger, E. and Izaurralde, E. (2011) Gene silencing by microRNAs: 
contributions of translational repression and mRNA decay. Nature Re-
views Genetics 12, 99–110
31. Apcher, S. et al. (2011) Major source of antigenic peptides for the MHC 
class I pathway is produced during the pioneer round of mRNA transla-
tion. Proc.Natl.Acad.Sci.U.S.A  of the National Academy of Sciences 108, 
11572–11577
32. Apcher, S. et al. (2012) The role of mRNA translation in direct MHC class 
I antigen presentation. Current Opinion in Immunology 24, 71–76
33. Kim, Y. et al. (2013) Positional bias of MHC class I restricted T-cell epit-
opes in viral antigens is likely due to a bias in conservation. Plos Comput 
ational Biology 9, e1002884
34. Gleimer, M. and Parham, P. (2003) Stress Management: MHC Class I and 
Class I-like Molecules as Reporters of Cellular Stress. Immunity 19, 469–
477
35. Marciniak, S.J. and Ron, D. (2006) Endoplasmic Reticulum Stress Signal-
ing in Disease. Physiological Reviews 86, 1133–1149
36. Baird, S.D. (2006) Searching for IRES. RNA 12, 1755–1785
37. Schweingruber, C. et al. (2013) Nonsense-mediated mRNA decay - mech-
anisms of substrate mRNA recognition and degradation in mammalian 
cells. Biochimica and Biophysica Acta 1829, 612–623
38. Yewdell, J.W. and Nicchitta, C.V. (2006) The DRiP hypothesis decennial: 
support, controversy, refinement and extension. Trends in Immunology 
27, 368–373
233
39. Pastor, F. et al. (2010) Induction of tumour immunity by targeted inhibi-
tion of nonsense-mediated mRNA decay. Nature 465, 227–230
40. Dolan, B.P. et al. (2011) Distinct pathways generate peptides from defec-
tive ribosomal products for CD8+ T cell immunosurveillance. The.Jour-
nal of Immunology 186, 2065–2072
41. Walther, T.C. and Mann, M. (2010) Mass spectrometry-based proteomics 
in cell biology. The Journal of Cell Biology 190, 491–500
42. Purcell, A.W. and Gorman, J.J. (2004) Immunoproteomics: Mass spec-
trometry-based methods to study the targets of the immune response. 
Molecular and Cellular Proteomics 3, 193–208
43. Engelhard, V.H. (2012) The contributions of mass spectrometry to un-
derstanding of immune recognition by T lymphocytes. International 
Journal of Mass Spectrometry 259, 32–39
44. Edwards, N.J. (2007) Novel peptide identification from tandem mass 
spectra using ESTs and sequence database compression. Molecular Sys-
tems Biology 3, 102
45. Schandorff, S. et al. (2007) A mass spectrometry-friendly database for 
cSNP identification. Nature Methods 4, 465–466
46. Nijveen, H. et al. (2010) HSPVdb—the Human Short Peptide Variation Da-
tabase for improved mass spectrometry-based detection of polymorphic 
HLA-ligands. Immunogenetics 63, 143–153
47. Stone, B. et al. (2012) Identification of novel HLA class II target epitopes 
for generation of donor-specific T regulatory cells. Clinical Immunology 
145, 153–160
48. Robbins, P.F. et al. (2013) Mining exomic sequencing data to identify 
mutated antigens recognized by adoptively transferred tumor-reactive 
T cells. Nature Medicine 19, 747–752
49. McCarroll, S.A. et al. (2005) Common deletion polymorphisms in the hu-
man genome. Nature Publishing Group 38, 86–92
50. Karakoc, E. et al. (2012) Detection of structural variants and indels with-
in exome data. Nature Methods 9, 176–178
51. Terakura, S. et al. (2005) A UGT2B17-positive donor is a risk factor for 
higher transplant-related mortality and lower survival after bone mar-
row transplantation. British Journal of  Haematology 129, 221–228
52. Ofran, Y. et al. (2010) Diverse patterns of T-cell response against mul-
234
tiple newly identified human Y chromosome-encoded minor histocom-
patibility epitopes. Clinical Cancer Research 16, 1642–1651
53. Redon, R. et al. (2006) Global variation in copy number in the human 
genome. Nature 444, 444–454
54. Abecasis, G.R. et al. (2012) An integrated map of genetic variation from 
1,092 human genomes. Nature 491, 56–65
55. Loveland, B. et al. (1990) Maternally transmitted histocompatibility an-
tigen of mice: a hydrophobic peptide of a mitochondrially encoded pro-
tein. Cell 60, 971–980
56. Morse, M.C. et al. (1996) The COI mitochondrial gene encodes a minor 
histocompatibility antigen presented by H2-M3. The.Journal of Immu-
nology 156, 3301–3307
57. Starck, S.R. and Shastri, N. (2011) Non-conventional sources of peptides 
presented by MHC class I. Cellular and Molecular Life Sciences 68, 1471–
1479
58. Bullock, T.N. and Eisenlohr, L.C. (1996) Ribosomal scanning past the pri-
mary initiation codon as a mechanism for expression of CTL epitopes 
encoded in alternative reading frames. The Journal of Experimental Med-
icine. 184, 1319–1329
59. Dolstra, H. et al. (1999) A human minor histocompatibility antigen spe-
cific for B cell acute lymphoblastic leukemia. The Journal of Experimen-
tal Medicine. 189, 301–308
60. Torikai, H. et al. (2004) A novel HLA-A*3303-restricted minor histocom-
patibility antigen encoded by an unconventional open reading frame of 
human TMSB4Y gene. The.Journal of Immunology 173, 7046–7054
61. Griffioen, M. et al. (2012) Identification of 4 novel HLA-B*40:01 restrict-
ed minor histocompatibility antigens and their potential as targets for 
graft-versus-leukemia reactivity. Haematologica 97, 1196–1204
62. Tykodi, S.S. et al. (2008) C19orf48 encodes a minor histocompatibility 
antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma 
patients. Clinical Cancer Research 14, 5260–5269
63. Warren, E.H. et al. (2006) An antigen produced by splicing of noncon-
tiguous peptides in the reverse order. Science 313, 1444–1447
64. Hanada, K.-I. et al. (2004) Immune recognition of a human renal cancer 
antigen through post-translational protein splicing. Nature 427, 252–
235
256
65. Vigneron, N. (2004) An Antigenic Peptide Produced by Peptide Splicing 
in the Proteasome. Science 304, 587–590
66. Hanada, K.-I. and Yang, J.C. (2005) Novel biochemistry: post-translation-
al protein splicing and other lessons from the school of antigen process-
ing. Journal of Molecular Medicine 83, 420–428
67. Fortier, M.-H. (2009), Développement de méthodes analytiques pour 
la protéomique et l’identification de peptides MHC I issus de cellules 
leucémiques. Université de Montréal
68. Elias, J.E. and Gygi, S.P. (2007) Target-decoy search strategy for increased 
confidence in large-scale protein identifications by mass spectrometry. 
Nature Methods 4, 207–214
69. Allmer, J. (2011) Algorithms for the de novo sequencing of peptides 
from tandem mass spectra. Expert Review of Proteomics 8, 645–657
70. Neefjes, J. et al. (2011) Towards a systems understanding of MHC class I 
and MHC class II antigen presentation. Nature Reviews Immunology 11, 
823–836
71. Engelhard, V.H. et al. (2006) Post-translational modifications of natu-
rally processed MHC-binding epitopes. Current Opinion in Immunology 
18, 92–97
72. Craiu, A. et al. (1997) Two distinct proteolytic processes in the genera-
tion of a major histocompatibility complex class I-presented peptide. 
Proc.Natl.Acad.Sci.U.S.A 94, 10850–10855
73. Nussbaum, A.K. et al. (1998) Cleavage motifs of the yeast 20S protea-
some beta subunits deduced from digests of enolase 1. Proc.Natl.Acad.
Sci.U.S.A 95, 12504–12509
74. Brickner, A.G. et al. (2001) The immunogenicity of a new human minor 
histocompatibility antigen results from differential antigen processing. 
The Journal of Experimental Medicine. 193, 195–206
75. Small, K.S. et al. (2011) Identification of an imprinted master trans regu-
lator at the KLF14 locus related to multiple metabolic phenotypes. Na-
ture Genetics 43, 561–564
76. Gartner, J.J. et al. (2013) Whole-genome sequencing identifies a recurrent 
functional synonymous mutation in melanoma. Proc.Natl.Acad.Sci.U.S.A 
110, 13481–13486
236
77. Shabalina, S.A. et al. (2013) Sounds of silence: synonymous nucleotides 
as a key to biological regulation and complexity. Nucleic Acids Res 41, 
2073–2094
78. Gingold, H. and Pilpel, Y. (2011) Determinants of translation efficiency 
and accuracy. Molecular Systems Biology 7, 1–13
79. van Endert, P. (2011) Post-proteasomal and proteasome-independent 
generation of MHC class I ligands. Cellular and Molecular Life Sciences 
68, 1553–1567
80. Evans, D.M. et al. (2011) Interaction between ERAP1 and HLA-B27 in an-
kylosing spondylitis implicates peptide handling in the mechanism for 
HLA-B27 in disease susceptibility. Nature Genetics 43, 761–767
81. Evnouchidou, I. et al. (2011) Cutting Edge: Coding Single Nucleotide Poly-
morphisms of Endoplasmic Reticulum Aminopeptidase 1 Can Affect An-
tigenic Peptide Generation In Vitro by Influencing Basic Enzymatic Prop-
erties of the Enzyme. The Journal of Immunology 186, 1909–1913
82. Andrés, A.M. et al. (2010) Balancing Selection Maintains a Form of ERAP2 
that Undergoes Nonsense-Mediated Decay and Affects Antigen Presenta-
tion. PLoS Genetics 6, e1001157
83. Hassan, C. et al. (2013) The Human Leukocyte Antigen-presented Ligan-
dome of B Lymphocytes. Molecular and Cellular Proteomics 12, 1829–
1843
84. Mommaas, B. et al. (2002) Identification of a novel HLA-B60-restricted 
T cell epitope of the minor histocompatibility antigen HA-1 locus. The.
Journal of Immunology 169, 3131–3136
85. Ng, S.B. et al. (2009) Targeted capture and massively parallel sequencing 
of 12 human exomes. Nature 461, 272–276
86. Perreault, C. et al. (1990) Minor histocompatibility antigens. Blood 76, 
1269–1280
87. Roopenian, D. et al. (2002) The immunogenomics of minor histocompat-
ibility antigens. Immunological Reviews 190, 86–94
88. Lindahl, K.F. (1991) Minor histocompatibility antigens. Trends Genetics 
7, 219–224
89. Admon, A. and Bassani-Sternberg, M. (2011) The Human Immunopepti-
dome Project, a suggestion for yet another postgenome next big thing. 
Molecular and Cellular Proteomics 10, O111.011833–O111.011833
237
90. Hooper, D.U. and Vitousek, P.M. 06-Aug-(1997), The Effects of Plant 
Composition and Diversity on Ecosystem Processes. Science. [Online]. 
Available: http://www.sciencemag.org/content/277/5330/1302.short. 
[Accessed: 06-Oct-2013]
91. Naeem, S. et al. (1994) Declining biodiversity can alter the performance 
of ecosystems. Nature 368, 734–737
92. Ingolia, N.T. et al. (2009) Genome-wide analysis in vivo of translation 
with nucleotide resolution using ribosome profiling. Science 324, 218–
223
93. Ingolia, N.T. et al. (2013) Genome-wide annotation and quantitation of 
translation by ribosome profiling. Current Protocols in Molecular Biology 
4, Unit 4.18
94. Ingolia, N.T. et al. (2011) Ribosome profiling of mouse embryonic stem 
cells reveals the complexity and dynamics of mammalian proteomes. 
Cell 147, 789–802
95. Larance, M. et al. (2013) Global Subcellular Characterization of Protein 
Degradation Using Quantitative Proteomics. Molecular and Cellular Pro-
teomics 12, 638–650
96. Klein, L. et al. (2009) Antigen presentation in the thymus for positive 
selection and central tolerance induction. Nature Reviews Immunology 
9, 833–844
97. St-Pierre, C. et al. (2013) Transcriptome sequencing of neonatal thymic 
epithelial cells. Scientific Reports 3, 1860
98. Ucar, O. et al. (2013) An evolutionarily conserved mutual interdepen-
dence between Aire and microRNAs in promiscuous gene expression. 
European Journal of Immunology  43, 1769–1778
99. Macedo, C. et al. (2013) Autoimmune regulator (Aire) controls the ex-
pression of microRNAs in medullary thymic epithelial cells. Immunobi-
ology 218, 554–560
100. Bleakley, M. and Riddell, S.R. (2011) Exploiting T cells specific for 
human minor histocompatibility antigens for therapy of leukemia. Im-
munology and Cell Biology 89, 396–407
APPENDIXES
xxiii
APPENDIX 1
ER stress affects processing of MHC class I-associated peptides
Diana P. Granados1, Pierre-Luc Tanguay2, Marie-Pierre Hardy1, Étienne Caron1, 
Danielle de Verteuil1, Sylvain Meloche2, Claude Perreault1*
1Department of Medicine, Institute for Research in Immunology and Cancer, 
Université de Montréal, Montréal, Canada, 2Department of Pharmacology, In-
stitute for Research in Immunology and Cancer, Université de Montréal, Mon-
tréal, Canada
* Corresponding author
 
This article was submitted for publication to BMC Immunology on November 
28, 2008, accepted on February 16, 2009 and published online on February 16, 
2009. 
BMC Immunology, Volume 10:10 (2009)
xxiv
Abstract 
Background. Viral infection and neoplastic transformation trigger endoplas-
mic reticulum (ER) stress. Thus, a large proportion of the cells that must be 
recognized by the immune system are stressed cells. Cells respond to ER stress 
by launching the unfolded protein response (UPR). The UPR regulates the two 
key processes that control major histocompatibility complex class I (MHC I)-
peptide presentation: protein synthesis and degradation. We therefore asked 
whether and how the UPR impinges on MHC I-peptide presentation.
Results. We evaluated the impact of the UPR on global MHC I expression and 
on presentation of the H2Kb-associated SIINFEKL peptide. EL4 cells stably 
transfected with vectors coding hen egg lysozyme (HEL)-SIINFEKL protein vari-
ants were stressed with palmitate or exposed to glucose deprivation. UPR de-
creased surface expression of MHC I but did not affect MHC I mRNA level 
nor the total amount of intracellular MHC I proteins. Impaired MHC I-peptide 
presentation was due mainly to reduced supply of peptides owing to an inhibi-
tion of overall protein synthesis. Consequently, generation of H2Kb-SIINFEKL 
complexes was curtailed during ER stress, illustrating how generation of MHC 
I peptide ligands is tightly coupled to ongoing protein synthesis. Notably, the 
UPR-induced decline of MHC I-peptide presentation was more severe when the 
protein source of peptides was localized in the cytosol than in the ER. This 
difference was not due to changes in the translation rates of the precursor 
proteins but to increased stability of the cytosolic protein during ER stress. 
Conclusion. Our results demonstrate that ER stress impairs MHC I-peptide 
presentation, and that it differentially regulates expression of ER- vs. cytosol-
derived peptides. Furthermore, this work illustrates how ER stress, a typical 
feature of infected and malignant cells, can impinge on cues for adaptive im-
mune recognition.  
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Background 
The ultimate role of the immune system in host defense is to eliminate infected 
and transformed cells [1, 2]. A fundamental feature of infected and neoplastic 
cells is that they are stressed cells [3-5]. In line with this, the innate immune 
system uses receptors such as NKG2D to recognize stressed cells [4, 6, 7]. One 
key question, however, is whether cellular stress can influence recognition of 
transformed or infected cells by the adaptive immune system [4, 8].
The single feature uniting different stress stimuli (heat shock, hypoxia, viral 
replication, abnormal proteins, starvation or transformation) is that they all 
ultimately lead to accumulation of unfolded or misfolded proteins in the lu-
men of the ER [4, 5]. Infection and neoplastic transformation increase protein 
translation and thereby the folding demand on the ER [9, 10]. This is particu-
larly true for cells submitted to hypoxia, nutrient deprivation or low pH in 
poorly vascularized bulky tumors, metastases and sites of inflammation [11, 
12]. Moreover, acquisition of numerous mutations during tumor progression 
leads to accumulation of abnormal proteins with an increased propensity to 
misfolding that further raises the ER folding burden [3, 13].
The ER responds to the accumulation of unfolded proteins by activating in-
tracellular signal transduction pathways, collectively called the unfolded pro-
tein response (UPR) [14, 15]. The UPR is a highly conserved adaptive response 
that allows survival to limited stress but leads to apoptosis in the presence of 
overwhelming stress [16, 17]. Mammalian UPR acts through three main trans-
ducers (PERK, ATF6 and IRE1) that are activated by dissociation of the master 
chaperone BiP/GRP78 [5, 15]. Activation of PERK leads to phosphorylation of 
the translation initiation factor eIF2α and attenuation of cap-dependent trans-
lation [18]. The endonuclease activity of IRE1 generates a frameshift splice 
variant of XBP-1 encoding an active transcription factor that activates genes 
involved in protein degradation and controls the transcription of chaperones 
[19-21]. Targets of the cleaved active form of ATF6 include the chaperones BiP 
and GRP94, and the transcription factors XBP-1 and CHOP [17, 19]. Activation 
of these UPR transducers has pervasive effects on cellular protein economy: 
i) attenuation of protein translation, ii) increased degradation of ER proteins 
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by ER-associated degradation (ERAD), iii) transcriptional activation of genes 
involved in the folding machinery of the ER and iv) increased degradation of 
ER-localized mRNAs [14, 22].
Presentation of MHC I-associated peptides to CD8 T cells is tightly linked to 
protein economy. MHC I peptides are preferentially generated from newly syn-
thesized but rapidly degraded polypeptides relative to slowly degraded pro-
teins [23, 24]. Following proteasomal degradation, peptides are translocated 
into the ER where they undergo N-terminal trimming, loading onto MHC I/β2-
microglobulin (β2m) heterodimers and export at the cell surface [25-29]. Since 
the UPR regulates the two key processes that shape MHC I peptide processing 
(protein translation and degradation) we reasoned that ER stress should im-
pinge on MHC I peptide presentation. We addressed this question and found 
that MHC I presentation was impaired during ER stress induced by palmitate 
or glucose starvation. Moreover, ER stress differentially affected presentation 
of peptides derived from a protein localized in the ER vs. the cytosol.
 
Results 
Engineering of Kb-SIINFEKL stable transfectant cell lines
Evidence suggests that subcellular localization of a protein (e.g., in the cytosol 
vs. the secretory pathway) may influence MHC I presentation of peptides de-
rived from that specific protein [30-32]. Moreover, the UPR is primarily orches-
trated to decrease protein overload in the ER [14, 15]. We therefore wished to 
determine whether the UPR would differentially affect MHC I presentation of 
peptides derived from a precursor protein located in the cytosol versus the ER. 
To this end, we created stable EL4 transfectant cell lines expressing a chimeric 
protein located either in the ER or the cytoplasm (Figure 1A). We selected the 
EL4 thymoma cell line as a model because it expresses relatively high levels of 
MHC I [33] which allows us to assess changes of MHC I abundance over a wide 
dynamic range. To create the chimeric constructs, a minigene coding for the 
SIINFEKL peptide was fused to previously described plasmids encoding hen 
egg lysozyme (HEL) targeted to the ER or the cytosol [34, 35] (see methods). 
The ovalbumin-derived SIINFEKL peptide is presented by H2Kb and cell sur-
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face expression of Kb-SIINFEKL complexes was assessed by staining with the 
25-D1.16 monoclonal antibody [36]. As shown in Figure 1B, EL4 stably trans-
fected clones, denoted EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL, can 
process and present SIINFEKL derived from an ER-localized or a cytosolic chi-
meric protein, respectively. These two clones, which display similar amounts 
of Kb-SIINFEKL at the cell surface, were used in further experiments.
Figure 1. EL4 stable transfectants express the SIINFEKL peptide derived from HEL 
targeted to the ER or to the cytosol
(A) Schematic representation of the constructs used to generate EL4 stable transfec-
tants. Modified coding sequences of HEL [34, 35] in frame with the region coding for 
the ovalbumin-derived peptide SIINFEKL and its flanking region were cloned into the 
pIRES-EGFP2 vector. HEL-ER-SIINFEKL possesses HEL N-terminal signal sequence (ss) 
and the ER-retention signal KDEL and targets HEL to the ER; HEL-Cyto-SIINFEKL lacks 
the N-terminal signal sequence and the ER-retention signal and targets HEL to the 
cytoplasm (see materials and methods). (B) EL4 stable transfectants express Kb-SIIN-
FEKL at the cell surface. EL4 cells were transfected with the pIRES-EGFP2 vector en-
coding HEL-ER-SIINFEKL or HEL-Cyto-SIINFEKL. Stable transfectants were selected by 
repeated cycles of FACS of EGFP-positive cells combined with drug resistance (1000 
µg/ml of G418). Cells were stained with 25-D1.16 monoclonal antibody, recognizing 
the Kb-SIINFEKL complex, followed by staining with APC-conjugated anti-mouse IgG1 
as secondary antibody. Depicted in the graphs are EGFP and Kb-SIINFEKL MFI values 
of untransfected EL4 cells (upper left), EGFP-transfected cells (lower left) and the two 
representative clones that were used in further studies: EL4/HEL-ER-SIINFEKL (upper 
right) and EL4/HEL-Cyto-SIINFEKL (lower right). Percentages represent the proportion 
of cells expressing EGFP and Kb-SIINFEKL.
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UPR activation impairs MHC I surface expression
Various pharmacological agents are widely used to induce ER stress. For in-
stance, tunicamycin and dithiothreitol are known to cause ER stress by pre-
venting N-linked glycosylation or disrupting disulfide bond formation in the 
ER, respectively [37, 38]. However, since MHC I proteins are glycosylated and 
contain disulfide bonds, we surmised that tunicamycin and dithiothreitol 
would directly hinder the assembly of MHC I molecules. We elected to use 
more physiological ER stress stimuli that should have less drastic effects on 
the synthesis of MHC I molecules: palmitate and glucose starvation. Palmi-
tate is a saturated fatty acid recently shown to cause ER stress by disrupting 
mainly the structure and integrity of the ER [39-41]. Palmitate is abundant in 
the ‘high fat Western diet’, which renders this type of stress more physiologi-
cal [42]. Glucose starvation is a common condition present for instance in vas-
cularized bulky tumors and metastases, and is also a prototypical and strong 
inducer of ER stress [43].
Activation of the UPR was monitored by quantitative real-time reverse tran-
scriptase polymerase chain reaction (RT-qPCR) analysis of BiP, CHOP and the 
normal and spliced XBP-1 transcripts, which are known to be induced during 
ER stress [19, 44]. As expected, treatment of both EL4 transfectants, EL4/HEL-
Cyto-SIINFEKL and EL4/HEL-ER-SIINFEKL (data not shown), with palmitate for 
18 hours induced a mild UPR that was similar in both EL4 cell lines and of 
lesser magnitude than that induced by tunicamycin stimulation (Figure 2A). 
Similarly, we monitored UPR induction in EL4 cell lines grown in high glucose 
(4.5 mg/ml), low glucose (1 mg/ml) or no glucose-containing medium for dif-
ferent time durations (Figure 2B). BiP, XBP-1 and CHOP transcripts were sig-
nificantly induced in both EL4 cell lines when they were completely deprived 
of glucose for 18 or 24 hours, indicating activation of the UPR under these 
conditions. However, none of these UPR markers were upregulated in cells 
grown in low glucose-containing medium, suggesting that 1 mg/ml of glucose 
is sufficient to keep the homeostasis of the ER in EL4 cells. The notable point 
here is that glucose starvation for 18-24h induced a robust UPR that seemed 
to be of greater magnitude than that induced by palmitate (Figures 2A and B). 
Thus, ER stress induced by palmitate treatment or glucose starvation activates 
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the UPR in EL4 cells, albeit to different extents.
Figure 2. Induction of ER stress in EL4 cells
(A) UPR activation induced by palmitate treatment. EL4/HEL-Cyto-SIINFEKL cells were 
either non-treated or treated with 0.25 mM of palmitate or 2.5 µg/ml of tunicamycin 
for 18 hours. BiP, XBP-1 and CHOP mRNA levels were analyzed by RT-qPCR. Expres-
sion levels were normalized to the endogenous control gene β-actin. Transcript levels 
of treated cells were compared with basal mRNA values of untreated cells (dotted 
line), which were set to 1. (B) UPR activation induced by glucose deprivation. EL4 
stable cell lines were incubated in DMEM medium lacking glucose or containing low 
glucose (1 mg/ml) or high glucose (4.5 mg/ml) for different durations. BiP, XBP-1 and 
CHOP mRNA levels were analyzed by RT-qPCR. Expression levels were normalized to 
the endogenous control gene β-actin. Transcript levels of cells incubated under low 
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(purple) or no glucose (green) were compared to levels of cells grown in high glucose 
medium (dotted line), which were set to 1. Similar results were obtained with EL4/HEL-
ER-SIINFEKL cells (data not shown). Bars represent the mean and SD from three in-
dependent experiments performed in triplicate. *P < 0.05 when comparing untreated 
with palmitate- or tunicamycin-treated cells, or high glucose with low glucose or no 
glucose conditions.
To evaluate the effect of the UPR on MHC I expression, we quantified by flow 
cytometry surface levels of H2Kb and H2Db in both EL4 cell lines submitted 
to ER stress (Figure 3). Cells in later apoptotic stages were excluded from the 
analysis by gating on propidium iodide-negative cells. Activation of the UPR 
with palmitate reduced cell surface expression of H2Db and H2Kb by 30-40% 
in both cell lines (Figure 3A). Likewise, we evaluated whether UPR induced by 
glucose deprivation also affected MHC I surface expression. EL4 stable cell 
lines were incubated in medium lacking glucose or containing low glucose 
(1 mg/ml) or high glucose (4.5 mg/ml) for 18 hours and MHC I surface levels 
were measured by flow cytometry (Figure 3B). MHC I expression was impaired 
in cells grown both in low or no glucose conditions, albeit to a different ex-
tent. Cells that were completely deprived of glucose expressed only 25-30% of 
normal H2Kb and H2Db levels, similar to the decline produced by tunicamycin 
(not shown). On the contrary, cells incubated in low glucose medium were less 
affected since around 70–90% of normal H2Kb and H2Db levels were detected. 
Of note, a glucose dose of only 1 mg/ml was sufficient to raise MHC I levels by 
around three-fold (compare no-glucose with low glucose conditions in Figure 
3B). As observed in the case of palmitate treatment, glucose starvation caused 
a similar downregulation of MHC I in the two stable cell lines (Figure 3B). These 
results show that ER stress induced by glucose deprivation or palmitate treat-
ment causes decreased expression of surface MHC I molecules in EL4 cells.
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Figure 3. ER stress impairs MHC I surface expression
(A) Decreased MHC I surface expression induced by palmitate treatment. EL4 cells 
were either non-treated (dotted line) or treated with 0.25 mM of palmitate (orange) for 
18 hours. EL4/HEL-Cyto-SIINFEKL (top) and EL4/HEL-ER-SIINFEKL (bottom) cells were 
stained with antibodies against H2Kb, H2Db or the corresponding isotypic control 
and analyzed by flow cytometry. Representative histograms of one of three indepen-
dent experiments are depicted. Bars represent % of MFI intensity in treated EL4/HEL-
Cyto-SIINFEKL (blue) and EL4/HEL-ER-SIINFEKL (red) cells relative to untreated cells 
(dotted line). Differences between untreated and treated cells are all significant (P < 
B
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0.05). (B) Decreased MHC I surface expression induced by glucose deprivation. EL4 
cells were incubated in medium lacking glucose (green) or containing low glucose (1 
mg/ml) (purple) or high glucose (4.5 mg/ml) (dotted line) for 18 hours and analyzed 
as in A. Bars represent % of MFI intensity in glucose-deprived EL4/HEL-Cyto-SIINFEKL 
(blue) and EL4/HEL-ER-SIINFEKL (red) cells relative to untreated cells (dotted line). Bars 
represent the mean and SD from three independent experiments performed in trip-
licate. Differences between control and glucose-deprived cells are all significant (P < 
0.05).
Posttranscriptional mechanism(s) cause decreased expression of surface 
MHC I molecules during ER stress
Since the UPR blocks transcription of numerous genes and can provoke prema-
ture degradation of mRNAs encoding secreted or membrane proteins [22], we 
investigated whether decreased MHC I surface expression was due to downreg-
ulation of MHC I transcripts. Using RT-qPCR, we found that mRNA expression 
levels of H2Kb, H2Db and β2m were unaffected in glucose-deprived or pal-
mitate-treated cells (Figure 4A). In fact, the abundance of the β2m transcript, 
whose protein is essential for the formation of stable MHC I-peptide com-
plexes, tended to increase in stressed cells relative to control cells (although 
this increase was not statistically significant). We therefore conclude that UPR 
induced with palmitate or glucose starvation leads to posttranscriptional at-
tenuation of cell surface MHC I molecules. 
To test whether diminished MHC I upon ER stress occurred only at the cell 
surface, we quantified total MHC I protein amount from whole lysates of cells 
previously treated with palmitate or deprived of glucose. We found that none 
of these conditions affected the steady state level of MHC I (Figure 4B). Nev-
ertheless, one of the consequences of UPR activation is attenuation of protein 
synthesis [18]. Thus, we tested whether the UPR could impact on synthesis 
of MHC I in metabolically-labeled EL4 cells previously subjected to glucose 
deprivation or palmitate treatment for 18 hours. We found that glucose star-
vation, and to a much lesser extent palmitate, curtailed the synthesis of new 
MHC I molecules by around 40% and 5%, respectively (Figure 4C). Of note, the 
MHC I band in the no-glucose condition migrated faster than the bands in the 
control and the palmitate conditions. This effect is likely due to incomplete 
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glycosylation of MHC I molecules in glucose-deprived cells. Thus, under our 
experimental conditions, ER stress did not affect the level of MHC I transcripts 
nor the total amount of MHC I protein (Figure 4A and B), but decreased the 
synthesis of new MHC I molecules (Figure 4C) and the amount of MHC I mol-
ecules at the cell surface (Figure 3).
Figure 4. ER stress impairs cell surface MHC I expression through posttranscrip-
tional mechanism(s)
EL4 cells were incubated in DMEM control medium containing glucose (4.5 mg/ml), or 
in medium lacking glucose or supplemented with 0.25 mM of palmitate for 18 hours. 
(A) ER stress does not decrease MHC I mRNA levels. H2Kb, H2Db and β2m mRNA lev-
els were assessed and analyzed by RT-qPCR. Expression levels were normalized to the 
endogenous control gene β-actin. Transcript levels of glucose-starved (green) or pal-
mitate-treated (orange) cells were compared with basal mRNA values of control cells 
(dotted line), which were set to 1. Bars represent the mean and SD from three indepen-
dent experiments performed in triplicate. No significant differences were detected 
between untreated and treated cells (P < 0.05). (B) ER stress does not affect total MHC 
I protein amount. MHC I proteins from whole cell lysates were detected by Western 
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blot with anti-MHC I antibodies. α-tubulin was used as loading control. A represen-
tative image of three independent experiments is shown. (C) ER stress differentially 
affects synthesis of MHC I. EL4 cells were incubated in control conditions, deprived 
of glucose or treated with 0.25 mM of palmitate for 17 hours and pulse-labeled with 
[35S]methionine/ [35S]cysteine for 1 hour. Cell extracts were lysed and subjected to 
immunoprecipitation with anti-MHC I antibody or the corresponding isotypic anti-
body. Immunoprecipitated proteins were separated by SDS-PAGE and analyzed by 
fluorography. One representative experiment out of two is shown.
Decreased overall protein synthesis hinders MHC I-peptide presentation 
during ER stress
To understand how ER stress decreased cell surface expression of MHC I pro-
teins, we evaluated the impact of ER stress on surface expression of a variety 
of glycoproteins (Figure 5). As shown before, palmitate treatment and glucose 
starvation severely impacted MHC I surface level. In contrast, surface expres-
sion of glycoproteins CD32, CD45.2, TCR-β and CD5 (Ly1) was minimally or 
not affected. These results show that the deleterious impact of the UPR is 
more severe on surface MHC I expression than on other glycoproteins. This 
suggests that reduction in the amount of cell surface MHC I molecules dur-
ing ER stress cannot be attributed solely to defective MHC I synthesis. That 
contention is further supported by two elements. First, a 5% decline of MHC 
I synthesis in palmitate-treated cells (Figure 4C) is not commensurate with a 
30-40% reduction of MHC I molecules at the cell surface (Figure 3A). Second, 
the total amount of MHC I proteins was not affected in stressed cells (Figure 
4B), suggesting that MHC I proteins were relatively stable and that they did not 
reach the cell surface because they were not properly loaded with their peptide 
cargo and were therefore retained in the ER.
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Figure 5. Differential effects of ER stress on surface expression of various glyco-
sylated proteins
EL4 cells were incubated in high glucose (4.5 mg/ml) medium (dotted line) or in medi-
um lacking glucose (green) or supplemented with 2.5 mM of palmitate (orange) for 18 
hours. (A) Effect of glucose starvation or palmitate treatment on surface expression 
of glycosylated proteins. Surface expression of H2Kb, H2Db, CD32, CD45.2, TCR-β 
and CD5 (Ly1) was determined by flow cytometry analysis. Representative histograms 
of one of three independent experiments are depicted. (B) Comparative effect of pal-
mitate treatment and glucose starvation on surface expression of glycosylated pro-
teins. Bars represent % of MFI intensity in glucose-starved (green) or palmitate-treated 
(orange) cells relative to control cells (dotted line). Bars represent the mean and SD 
from three independent experiments. *P <0.05 and **P<0.01 when comparing no glu-
cose or palmitate with control conditions.
Assembly and presentation of MHC I-peptide complexes at the cell surface 
requires peptide delivery to the ER [28, 45]. Since MHC I binding peptides de-
rive mostly from recently synthesized proteins [23], we investigated whether 
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glucose starvation and palmitate treatment attenuated protein translation. To 
test this idea we determined the rate of global protein synthesis in ER-stressed 
EL4 cells by measuring the rate of [3H]leucine incorporation. Translation was 
severely compromised in cells deprived of glucose, which showed a 75% de-
cline in the rate of protein synthesis (Figure 6A). The impact on protein synthe-
sis was comparable to that observed with the translation inhibitor cyclohexi-
mide (Figure 6A). Protein synthesis was less attenuated in palmitate-treated 
cells, but yet decreased by approximately 25%. Of note, ER stress produced 
similar inhibition of protein synthesis in EL4/HEL-Cyto-SIINFEKL and EL4/HEL-
ER-SIINFEKL cells.
Figure 6. ER stress inhibits protein synthesis through phosphorylation of eIF2α in 
EL4 stable cell lines
(A) Decreased overall rate of protein synthesis upon ER stress. EL4 stable cell lines 
were deprived of glucose, treated with 0.25 mM of palmitate, 100 µg/ml of cyclo-
heximide or cultured under control conditions for 19 hours. [3H]Leucine (10µCi/mL) 
was added during the last hour. The rate of protein synthesis was measured by [3H]
leucine incorporation. The results are expressed as the % of [3H]leucine incorporation 
per cell relative to control cells (dotted line) in EL4/HEL-Cyto-SIINFEKL (blue) and EL4/
HEL-ER-SIINFEKL (red) cells. Bars depict the mean and SD of one representative experi-
ment performed in triplicate. Differences between untreated and treated cells are all 
significant (P < 0.05). (B) Phosphorylation of eIF2α. EL4 cells were deprived of glucose 
or treated with 0.25 mM of palmitate for different durations over a 24-h period. Total 
cell lysates were immunoblotted against phosphorylated eIF2α (Ser51) or total eIF2α. 
α-tubulin was used as loading control. One representative experiment out of three is 
shown.
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Following UPR signaling, inhibition of cap-dependent translation occurs via 
phosphorylation of Ser51 of the translation initiation factor eIF2α by activated 
PERK [18]. In line with this, we detected a rapid phosphorylation of eIF2α in 
EL4 cells after only 1 hour of glucose deprivation or treatment with palmitate 
(Figure 6B). This phosphorylated form persisted for 24 hours in both cases. 
These results show that eIF2α-mediated inhibition of protein synthesis occurs 
during glucose starvation or palmitate treatment and support the idea that 
impaired surface MHC I expression is caused by an inadequate peptide supply.
Differential cell surface presentation of ER- vs. cytosol-derived peptide by 
MHC I molecules during ER stress
In the next series of experiments, we studied the impact of ER stress on MHC 
I-peptide presentation, using the SIINFEKL peptide as a model. Kb-SIINFEKL 
surface expression was quantified by flow cytometry in EL4 stable cell lines 
submitted to ER stress by glucose deprivation or palmitate treatment for 18 
hours. We found that abundance of cell surface Kb-SIINFEKL decreased by more 
than 40% in cells that were completely deprived of glucose relative to control 
cells (Figure 7A). Similarly, Kb-SIINFEKL complexes were diminished by 20% or 
more in the presence of palmitate and by 10% in cells grown in the presence 
of low glucose. Thus, consistent with what we observed in the case of surface 
MHC I molecules, MHC I-peptide presentation is reduced during ER stress.
In addition, we found that although Kb-SIINFEKL expression was reduced in 
both cell lines upon ER stress, EL4/HEL-ER-SIINFEKL cells presented signif-
icantly more complexes than EL4/HEL-Cyto-SIINFEKL cells (Figure 7A). This 
difference occurred during complete glucose starvation, or treatment with 
palmitate (Figure 7A) or tunicamycin (not shown), but not when the glucose 
concentration was low, suggesting that it is UPR-specific (Figure 7A). Of note, 
both cell lines displayed similar amounts of Kb-SIINFEKL complexes under 
normal conditions (Figure 1B and Figure 7B top). We wish to emphasize that 
differences in abundance of Kb-SIINFEKL among the two types of EL4 transfec-
tants during ER stress (Figure 7A) cannot be ascribed to an overall difference 
in expression of H2Kb at the cell surface (Figure 3A and B). We therefore con-
clude that during ER stress, diminution of Kb-SIINFEKL presentation was more 
drastic when the peptide derived from a protein localized in the cytosol than 
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from an ER-retained protein.
Figure 7. Increased presentation of SIINFEKL peptide derived from ER-localized 
relative to cytosolic HEL protein during ER stress
(A) ER stress differentially affects surface expression of Kb-SIINFEKL complexes. EL4 
stable cell lines were incubated in medium lacking glucose or containing low glucose 
(1 mg/ml) or high glucose (4.5 mg/ml) or supplemented with palmitate (2.5 mM) for 
18 hours. Kb-SIINFEKL abundance was assessed with the 25-D1.16 monoclonal an-
tibody and APC-conjugated anti-mouse IgG1 antibody. Graph represents MFI values 
of glucose-deprived EL4/HEL-Cyto-SIINFEKL (blue) or EL4/HEL-ER-SIINFEKL (red) cells 
normalized to values of control cells, which were set to 1 (dotted line). (B) ER stress 
differentially affects surface expression of newly generated Kb-SIINFEKL complexes. 
EL4 stable cell lines were incubated under control conditions (top), deprived of glu-
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cose (middle) or treated with 0.25 mM of palmitate (bottom) for 18 hours. Existent 
MHC-I complexes were eluted by acid strip and expression of new Kb-SIINFEKL com-
plexes was assessed as in A at the indicated times. MFI values of unstripped cells 
incubated under normal conditions and representing normal level of Kb-SIINFEKL in 
each cell line were used to normalize MFI values of stripped cells. Bars represent the 
mean and SD from three independent experiments performed in triplicate. *P<0.05 
and **P<0.01 when comparing normalized Kb-SIINFEKL expression in EL4/HEL-Cyto-
SIINFEKL with that of EL4/HEL-ER-SIINFEKL.
Cell surface Kb-SIINFEKL complexes have been shown to be very stable [46]. We 
therefore postulated that monitoring Kb-SIINFEKL in the aforementioned ex-
perimental conditions might lead us to underestimate the impact of ER stress 
on exportation of “new” MHC I-peptide complexes at the cell surface. Thus, 
in the next series of experiments, we took advantage of the fact that cell sur-
face MHC I-peptide complexes can be disrupted by mild acid elution at pH 3.3 
[47-49]. EL4 stable cell lines were submitted or not to ER stress, then existent 
Kb-SIINFEKL complexes were acid stripped and generation of new complexes 
was measured at different time points. We reasoned that in this way we could 
directly assess the effect of the UPR on the generation of new Kb-SIINFEKL 
complexes. In control conditions, cells rapidly re-expressed Kb-SIINFEKL and 
initial control levels were reached 9 hours after acid stripping (Figure 7B, top). 
Notably, EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL cell lines showed 
similar kinetics. In contrast, stressed cells were not able to reach basal amount 
of Kb-SIINFEKL after acid strip (Figure 7B, middle and bottom). This effect 
was more striking in glucose-starved than in palmitate-treated cells, consis-
tent to what we observed for MHC I expression (Figure 5B). Remarkably, EL4/
HEL-ER-SIINFEKL cells generated significantly more cell surface Kb-SIINFEKL 
complexes than EL4/HEL-Cyto-SIINFEKL during ER stress (Figure 7B, middle 
and bottom). It should be noted that it was not possible to measure generation 
of complexes at time points later than 9 hours after acid strip, since at this 
time cells had already been stressed for 24 hours and cell death became a con-
founding variable. We conclude that ER stress decreases presentation of both 
existent (Figure 7A) and newly generated (Figure 7B) Kb-SIINFEKL complexes 
and that it differentially affected abundance of SIINFEKL derived from an ER- 
vs. a cytosol-localized protein.
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Changes in stability of cytosolic and ER-retained HEL during ER stress
As mentioned above, newly synthesized proteins are the major substrates for 
MHC I processing. In addition, it has been shown that the protein synthesis 
machinery of the cytosol and ER compartments is under distinct regulatory 
control during the UPR [50]. Thus the differential effect of ER stress on presen-
tation of ER- or cytosol-derived SIINFEKL could be due to changes in the trans-
lation rates of the source proteins. We explored this possibility and compared 
the synthesis rate of HEL-ER and HEL-Cyto in EL4 stable cell lines under normal 
conditions and during glucose starvation in metabolic labeling experiments. 
The rate of synthesis of cytosolic HEL and ER-retained HEL was not affected by 
glucose deprivation (Figure 8A). Hence, the different abundance of SIINFEKL at 
the surface of these cell lines during ER stress is not due to changes in the rate 
of synthesis of the precursor proteins
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Figure 8. Stability of cytosolic HEL and ER-retained HEL during ER stress
(A) Rate of synthesis of cytosolic HEL and ER-retained HEL. EL4/HEL-ER-SIINFEKL and 
EL4/HEL-Cyto-SIINFEKL cells were incubated in control conditions (4.5 mg/ml) or de-
prived of glucose for 17 hours and pulse-labeled with [35S]methionine/ [35S]cyste-
ine for 1 hour. Cell extracts were lysed and subjected to immunoprecipitation with 
anti-HEL antibody. Immunoprecipitated proteins were separated by SDS-PAGE and 
analyzed by fluorography. One representative experiment out of two is shown. (B) Sta-
bility of cytosolic HEL and ER-retained HEL. EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-
SIINFEKL cell lines were incubated in control conditions (4.5 mg/ml) or deprived of 
glucose for 18 hours. Then, 100 µg/ml of cycloheximide were added to inhibit protein 
synthesis and cell lysates taken at different times were immunoblotted against HEL 
or β-actin (used as loading control). One representative immunoblot out of three is 
shown. (C) Graph represents relative intensities of HEL (means and SD) from three in-
dependent experiments. *P <0.05 when comparing control vs. no glucose conditions.
MHC I-peptide presentation not only relies on protein synthesis but also on 
protein degradation. Therefore, we explored whether the stability of these pro-
teins could be differentially affected during ER stress. EL4 stable cell lines were 
deprived or not of glucose for 18 hours and then treated with cycloheximide to 
inhibit protein synthesis. The protein levels of cytosolic HEL and ER-retained 
HEL were assessed by Western blot thereafter. We observed an increased stabil-
ity of cytosolic HEL in the absence of glucose compared to control conditions 
(Figure 8B and C). In contrast, the stability of ER-retained HEL was the same in 
control conditions and during glucose starvation. These results suggest that 
reduced presentation of SIINFEKL by H2Kb when the peptide derives from the 
cytosolic protein compared to the ER-retained protein is due to increased sta-
bility of the cytosolic protein during ER stress.
 
Discussion 
The ER stands at the crossroad of two fundamental cellular processes: MHC I 
antigen presentation and UPR activation during ER stress. The UPR regulates 
protein synthesis and degradation, chaperoning and decay of ER mRNAs [14, 
15]. Thus, it has enormous potential to impinge on MHC I antigen processing 
which relies on all these processes. Here, we assessed the effect of ER stress on 
the final outcome of antigen processing and presentation: MHC I-peptide abun-
dance. We demonstrated that ER stress induced by tunicamycin, palmitate or 
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glucose deprivation, decreases peptide presentation by MHC I molecules. This 
finding is consistent with prior studies reporting reduced MHC I surface levels 
in human cells expressing a mutant HFE protein or overexpressing transcrip-
tionally active isoforms of UPR-activated transcription factors ATF-6 and XBP-
1 [51, 52]. Recently, reduced expression of MHC I molecules was also observed 
in antigen presenting cells during palmitate treatment [53]. Thus, diminution 
of MHC I surface expression upon UPR activation appears to be a generalized 
phenomenon occurring during ER stress induced by a variety of stimuli (phar-
macological agents, mutant proteins, glucose starvation and saturated fatty 
acid). 
Since the UPR provokes the degradation of ER-localized mRNAs [22], acceler-
ated decay of MHC I mRNA might have been responsible for the reduction of 
cell surface MHC I expression. However, the presence of normal levels of MHC 
I and β2m transcripts allowed us to exclude this possibility. During ER stress, 
transducers of the UPR seek to decrease the ER burden by suppressing trans-
lation initiation through phosphorylation of eIF2α by activated PERK [14, 15]. 
We demonstrated that inhibition of protein synthesis and phosphorylation of 
eIF2α did occur in EL4 cells treated with palmitate or deprived of glucose. Of 
note, the effect of these two treatments on phosphorylation of eIF2α was simi-
lar, yet inhibition of overall protein synthesis was more severe in glucose-de-
prived than in palmitate-treated cells. We presume that this discrepancy was 
due to brisk inhibition of the mammalian target of rapamycin (mTOR) pathway 
during glucose starvation [54]. Inhibition of mTOR blocks phosphorylation of 
p70 ribosomal S6 kinase and eukaryotic initiation factor 4E binding protein 1 
and thereby leads to inhibition of protein synthesis. Given the dramatic inhi-
bition of protein synthesis during glucose starvation, it was notable that the 
translation rate of the two HEL variants was not affected. That feature of our 
HEL variants is not unique as there are several proteins whose synthesis is un-
affected during ER stress [9, 54].
We found that ER stress-induced inhibition of overall protein synthesis cur-
tails the synthesis of new MHC I molecules. Nevertheless, we do not believe 
that decreased synthesis of MHC I proteins per se was a leading factor respon-
sible for decreased levels of MHC I molecules at the cell surface. Our assertion 
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is based on three lines of evidence: i) a 5% decline of MHC I synthesis in pal-
mitate-treated cells was not commensurate with a drop of 30-40% of surface 
MHC I, ii) during ER stress, cell surface levels of MHC I proteins were decreased 
much more than those of other glycoproteins that must also pass through the 
same maturation process and quality control in order to be exported at the 
cell surface, and iii) the total amount of intracellular MHC I proteins was not 
decreased during stress suggesting that MHC I molecules did not reach the 
cell surface mainly because they were sequestered in the ER. In addition, de 
Almeida et al. showed that a partial UPR signaling induced by overexpression 
of ATF-6 or XBP-1 in the absence of genuine stress stimulus also resulted in de-
creased MHC I surface expression [52]. MHC I heavy chains and β2m are pres-
ent in excess in the ER. The limiting factor in the assembly and presentation 
of MHC I-peptide complexes is peptide delivery to the ER [28, 45]. Moreover, 
peptides presented by MHC I molecules derive mainly from proteins that are 
degraded a few seconds or minutes after their synthesis as opposed to stable 
proteins with a slow turnover. Thus, generation of MHC I peptide ligands is 
tightly coupled to ongoing protein synthesis and inhibition of translation rap-
idly decreases the amount of cell surface MHC I-peptide complexes [55]. Our 
favorite hypothesis is therefore that decreased MHC I presentation during ER 
stress is due mainly, albeit not exclusively, to restriction of peptide availabil-
ity. Given that MHC I molecules preferentially sample polypeptides that are 
being actively translated [55], we posit that global attenuation of protein syn-
thesis caused by palmitate and glucose starvation limits the amount of a vast 
repertoire of peptides available for insertion in MHC I molecules. Nevertheless, 
we do not exclude the possibility that defective synthesis of MHC I and other 
possible mechanisms such as inappropriate loading of peptides, contribute 
to diminution of MHC I-peptide presentation. This would be mainly the case 
of peptides deriving from proteins whose synthesis is not curtailed upon ER 
stress. For instance, our results show that ER stress diminished presentation 
of Kb-SIINFEKL complexes even though the synthesis of the proteins source of 
this particular peptide (HEL variants) was not affected. 
A main conclusion of our work is that ER stress-induced attenuation of MHC 
I-peptide presentation is more severe when the source protein is localized in 
the cytosol than in the ER. The difference between proteins in these two cell 
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compartments was UPR-specific because it did not occur in the low glucose 
condition in which no UPR markers were significantly induced. Our cell lines 
expressing HEL-Cyto-SIINFEKL and HEL-ER-SIINFEKL displayed identical re-
sponses to palmitate treatment or glucose starvation. The two cell lines showed 
similar upregulation of UPR markers and equivalent reduction in cell surface 
levels of H2Kb and H2Db during ER stress. Despite the fact that the translation 
rates and degradation profiles normally differ in both cell lines, they displayed 
similar levels of Kb-SIINFEKL complexes under steady-state conditions. On the 
contrary, presentation of Kb-SIINFEKL complexes was differentially affected in 
these cell lines during ER stress. Only 1-2 out of every 10,000 peptides gener-
ated by the proteasome bind to MHC I molecules [28]. Our data therefore beg 
the question: how would an ER-retained protein generate more peptides than 
a cytosolic protein during ER stress? We showed that this difference was not 
due to variations in the translation rate of each precursor protein during ER 
stress. This suggests that differences in peptide presentation resulted from 
discrepancies in the degradation of ER vs. cytosolic proteins during ER stress. 
UPR transducers specifically enhance degradation of proteins in the secretory 
pathway in order to decrease the ER folding load. During ER stress, cotransla-
tional protein translocation is inhibited and newly-synthesized ER proteins are 
triaged for degradation (ERAD) [38, 56, 57]. Furthermore, retrotranslocation of 
ER-resident proteins in the cytosol for proteasomal degradation is enhanced 
[58]. Based on this, we expected to see an increased degradation of the ER-
retained HEL variant during ER stress. However, the stability of the ER-retained 
protein remained unchanged while the stability of the cytosolic HEL variant 
increased during ER stress. The most parsimonious explanation for the lat-
ter findings would be that during ER stress, proteasomes focus primarily on 
degradation of ER as opposed to cytosolic proteins. This would be consistent 
with the fact that the primary role of the UPR is to decrease the folding bur-
den in the stressed ER. We therefore propose that regulation of proteasomal 
degradation during ER stress leads to a reduction in MHC I peptide ligands 
generated from cytosolic precursors. Further studies will be needed to deter-
mine whether this concept can be generalized to other proteins and other MHC 
I-associated peptides.
What might be the impact of the UPR on immune recognition of infected and 
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neoplastic cells? Paradoxically, if the decreased generation of MHC I-peptide 
complexes results mainly from inhibition of translation, it could facilitate rec-
ognition of virus-infected cells. Phosphorylation of eIF2α hampers canonical 
cap-dependent translation initiation which regulates synthesis of 95-98% of 
cellular mRNAs [9]. However, some viruses can use internal ribosomal entry 
sites in their 5’ noncoding region to initiate cap-independent translation [9, 
59]. Thus, by preferentially repressing presentation of self peptides, the UPR 
could facilitate recognition of viral peptides (the needle in the haystack [60]). 
The potential impact of the UPR on recognition of neoplastic cells is not inher-
ently obvious. On the one hand, by repressing production of MHC I-peptide 
complexes, the UPR may hinder presentation of tumor antigens to CD8 T cells. 
Indeed, generation of optimal CD8 T cell responses is promoted by high epi-
tope density on antigen presenting cells [61, 62]. However, an elegant study 
by Schwab et al. has shown that upon induction of eIF2α phosphorylation by 
ER stress, cells can generate MHC I-associated peptides derived from cryptic 
translational reading frames [63]. Expression of such cryptic peptides by neo-
plastic cells might trigger recognition of stressed cells by CD8 T lymphocytes. 
Finally, a high fat diet rich in saturated fatty acids such as palmitate, could 
potentiate the conditions of ER stress found in tumour cells and lessen even 
more MHC I-peptide presentation. In fact, obesity has been associated with 
increased susceptibility to infection and impaired immune responses [53, 64]. 
We anticipate that high-throughput sequencing of MHC I-associated peptides 
[33] will be necessary to comprehensively evaluate how ER stress molds the 
peptide repertoire (in terms of both abundance and diversity), and to gain fur-
ther insights into the global impact of the UPR on recognition of stressed cells 
by CD8 T lymphocytes. 
 
Conclusions 
Our work shows that ER stress impinges on the MHC I peptide repertoire in 
two ways: by decreasing overall MHC I-peptide presentation and by changing 
the relative contribution of ER- vs. cytosol-proteins to the MHC I peptide rep-
ertoire. Since ER stress is a characteristic feature of infection and malignancy, 
dysregulation of MHC I-peptide presentation could have major implications in 
the recognition of infected and transformed cells by CD8 T lymphocytes.
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Methods
Cell lines 
EL4 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO Burlington, ON, Canada) supplemented with 5% fetal bovine serum 
(FBS) and antibiotics. EL4 stable transfectants were grown in the same medium 
supplemented with 1000 µg/ml of G418. 
DNA constructs
pHYK/HEL-ER/myc and pCMV/HEL-Cyto/myc plasmids encoding ER-retained 
or cytoplasmic HEL, respectively, were provided by S. Ostrand-Rosenberg (Uni-
versity of Maryland, Baltimore, USA). The pHYR/HEL-ER plasmid contains the 
HEL gene (that includes a signal sequence) fused to the ER-retention signal 
KDEL, whereas pCMV/HEL-Cyto codes for HEL with a modified N-terminus and 
lacks ER-retention signal. These plasmids have successfully been shown to tar-
get HEL to the ER or to the cytosol [34, 35]. pHYK/HEL-ER and pCMV/HEL-Cyto 
were sequenced to ascertain correct sequence and reading frame. Fragments 
coding for HEL-ER or HEL-Cyto were fused by PCR to the region coding for 
the ovalbumin-derived peptide SIINFEKL, flanked by a sequence of 18 bp (LE-
QLE-SIINFEKL-TEWTS, here referred to as SIINFEKL) to ensure proteasome- and 
TAP-dependent peptide processing [65, 66]. PCR amplification products were 
subcloned into the pPCR-Script Amp cloning vector (Stratagene, Cedar Creek, 
TX, USA). HEL-ER-SIINFEKL or HEL-Cyto-SIINFEKL were excised and cloned into 
the bicistronic pIRES-EGFP2 vector (Clontech, Mountain View, CA, USA) to gen-
erate pIRES-EGFP2/HEL-ER-SIINFEKL and pIRES-EGFP2/HEL-Cyto-SIINFEKL (Fig-
ure 1A). Both constructs were sequenced to ascertain correct sequence and 
reading frame.
Stable transfectants
EL4/HEL-ER-SIINFEKL and EL4/HEL-Cyto-SIINFEKL were generated by transfect-
ing EL4 cells with the appropriate HEL-containing pIRES-EGFP2 plasmid. Trans-
fections were done with Lipofectamine LTX Reagent (Invitrogen, Burlington, 
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ON, Canada) as instructed by the manufacturer. 24 hours after transfection, 
single cells expressing the brightest signal of EGFP were sorted by fluores-
cence-activated cell sorting (FACS) on a FACSAria cell sorter (BD Biosciences, 
Mississauga, ON, Canada). Stable transfected clones were further selected by 
drug resistance (1000 µg/ml of G418) in combination with repeated cycles of 
FACS of EGFP-positive cells. Clones expressing similar levels of Kb-SIINFEKL at 
the cells surface were selected for use in further experiments.
Stress induction 
ER stress was induced by incubating cells in fresh medium containing 0.25 mM 
of palmitate or 2.5 µg/ml of tunicamycin (Sigma-Aldrich, St. Louis, MO, USA) 
for the indicated times. Palmitate was prepared as described previously [67] 
and delivered as a complex with fatty acid-free BSA. Glucose starvation was in-
duced by culturing cells in glucose and sodium pyruvate-free or in low glucose 
(1000 mg/L) DMEM medium (GIBCO) supplemented with 5 % dialyzed FBS and 
antibiotics for the indicated times. Control cells were grown in high glucose 
DMEM medium, containing 4500 mg/L of glucose and 110mg/L of sodium py-
ruvate supplemented with 5% FBS and antibiotics. 
Flow cytometry
MHC I molecules at the cell surface were stained with biotin-conjugated an-
ti-H2Kb (clone AF6-88.5) and biotin-conjugated anti-H2Db (clone KH95), fol-
lowed by PeCy5 or APC-conjugated streptavidin. Other cell surface glycosyl-
ated proteins were stained with FITC-conjugated anti-CD45.2, FITC-conjugated 
anti-CD5 (Ly1), APC-conjugated anti-TCR-β and PE-conjugated anti-CD32. All 
antibodies were purchased from BD Biosciences. Kb-SIINFEKL levels were de-
termined with the 25-D1.16 antibody [36] followed by staining with APC-con-
jugated anti-mouse IgG1 (Clone X56). Propidium iodide (BD Biosciences) was 
used to exclude cells in later apoptotic stages from the analysis. Cells were 
analyzed on a BD LSR II flow cytometer using FACSDiva (BS Biosciences) and 
FCS Express softwares (De Novo Software, Los Angeles, CA, USA) [68, 69].
Acid strip assay
xlviii
MHC I-peptide complexes were eluted with acid treatment as previously de-
scribed [47-49]. Briefly, cells (~5 x 105) were resuspended in 0.2 ml of ci-
trate phosphate buffer at pH 3.3 (0.131 M citric acid/0.066 M Na2HPO4, NaCl 
150mM) for 1 minute, neutralized with appropriate medium pH 7.4 and either 
reincubated in fresh medium or stained for flow cytometry analysis.
RNA extraction, reverse transcription and RT-qPCR
Total RNA was isolated with TRIzol reagent (Invitrogen) according to the man-
ufacturer’s instructions. Purified RNA was reverse transcribed using the High 
Capacity cDNA reverse transcription Kit with random primers (Applied Biosys-
tems, Foster City, CA, USA) as described by the manufacturer. A reference RNA 
(Stratagene, La Jolla, CA, USA) was also transcribed in cDNA. Expression level 
of target genes was determined using primer and probe sets from Universal 
ProbeLibrary (https://www.roche-applied-science.com/sis/rtpcr/upl/index.
jsp) or Applied Biosystems (ABI Gene Expression Assays or SYBR green PCR 
Master Mix, http://www.appliedbiosystems.com/). Primer sequences are given 
in Additional file 1. RT-qPCR assay for XBP-1 was designed to amplify both the 
normal and spliced forms.  Pre-developed TaqMan® assays for β-actin were 
used as endogenous controls. RT-qPCR analyses were performed as described 
using a PRISM® 7900HT Sequence Detection System (Applied Biosystems) [70]. 
The relative quantification of target genes was determined by using the rrCT 
(cycle threshold) method. Relative expression (RQ) was calculated using the 
Sequence Detection System (SDS) 2.2.2 software (Applied Biosystems) and the 
formula RQ = 2-rrCT. 
Protein synthesis and metabolic labeling
To measure protein synthesis, EL4 cell lines were cultured in presence or ab-
sence of glucose (4.5 mg/ml) for 18 hours. [3H]Leucine (10µCi/mL) was added 
during the last hour. Cells were washed twice with ice-cold PBS and fixed for 
30 minutes on ice with 10% TCA. Cells were then rinsed with water and lysed 
with 0.1N NaOH. Radioactivity incorporation was determined with a liquid 
scintillation analyzer Tri-CArb 2800TR (Perkin Elmer).
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In vivo biosynthetic labeling experiments were carried out as described previ-
ously [71]. Briefly, to evaluate the rate of synthesis of HEL and MHC I, EL4 cell 
lines were grown in control conditions or in the presence of 2.5 mM of palmi-
tate or in the absence of glucose for 17 hours. After this period, 107 cells per 
condition were starved of methionine and cysteine for 30 min. 35S-labeled 
methionine and cysteine (220µCi/mL) were then added for 1 hour. Cells were 
harvested and lysed in Triton X-100 buffer (50mM Tris pH7.5, 150mM NaCl, 
1% Triton X-100, 1mM EDTA, 40mM β-glycerophosphate) supplemented with 
complete protease inhibitor cocktail (Roche Molecular Biochemicals, Laval, QC, 
Canada) and phosphatase inhibitors (1 mM Na3VO4 and 5 mM NaF). Immuno-
precipitation of ER-retained HEL or cytosolic HEL and MHC I were performed 
using anti-HEL antibody purchased from Affinity BioReagents (Golden, CO, 
USA) or anti-H2Kb or anti-H2Db hybridoma culture supernatans antibody [49], 
according to the method described previously [71]. Proteins were separated by 
SDS-PAGE and labeled proteins were detected by fluorography.
Immunoblotting
EL4 cell lines were cultured under control conditions or submitted to glucose 
deprivation or palmitate treatment (0.25 mM) for the indicated times. When 
indicated, 100 µg/mL of cycloheximide (Sigma-Aldrich) was used for various 
durations to measure the stability of HEL variants. Cells were harvested and 
lysed in Triton X-100 buffer. The lysates were cleared by centrifugation and 
the protein content was measured by the Bradford method (Biorad, Mississau-
ga, ON, Canada). Samples were resolved by SDS-PAGE and immunoblotted with 
the following antibodies: anti-β-actin (AC-15) from Sigma-Aldrich, anti-HEL 
from Affinity BioReagents, anti-MHC class I (2G5) from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA), anti-α-tubulin, anti-phospho-eIF2α (Ser51), anti-
eIF2α and horseradish peroxidase (HRP)-conjugated anti-rabbit IgG from Cell 
Signaling Technology (Beverly, MA, USA), and HRP-conjugated goat anti-mouse 
IgG from BD Pharmigen (San Diego, CA, USA). Chemiluminescent signal was 
detected using a LAS3000 imaging system (Fujifilm, Tokyo, Japan) and quanti-
fication of band intensities was done using the Multi Gauge v3.0 (Fujifilm) and 
the ImageQuaNT v5.0 (Molecular Dynamics, Sunnyvale, CA, USA) softwares.
lStatistical analysis
The means of normally distributed data were compared using the Student t 
test, with a P value of < 0.05 considered significant. Data are presented as the 
mean and SD. Whenever the results are expressed as a percentage of control, 
the statistical analysis was performed on the actual value.
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FIG. 2. The MIP repertoire conceals a cell–type specific signature. (A) Venn diagram representation of the relation between MIPs (and
their source proteins) eluted from C57BL/6 thymocytes and DCs. (B) Cell surface expression of MHC I allelic products was evaluated by flow
cytometry. Histogram shows the DC/thymocyte mean fluorescence intensity ratio for H2Db (p 6 10 5; Student t test), H2Kb (p 6 10 7),
Qa1 (p 7 10 6) and Qa2 (p 3 10 2) (mean S.D. of triplicate experiments). (C) Proportion of peptides associated to different MHC
I allelic products in DCs and thymocytes. (D) Pie charts represent the relations between peptide source genes (389 for DCs, 186 for thymocytes)
and KEGG pathways. Examples of pathways enriched in the gene datasets are depicted (with p value for enrichment in parentheses).
APPENDIX 2 
I participated in the analysis of the MHC I immunopeptidomes from mouse 
DCs and thymocytes. The results were included in a published article: 
Deletion of Immunoproteasome subunits imprints on the transcriptome 
and has a broad impact on peptides presented by major histocompatibil-
ity complex I molecules
Danielle de Verteuil, Tara L. Muratore-Schroeder, Diana P. Granados, et. al. Mo-
lecular & Cellular Proteomics, Volume 9:2034-2047 (2010)Comparison of both sets of peptides revealed that the MHC I peptide-repertoire (MIP) of DCs conceals a unique signature.
